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INTRODUCCIÓN 
 
La Lesión Pulmonar Aguda (LPA) y su forma más grave, el Síndrome de Distrés 
Respiratorio Agudo (ARDS), es un síndrome frecuente y una causa importante de 
morbi-mortalidad en enfermos críticos. Se caracteriza por un daño alveolar difuso con 
aumento de la permeabilidad de la membrana alveolo-capilar y acumulación de edema 
alveolar proteináceo.  El desarrollo del daño del epitelio alveolar es la principal 
característica de la LPA que determina la gravedad de la enfermedad y el pronóstico 
de estos pacientes. 
 
El sistema formado por el receptor Fas y su ligando natural, Fas Ligando (FasL), 
parece estar implicado en la patogénesis de la LPA/SDRA. Fas ligando es una 
proteína que existe tanto unida a la membrana celular como en forma soluble. El FasL 
se une y agrega el receptor Fas en la superficie de la membrana celular de las células 
diana, e induce apoptosis y activación de repuestas inflamatorias. La forma soluble de 
FasL (sFasL) se genera principalmente a partir de la segmentación del FasL de 
membrana (mFasL) por la acción proteolítica de metaloproteinasas (MMPs) y otras 
enzimas.  
 
En humanos, el sFasL está incrementado en el fluido de lavado bronquio-alveolar 
(LBA) en pacientes de riesgo para SDRA, así como en pacientes con SDRA 
establecido. Sin embargo, sólo el sFasL del fluido del LBA de pacientes con SDRA 
induce apoptosis en células epiteliales pulmonares humanas in vitro. Esta observación 
sugiere que existen factores que modulan la actividad de sFasL en el espacio aéreo de 
los pulmones de pacientes con LPA/SDRA. 
 
Los mecanismos responsables de la bioactividad del sFasL no son bien conocidos. Se 
han identificado diferentes sitios de segmentación para la acción proteolítica de las 
metaloproteinasas -3 y -7 (MMP-3, -7) en la porción extracelular del mFasL, lo cual 
puede dar lugar a variantes estructurales del sFasL. Las dos formas principales de 
sFasL generadas de esta manera serían: una forma larga compuesta por el dominio 
TNF en el C-terminal y la región “stalk” en el N-terminal, y una forma corta formada 
solamente por el domino TNF. El dominio TNF media la unión del FasL al receptor 
Fas, pero la función de la región stalk se desconoce. El estado de agregación y de 
oxidación del sFasL son posibles factores que pueden modular la bioactividad del 
sFasL. Varias líneas de investigación sugieren que la bioactividad del sFasL depende 
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de su grado de agregación. Asimismo, es bien conocido que la oxidación puede alterar 
el estado de agregación y la actividad de múltiples proteínas. En los pulmones de los 
pacientes con LPA/SDRA existe un incremento de oxidantes por lo que muchas 
proteínas acumuladas en el edema pulmonar de estos pacientes, entre ellas el sFasL, 
pueden estar oxidadas. 
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OBJETIVOS Y PLANTEAMIENTO EXPERIMENTAL 
 
En el presente estudio, nuestros objetivos principales fueron identificar los 
determinantes estructurales intrínsecos que modulan la actividad del sFasL humano, 
así como determinar los factores que modifican la estructura y la bioactividad del 
sFasL humano en el espacio aéreo pulmonar de pacientes con LPA/SDRA. Para ello 
clonamos, expresamos y purificamos una variante larga (con la región stalk) y una 
variante corta (sin la región stalk) del sFasL humano. Para determinar la importancia 
de la región stalk en la actividad de esta proteína, desarrollamos un modelo animal en 
ratones en los que instilamos por vía intratraqueal una dosis de la forma larga o corta 
del sFasL humano. Para determinar si el LBA de pacientes con LPA/SDRA contiene 
oxidantes que modifican la estructura y la actividad del sFasL humano, realizamos 
estudios in vitro en los que usamos fluido de LBA de pacientes con LPA/SDRA, así 
como oxidantes derivados de mieloperoxidasas. Finalmente, realizamos también 
estudios in vitro para determinar cuáles son los aminoácidos claves implicados en las 
alteraciones estructurales y funcionales del sFasL bajo condiciones oxidantes. 
 
 
CONCLUSIONES 
 
De los hallazgos encontrados en el presente estudio podemos extraer las siguientes 
conclusiones: 
 
1. La forma soluble de Fas Ligando (sFasL) induce lesión en pulmones de ratón 
mediante la activación específica del receptor Fas. 
 
2. La región stalk en el N-terminal es un determinante crítico para la actividad 
biológica del sFasL humano tanto en pulmones in vivo como en células Jurkat in 
vitro. La región stalk, sin embargo, no afecta el grado de agregación de sFasL. La 
región stalk del sFasL puede ser segmentada in vitro por la MMP-7, lo cual resulta 
en una disminución de su bioactividad. 
 
3. El fluido del LBA de pacientes con SDRA contiene factores que: 
a. Incrementan la actividad del sFasL. 
b. Aumentan la agregación del sFasL mediante la formación de enlaces 
covalentes intermoleculares, lo cual le confiere una mayor estabilidad y 
mayor resistencia a la degradación. 
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4. Los residuos de metionina del sFasL humano son determinantes críticos de la 
actividad de esta proteína bajo condiciones pro-oxidantes. En particular, la 
exposición a HOCl, un oxidante derivado de la mieloperoxidasa, modifica la 
bioactividad del sFasL y promueve su agregación por mecanismos derivados de la 
oxidación de las metioninas presentes en esta proteína. 
 
 
En base a estos resultados, nosotros proponemos que la actividad biológica del sFasL 
en fluidos fisiológicos podría estar determinada por la proporción relativa de sus 
variantes estructurales. Los oxidantes derivados de neutrófilos presentes en el edema 
pulmonar de pacientes con LPA/SDRA podrían modificar la estructura y la actividad 
del sFasL en los pulmones de estos pacientes. Un mejor conocimiento de los 
mecanismos moleculares que modulan la actividad del sFasL podría resultar en 
estrategias terapéuticas dirigidas a modificar la actividad biológica del sFasL in vivo. 
En este sentido, la región stalk o las metioninas podrían ser dianas terapéuticas para 
modular la actividad del sFasL al inicio del desarrollo de la LPA/SDRA. 
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4.1.  GENERALITIES OF ACUTE LUNG INJURY 
 
4.1.1.   DEFINITION OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY 
DISTRESS SYNDROME 
 
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are common 
problems in the ICU that affect both medical and surgical patients.  ALI/ARDS is a 
major cause of acute respiratory failure with high morbidity and mortality in critically ill 
patients.   ALI and ARDS are the same clinical disorder but they are distinguished by 
the severity of hypoxemia.  ALI/ARDS is characterized by widespread inflammation and 
non-hydrostatic pulmonary edema resulting from alveolar-capillary damage caused by 
multiple factors.  Acute lung injury is defined by physiologic and radiographic criteria in 
which widespread damage to cells and structures of the alveolar capillary membrane 
occurs within hours to days of a predisposing insult.  The first description of acute 
respiratory distress syndrome appeared in 1967, when Ashbaugh and colleagues 
described 12 patients with acute respiratory distress, cyanosis refractory to oxygen 
therapy, decreased lung compliance, and diffuse infiltrates evident on the chest 
radiograph 1.  Initially called the adult respiratory distress syndrome 2, this entity is now 
termed the acute respiratory distress syndrome, since it does occur in children.  The 
first description of this illness paralleled the creation of Respiratory Intensive Care Units 
(ICU) and the treatment of acute respiratory failure with positive pressure. 
 
Although the concept of ARDS was clear, more objective and validated parameters 
were needed to systematically identify all patients with this disease.  In 1988, Murray 
and colleagues developed the Lung Injury Score to unify diagnostic criteria 3.  The 
score quantified the physiologic respiratory impairment through the use of a four-point 
lung-injury scoring system that was based on the level of positive end-expiratory 
pressure (PEEP), the ratio of the partial pressure of arterial oxygen to the fraction of 
inspired oxygen, the static lung compliance, and the degree of infiltration evident on 
chest radiographs.  Other factors included in the assessment were the inciting clinical 
disorder, and the presence or absence of nonpulmonary organ dysfunction.  Although 
this score helped quantify the severity of lung injury, it had limited clinical utility since it 
did not predict outcomes during the first 24 to 72 hours after the onset of the acute 
respiratory distress syndrome 4, 5.  By four to seven days after the onset of the 
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syndrome, scores of 2.5 or higher predicted a complicated course with the need for 
prolonged mechanical ventilation 6. 
 
In 1994, a new definition was recommended by the American–European Consensus 
Conference (AECC) Committee (Table 4.1) 7.  This new definition is currently used in 
most intensive care units and has important advantages.  It recognizes that acute lung 
injury is a progressive disorder with different degrees of severity.  Patients with less 
severe hypoxemia (as defined by a ratio of the partial pressure of arterial oxygen to the 
fraction of inspired oxygen of 300 or less) are considered to have acute lung injury 
(ALI), and those with more severe hypoxemia (as defined by a ratio of 200 or less) are 
considered to have the acute respiratory distress syndrome (ARDS) 4, 5. 
 
Table 4.1 
 
 
This new definition permits earlier identification of patients with this disorder, although 
distinguishing ALI from ARDS is arbitrary, because hypoxemia correlates poorly with 
lung pathology and clinical course.  However, the definition is simple and easy to use, 
especially in clinical trials.  It has some limitations because it does not include 
important factors that influence outcome, such as the underlying cause, and whether 
other organ systems are affected 9-11.  In addition, the criterion for the presence of 
bilateral infiltrates on chest radiography is not sufficiently specific to be applied 
uniformly by experienced clinician 12, 13.  The PaO2/FiO2 relationship cannot be precise, 
Consensus Definition of ALI/ARDS by the 
American–European Consensus Conference (AECC)                            
1994, Bernard et al 8 
Acute onset of respiratory failure 
Bilateral infiltrates on chest radiograph 
Absence of left atrial hypertension (pulmonary artery occlusive pressure* [PAOP] ≤ 18 
mm Hg) or no clinical evidence of left atrial hypertension 
Hypoxemia, defined as PaO2/FIO2 ≤ 300 (ALI) or ≤ 200 (ARDS) mmHg † 
* If available.  There is no consensus mandating pulmonary artery catheter insertion in suspected 
ALI/ARDS unless otherwise clinically indicated. 
† PaO2 = partial pressure of arterial oxygen (in mm Hg), 
FIO2 = fraction of inspired oxygen (in decimal fraction (eg, 0.5)). 
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because it can vary when the FiO2 and/or other parameters of ventilatory support are 
modified 14, 15.  Esteban et al. compared these accepted clinical criteria with post-
mortem examinations of the lungs of patients with ARDS, and found that the definition 
of ARDS given by the  American–European Consensus Conference Committee had a 
moderate ability to identify patients with ARDS defined by pathology (sensitivity = 75% 
y specificity = 84%) 16. 
 
Nevertheless, the widespread acceptance of the 1994 consensus definition facilitates 
the early identification of patients with ARDS in the clinical setting 7, particularly those 
who would benefit from mechanical ventilation with low tidal volumes 17, and it also 
permits a better standardization of clinical research and trials. 
 
 
4.1.2.   EPIDEMIOLOGY AND SOCIAL RELEVANCE OF ACUTE LUNG INJURY 
 
4.1.2.1.   Incidence 
 
ALI/ARDS is a cause of acute respiratory failure that develops in patients of all ages 
from a variety of clinical disorders, including pneumonia (bacterial, viral, and fungal), 
sepsis (pulmonary and nonpulmonary), aspiration of gastric and oropharyngeal 
contents, major trauma, and several other clinical disorders including severe acute 
pancreatitis, drug over dose, and transfusion of blood products 18, 19.  Most patients 
require assisted ventilation with positive pressure. 
 
The exact incidence of ALI/ARDS has been difficult to estimate because of the 
absence of a common definition, and the wide variety of causes and coexisting 
diseases.  The National Institutes of Health (NIH) first estimated the incidence at 75 per 
100,000 persons in 1977 20.  Since then, a number of studies reported lower incidences 
21.  For example, in the late 1980s and early 1990s, studies found relatively low ARDS 
incidence rates (1.5 to 8.3 cases per 100,000 population per year) 22-24.  However, from 
1997 onward, studies using the more liberal AECC criteria found higher incidence rates 
(4.9 to 75 cases per 100,000 population per year) 25-28.  In particular, a study by the 
National Heart, Lung and Blood Institute-sponsored ARDS Network of 20 hospitals 
estimated that the incidence of ALI/ARDS could be as high as 64 cases per 100,000 
persons per year; not far off from the original NIH estimate.  This dataset has the 
R. Herrero                                                  INTRODUCTION – Generalities of acute lung injury 
 
13 
 
advantage of being prospectively collected from a large number of academic medical 
centers 29. 
 
4.1.2.2.   Mortality 
 
Until recently, the fatality rate of ARDS was considered to exceed 50% 5, 30, 31.  The 
majority of deaths are caused by sepsis or multiorgan dysfunction rather than primary 
respiratory failure 4, 5, 9, 10, 28, 32, however, the therapeutic success of ventilation with low 
tidal volumes indicates that in some cases death is directly related to lung injury 30, 33.  
Recent epidemiologic data indicate that ARDS may account for 73,000 deaths per year 
in a country the size of the U.S. 25.  Although there is evidence that mortality in patients 
with ALI/ARDS may have declined over the last 10 to 15 years, it remains high (30-
40%), and it is an important cause of pulmonary and nonpulmonary morbidity in 
patients who leave the hospital 34-37.  Possible reasons for the decrease in mortality 
include more effective treatments for sepsis, changes in the method of mechanical 
ventilation, and improvement in the supportive care of critically ill patients.  This 
decrease in mortality suggests that there are additional opportunities to improve 
outcomes in ALI/ARDS if we can increase our knowledge at the basic, translational, 
and clinical levels. 
 
 
4.1.3.   ETIOLOGY AND RISK FACTORS 
 
ALI/ARDS is caused by a multitude of disorders that directly or indirectly injure the 
lungs (Table 4.2) 38.  The most common cause of direct lung injury is pneumonia which 
may be of bacterial, viral or fungal origin.   Sepsis is the most common cause of indirect 
lung injury with an overall risk of progression to ALI or ARDS of 30% to 40%38, 39 40, 41.  
Severe trauma with shock and multiple transfusions are also important predisposing 
conditions to indirect lung injury 42-47.  Multiple clinical conditions are considered to be 
risk factors for the development of ALI/ARDS.  The most frequently encountered 
clinical risk factors include severe trauma (particularly lung contusion, fat emboli from 
long bone fractures), acute pancreatitis, aspiration of gastric contents, multiple 
transfusions of blood products, especially of fresh-frozen plasma, high net fluid balance 
48, cardiopulmonary bypass, shock and the systemic inflammatory response syndrome 
(SIRS), near-drowning, burns and disseminated intravascular coagulation (DIC) 19, 38, 45, 
R. Herrero                                                  INTRODUCTION – Generalities of acute lung injury 
 
14 
 
49.  When more than one of these clinical risk factors are present, the likelihood of 
ARDS is greater than just the sum of the collective risk factors 40.  Physiological risk 
factors for ARDS include metabolic acidosis, hypoalbuminemia and low respiratory 
compliance 50-52. 
 
The risk of developing acute lung injury also depends on patients’ characteristics, such 
as pre-existing chronic illness, particularly chronic lung diseases 51, postoperative state, 
alcoholism 53, malnutrition, advanced age, morbid obesity and cigarette smoking54, 55.  
To some extent, every patient in the ICU is at risk for the development ALI/ARDS. 
 
Table 4.2. 
Clinical Conditions Associated with Development of 
Acute Respiratory Distress Syndrome 
Direct Lung Injury  Indirect Lung Injury  
Common causes 
Pneumonia 
Aspiration of gastric contents 
Common causes 
Sepsis  
Severe trauma 
Less common causes 
Pulmonary contusion 
Fat embolism 
Near-drowning 
Inhalation injury  
Reperfusion pulmonary edema post lung 
transplantation or pulmonary embolectomy 
Lung transplantation 
Diffuse alveolar hemorrhage 
   
   
Less common causes 
Acute pancreatitis 
Cardiopulmonary bypass 
Massive blood transfusion (>15 U) (TRALI)* 
Drug overdose (eg, aspirin, cocaine, opioids, 
phenothiazines, tricyclics) 
Disseminated intravascular coagulation (DIC) 
Bone marrow transplantation  
Burns 
Radiographic contrast (rare) 
Stroke or seizure (neurogenic pulmonary edema) 
Organ transplantation (specially when transplant 
rejection occurs) 
Adapted from Ware LB and Matthay MA: The acute respiratory distress syndrome.  N Engl J Med 2000; 342(18):1334–1349. 
*TRALI= Transfusion related acute lung injury 
 
It is not clear whether the distinction between direct (pulmonary) and indirect 
(extrapulmonary) lung injury is clinically useful.  Some investigators have demonstrated 
reduced respiratory system compliance in patients with ARDS due to direct pulmonary 
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injury as compared with the indirect causes, although total respiratory system 
compliance (including the chest wall) is similar.  Patients with direct lung injury may be 
more likely to have improved lung mechanics with application of positive end-expiratory 
pressure (PEEP).  However, in the largest cohort of patients studied there was no 
difference in mortality between those with direct and indirect causes of lung injury 56 57, 
58 The outcomes are similar in both categories if age, underlying chronic illnesses, and 
severity of non-pulmonary illness and gas-exchange abnormalities are controlled for 57, 
59, 60.   Regardless of the underlying cause of ALI/ARDS most patients with ALI/ARDS 
appear to have a systemic inflammatory response syndrome (SIRS), which can lead to 
multiorgan dysfunction 61.   
 
The identification of risk factors to develop ALI/ARDS is very important to initiate early 
treatments and to prevent the progression of lung damage in patients with high risk.  In 
recent years, new risk factors have been described, for example the infection of the 
virus of the Severe Acute Respiratory Syndrome (SARS) 62 and the ventilator-inducing 
lung injury (VILI) when conventional parameters of ventilation are used (high tidal 
volume, peak pressure > 30 cmH2O and PEEP > 5 cmH2O) 33, 63.  Development of new-
onset ARDS is a relatively common complication (152 of 798 patients) in those 
receiving mechanical ventilation for ≥ 48 h in the ICU 50.  High airway pressure and tidal 
volume were the most important ventilator-associated risk factors for the development 
of new ARDS 50. 
Recent data now suggest the possibility of a genetic predisposition that influences sus-
ceptibility to ALI/ARDS.  In sepsis, trauma, and other triggering conditions, only a 
subset of patients develops ALI/ARDS even among those in whom the pathologic 
stimuli are apparently equivalent, suggesting that there are genetic features that may 
influence its onset.  There is suggestive evidence for genetic variations in ALI/ ARDS 
and in predisposing conditions such as sepsis.  Polymorphisms in genes related to 
inflammatory markers (tumor necrosis factor alpha, surfactant proteins, interleukin-6, 
IL-1RA), angiotensin converting enzyme, and pathogen receptors (CD14, toll-like 
receptors) appear to correlate with incidence and/or outcome of sepsis 64, 65 66, 67 and/or 
ALI/ARDS 68, 69.  These observations were based on case-control association studies.  
Family-based association studies and case-controlled association studies may be 
beneficial to explore in well-defined subgroups of patients with ALI/ARDS.   
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4.1.4.   CLINICAL MANIFESTATIONS AND DIAGNOSIS 
 
In the majority of patients, the initial diagnosis of ALI/ARDS is made following clinical 
criteria because currently there is no laboratory test that determines the presence or 
absence of ALI/ARDS.  Once diagnosed, testing to identify the underlying cause is 
required.  Symptoms and signs are nonspecific and typically develop within 24 to 48 h 
of initial injury or illness.  Dyspnea is the primary symptom, occasionally accompanied 
by cough or chest pain.  Signs invariably include tachypnea and tachycardia.  
Accessory muscle use, cyanotic skin, and abnormal breath sounds (crackles, rhonchi, 
and/or wheezes) may be present.  ALI/ARDS is suspected when dyspnea and 
respiratory insufficiency rapidly develop in settings that predispose to ARDS, and 
requires the acute onset of bilateral radiographic infiltrates.  Although the presence of 
bilateral infiltrates is a hallmark of ALI/ARDS, the radiographic findings are not specific.  
A similar clinical presentation can result from acute heart failure and from bilateral 
pulmonary infections.  All patients should have arterial blood gases (ABGs) and a chest 
x-ray.  The diagnosis is confirmed by demonstration of hypoxemia and widespread 
chest x-ray infiltrates in the absence of clinical or manometric signs of left atrial 
hypertension.  According to the AECC criteria, the pulmonary artery wedge pressure 
(PAWP) should be less than or equal to 18 mm Hg if measured (a PAOP > 20 mm Hg 
suggests heart failure or hypervolemia) but this measurement is not foolproof because 
ALI/ARDS can be complicated by volume overload, severe hypoproteinemia or heart 
failure with concomitant increases in the left atrial pressure 7, 12, 70, 71. 
Invasive techniques for diagnosis have limited clinical utility and the benefits rarely 
outweigh the risk.  In the past, open lung biopsy was obtained more frequently for 
diagnosis.  Interestingly, the degree of histologic abnormality on lung biopsy did not 
correlate with ultimate outcome as measured by pulmonary function.  Open or 
thoracoscopic lung biopsy may still be useful in some cases where the diagnosis is 
uncertain and the underlying cause in not apparent.  Occasionally unsuspected 
diagnoses requiring specific therapy can be made such as miliary tuberculosis, 
pulmonary blastomycosis, eosinophilic pneumonia, or bronchiolitis obliterans 
organizing pneumonia 72, 73.  Bronchoscopy also has a limited role in diagnosis and 
may be most useful in the immunocompromised host.  Bronchoalveolar lavage (BAL) 
for cultures and cytologic examination can identify the cause of pneumonia and is 
particularly useful in the diagnosis of opportunistic infections 74.  Bronchoalveolar 
Lavage fluid (BAL) usually has a predominance of neutrophils and there may be 
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evidence of diffuse alveolar hemorrhage.  When the cause is still uncertain, cytologic 
examination of BAL fluid can be used to confirm the presence of diffuse alveolar 
damage, malignancy or other disorders75, 76-78. 
 
4.1.4.1.   Early phase of ALI/ARDS 
 
Clinically, the acute phase is manifested by the acute onset of radiographic infiltrates 
consistent with pulmonary edema, hypoxemia and increased work of breathing.  The 
chest x-ray shows bilateral infiltrates (by definition), symmetrical or asymmetrical, that 
can be patchy or diffuse, and fluffy or dense.   Chest computed tomographic (CT) 
imaging, although rarely of use clinically, has been employed as an investigative tool to 
better define the nature of the infiltrates in patients with ALI/ARDS.  The distribution of 
infiltrates by CT is very patchy; areas of alveolar filling and consolidation occur 
predominantly in dependent lung fields (dorsal caudal in supine patients) with 
interlobular septal thickening, and often small pleural effusions 79, 80, 81.  The 
nondependent regions can appear relatively spared.  Even areas that appear spared in 
radiographic images may have substantial inflammation when sampled using 
bronchoalveolar lavage 82. 
 
The hypoxemia that characterizes early ALI/ARDS is usually relatively refractory to 
supplemental oxygen because the pathophysiology involves shunting of blood through 
areas of unventilated lung.  The increased work of breathing in the acute phase of 
ALI/ARDS is due to decreased lung compliance as a result of alveolar and interstitial 
edema combined with increased airflow resistance 81.  The combination of hypoxemia 
and increased work of breathing usually necessitates endotracheal intubation and 
mechanical ventilation, although occasionally patients can be managed with 
noninvasive ventilation. 
 
4.1.4.2.   Late fibroproliferative phase of ALI/ARDS 
 
In most patients, ALI/ARDS will resolve after the acute phase.  However, in others a 
fibrosing alveolitis becomes clinically apparent after 7 to 10 days, although evidence of 
deposition of extracellular matrix has been identified in alveolar lining fluid from patients 
as early as the first day after intubation 83, 84.  Radiographically, reticulonodular and 
ground-glass opacities with honeycombing and/or bullae are apparent on chest x-ray 
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and CT consistent with the evolving fibrosis.  Histologically, pulmonary edema and 
neutrophilic inflammation are less prominent.  A severe fibroproliferative process fills 
the airspaces with granulation tissue that contains extracellular matrix rich in collagen 
and fibrin as well as new blood vessels and proliferating mesenchymal cells 81, 85. 
 
Clinically the late fibroproliferative phase of ALI/ARDS is characterized by continued 
need for mechanical ventilation often with persistently high levels of PEEP and FiO2.  
The lung compliance may fall even further and pulmonary dead space is elevated 81, 85.  
Pulmonary hypertension may develop due to obliteration of the pulmonary capillary bed 
and right ventricular failure may occur 86.  A prolonged stage of fibrosing alveolitis can 
make weaning from the mechanical ventilation difficult. 
 
4.1.4.3.   Resolution of ALI/ARDS 
 
Lung biopsy samples from ALI/ARDS survivors typically show normal or near-normal 
lung histology.  For a complete histological resolution of ALI/ARDS, a variety of 
processes must be reversed.  Alveolar edema is actively reabsorbed by the vectorial 
transport of sodium and chloride from the distal airway and alveolar spaces into the 
lung interstitium.  Water is passively absorbed along the osmotic gradient, through 
water channels, the aquaporins.  The majority of patients with early ALI/ARDS have 
impaired alveolar transport 87-91. Faster rates of alveolar epithelial fluid transport are 
associated with a better outcome 92.  Soluble and insoluble protein must also be 
cleared by lymphatics.  Insoluble protein is most likely cleared by macrophage 
phagocytosis or alveolar epithelial cell endocytosis and transcytosis 93, 94. 
 
The denuded alveolar epithelium must be repaired 91.  The alveolar epithelial type II cell 
serves as the progenitor cells for repopulating the alveolar epithelium.  Alveolar 
epithelial type II cells proliferate migrate and differentiate to reconstitute a tight alveolar 
epithelial type I cell barrier87 38.  The inflammatory cell infiltrate must also resolve, but 
here the mechanisms are less clear.  Resolution of neutrophil inflammation may be 
predominant via neutrophil apoptosis and phagocytosis by macrophages.  However, 
neutrophil apoptosis is impaired in the lungs of patients with ALI/ARDS 95, 96.  The 
resolution of fibrosis is also unclear.  In patients with advanced fibrosis, resolution 
takes place over many months as pulmonary abnormalities improve 97, 98.   
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4.1.5.   HISTOLOGICAL FEATURES OF ALI/ARDS 
 
ALI/ARDS is a progressive syndrome characterized by distinct stages:  exudative (or 
acute), and fibroproliferative phases, which have different histopathological 
manifestations.  The course of each phase and the overall disease progression is 
variable.  The exudative phase includes diffuse alveolar damage with alveolar flooding 
by protein-rich edema fluid, neutrophil influx and hemorrhage into the alveolar space, 
loss of alveolar epithelial cells, deposition of hyaline membranes on the denudated 
basement membrane, and formation of microthrombi 99 38.  Alveolar flooding occurs as 
a result of injury to the alveolar-capillary barrier, which is formed by two separate cell 
layers: the microvascular endothelium and the alveolar epithelium.  Ultrastructural 
studies reveal a vacuolization and swelling of the vascular endothelium 38.  This 
endothelial damage is associated to a procoagulant tendency responsible for the 
formation of capillary thrombosis 100, 101.  Despite this widespread endothelial damage, 
the hallmark of this syndrome is the disruption of the alveolar epithelium, which is a 
major determinant of the hypoxemia and altered lung mechanics that characterize early 
ALI/ARDS 87.  Damage of the epithelial barrier exacerbates the tendency for alveolar 
flooding, and delays recovery by impairing fluid clearance.  Type I alveolar cells are 
irreversibly damaged and the denuded space is replaced by the deposition of proteins, 
fibrin, and cellular debris, producing hyaline membranes, while injury to the surfactant-
producing type II cells contributes to alveolar collapse 91, 102-107.  The alveolar flooding in 
ALI/ARDS is characteristically with a protein-rich edema fluid due to the increased 
permeability of the alveolar capillary barrier, in contrast to the low protein pulmonary 
edema that results from hydrostatic causes such as congestive heart failure or acute 
myocardial infarction 99, 108, 109. 
 
Although ALI/ARDS may resolve completely in some patients after the acute phase, in 
others it progresses to a fibroproliferative phase 85, 109, 110.  It is characterized by 
reepithelialization of the epithelial barrier by the proliferation of the alveolar type II cells.  
In the alveolar wall, fibroblasts also proliferate and migrate through the basement 
membrane into the fibrinous intra-alveolar exudate.  In some patients, this progresses 
to an irreversible fibrosis of the lung involving collagen deposition in alveolar, vascular, 
and interstitial beds111-113, 114.    
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4.1.6.   TREATMENT AND CLINICAL COMPLICATIONS 
 
Improvement in the supportive care of patients with ALI/ARDS, particularly the use of a 
lung protective ventilatory strategy, has contributed to reducing the mortality rate.  
However, despite numerous randomized controlled clinical trials, there is no specific 
treatment for ALI/ARDS, aside from reducing tidal volume and using a conservative 
fluid strategy. 
 
4.1.6.1.   Treatment of predisposing factors 
 
A search for the underlying cause of ALI/ARDS should be undertaken.  Appropriate 
treatment for any precipitating infection such as pneumonia or sepsis is critical to 
enhance the chance of survival.  Abdominal infection should be treated promptly with 
antimicrobial agents or surgery. 
 
4.1.6.2.   Basic management  
 
4.1.6.2.1.   Prevention of common complications  
 
During the course of ALI/ARDS, the patients can undergo multiple complications, most 
of which are preventable.  Common complications include deep venous thrombosis 
and pulmonary embolism, stress-related gastrointestinal hemorrhage, ventilator 
associated pneumonia and nosocomial infections, metabolic abnormalities, 
polyneuropathy and malnutrition.  Anticipation and prevention of these complications is 
vitally important 32, 49.  Prevention of gastrointestinal bleeding and thromboembolism is 
also very important 115.   
 
4.1.6.2.2.   Nutrition 
 
Many lines of evidence favor the provision of adequate nutrition in critically ill patients.  
The enteral route is preferred to the parenteral route and is associated with less 
infectious complications.  Enteral feeding also has other beneficial effects.  The use of 
enteral nutrition is also important to prevent stress-related gastrointestinal bleeding and 
to maintain the normal barrier function of the gastrointestinal mucosa.  Loss of the 
gastrointestinal barrier function has been associated with the translocation of bacteria 
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and/or toxins into the mesenteric lymph nodes and portal circulation which perpetuates 
the injury process 116.  In normal volunteers, administration of parenteral nutrition with 
bowel rest increased circulating levels of tumor necrosis factor-alpha, glucagon, and 
epinephrine and increased febrile responses compared with volunteers who received 
enteral nutrition 117-119.   
 
The goal of the nutritional support includes providing adequate nutrients and the 
treatment of any deficiencies in micronutrients or macronutrients.  Whether a particular 
dietary composition could be beneficial in patients with ALI/ARDS is unclear.  In an 
attempt to improve the immune response, a diet containing a combination of omega-3 
fatty acids, ribonucleotides, arginine and glutamine has been used.  A meta-analysis of 
these trials suggested a beneficial effect on infection rate but not overall mortality.  One 
randomized controlled trial in patients with ALI/ARDS has tested a diet rich in fish oil, 
gamma-linoleic acid and antioxidants; this diet was associated with shorter duration of 
mechanical ventilation and fewer organ failures, but no difference in mortality was 
observed.  Overall, there is still no compelling evidence to support the use of anything 
other than standard enteral nutritional support with avoidance of overfeeding, in 
patients with ALI/ARDS to maintain the proper level of immune function and prevent 
malnutrition 116-118, 120.   
 
4.1.6.3.   Fluid and hemodynamic management 
 
Controversy also surrounds the management of volume status and hemodynamics in 
patients with ALI/ARDS.  A theoretical case can be made for aggressive diuresis, in an 
effort to reduce the formation of pulmonary edema.  Indeed, in experimental lung injury, 
lower left atrial pressures are associated with less formation of pulmonary edema.  
Several studies have reported increase survival associated with low pulmonary 
capillary occlusion pressure in the setting of ALI/ARDS 121-123.  However, reduction in 
intravascular volume can have adverse effects on cardiac output and tissue perfusion, 
factors that can contribute to multiple organ failure.  This is a legitimate concern, 
because mortality in ALI/ARDS is usually from nonpulmonary causes including other 
organ failures.  This concern led to additional studies from the ARDS Network to 
evaluate liberal versus conservative fluid replacement strategy (FACTT trial) 124.  The 
liberal fluid management arm had an average net again of almost 7 L over the first 7 
days after the initial 24 hr of volume resuscitation, whereas the conservative fluid 
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management group averaged a loss of 136 mL over the same period of time.  The use 
of a conservative fluid management strategy was associated with a significant 
improvement in oxygenation index and lung injury score and increased the number of 
ventilator-free days compared with the more liberal strategy.  There was no difference 
in the development of shock or the need for renal replacement therapy between the 
two fluid management strategies 125.   In addition, this trial also evaluated the utility and 
safety of using a pulmonary artery (PA) catheter to guide the volume replacement 
versus a central venous catheter in 1000 patients with established ALI.  There was no 
difference in the fluid replacement but the pulmonary artery group did have twice as 
many catheter-related complications, predominantly in the form of arrhythmias, 
compared with the central venous catheter group 126.  In the study by Marty et al., 
human serum albumin was used to support vascular volume while diuresis was 
simultaneously accomplished using furosemide to reduce lung edema.  In this pilot 
randomized clinical trial (n-37), such treatment produced transient improvements in 
oxygenation without compromising the circulation, although more studies are needed to 
evaluate the ultimate outcome 127.  Besides the controversies, a reasonable strategy is 
to achieve the lowest intravascular volume that maintains adequate tissue perfusion as 
measured by urine output or other organ perfusion and metabolic acid-base status.  If 
organ perfusion cannot be maintained in the setting of adequate intravascular volume, 
then administration of vasopressors and/or inotropes should be used to restore end-
organ perfusion 128. 
 
4.1.6.4.   Mechanical ventilation 
 
Over the past decade there has been increasing recognition that the ventilatory support 
strategy used in the management of patients with ALI/ARDS may produce or augment 
lung injury and/or impair the healing process 129.  These fears initially arose from the 
results of experimental animal studies that demonstrated clinical, physiological, and 
histological evidence of lung injury, similar to that observed in patients with ARDS, 
when the animals were ventilated with large tidal volumes or were given high inflation 
pressures.  The alveolar overdistension produced by these ventilatory modes was felt 
to be the critical element in production of the lung injury 130.  Lung injury could result 
form the administration of large volumes or the administration of positive or negative 
pressure breaths (termed volutrauma).  Other mechanisms that could potentially result 
in lung injury were the repetitive recruitment-derecruitment of distal airways and alveoli 
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(termed atelectotrauma) and/or the disruption of alveoli resulting in translocation of 
organisms or air emboli 131-134.  Alveolar overdistention can also give rise to systemic 
inflammatory molecules that may contribute to the SIRS response and drive the 
development of MODS/MOF 135-137.  This has been termed biotrauma.  A multicenter 
trial of low versus large tidal volume ventilation in patients with ALI/ARDS 
demonstrated increased proinflammatory cytokines in the serum and bronchoalveolar 
lavage fluid of patients ventilated with large traditional tidal volumes, supporting the 
concept of biotrauma from alveolar overdistention 135, 138-141.  Interestingly, the lung 
injury produced by high inflation pressure or large tidal volumes in these experimental 
models could be ameliorated by the addition of therapeutic amounts of PEEP 142.     
 
Although historically a tidal volume of 12 to 15 mL/kg was recommended in patients 
with ALI/ARDS, it is now clear that a low tidal volume reduces mortality.  The NIH 
ARDS Network published the findings of their first randomized, controlled, multicenter 
clinical trial in 861 patients 143.  The rationale for this trial was the growing clinical and 
experimental evidence suggesting that mechanical ventilation with high tidal volumes 
and high plateau pressures might be harmful to the injured lung.  The trial was 
designed to compare a low tidal volume ventilatory strategy (6 ml/kg predicted body 
weight, plateau pressure less than 30 cm H2O) with a higher tidal volume (12 mL/kg 
predicted body weight, plateau pressure less than 50 cm H2O).  The in-hospital 
mortality rate was 40% in the 12 mL/kg group and 31% in the 6 mL/kg group, a 22% 
reduction (p=0.007).  This was the first clinical trial to demonstrate a mortality benefit of 
this lung protective ventilatory strategy.  A significant difference occurred in the length 
of hospital stay between the low and high tidal volume groups.  The use of lower tidal 
volumes typically results in a controlled hypoventilation or permissive hypercapnia and 
can lead to hypercapnic acidosis.   A rise in the respiratory rate is usually sufficient to 
compensate for the decreased tidal volume; a rate as high as 35 breaths/min was used 
in the clinical trial 33.    
 
Some experimental animal models of lung injury suggest that hypercapnic acidosis 
may be beneficial to the lung and produce less lung injury as measured by 
extravascular lung water 144.  The PEEP is also a major component of the ventilatory 
support strategy for the patient with ALI/ARDS.  In fact, PEEP may have a direct 
therapeutic role in the prevention of ventilator-induced lung injury, as noted in some of 
the experimental models of ventilator-inducing lung injury (VILI).  The use of PEEP has 
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assisted in the recruitment of atelectatic lung units, prevented recruitment-
derecruitment, increased the functional residual capacity (FRC), decreased the shunt 
fraction, and allowed for a reduction to a less toxic FiO2, while still maintaining 
adequate oxygenation saturation and tissue oxygen delivery 142.  All these protective 
ventilatory strategies were associated with decreased serum cytokine and chemokine 
levels 145, decreased levels of organ dysfunction, and decreased mortality in patients 
with ARDS 146. 
 
During mechanical ventilation, some patients have significant dyssynchrony with the 
ventilator.  Increasing the inspiratory flow rate and, if necessary, the level of sedation is 
usually sufficient to manage these problems.  Patients with severe refractory 
hypoxemia not responding even to a FiO2 of 1.0 and a PEEP level of 24 cm H2O or 
more will require deeper sedation and neuromuscular blockade, although the latter 
must be considered a rescue therapy as it can increase the risk of polyneuropathy and 
myopathy 147. 
 
4.1.6.5.   Non-invasive ventilation 
 
Non-invasive positive-pressure ventilation delivered by nasal or full facemask has been 
successful in avoidance of intubation in patients with exacerbation of chronic 
obstructive pulmonary disease (COPD).  The role for non-invasive ventilation in 
ALI/ARDS is less clear.  In one large had a failure rate of 30% for 354 patients who 
were not already intubated, and 51% for the patients with ARDS 148.  It seems likely 
that the majority of patients with ALI/ARDS will still require invasive mechanical 
ventilation. 
 
4.1.6.6.   Inhaled Nitric Oxide 
 
Inhaled nitric oxide is a potent endothelium derived relaxing factor of the bronchial and 
vascular smooth muscle reported to decrease platelet adherence and have anti-
inflammatory properties.  It has been shown to increase oxygenation by improving 
blood flow to well-ventilated areas and decrease intrapulmonary shunting in the lung.  
A reduction in pulmonary arterial pressure and pulmonary vascular resistance also 
occurs, and has minimal systemic effects 149.  Phase II and III trials with inhaled nitric 
oxide alone in patients with ARDS showed mild and transient improvement in 
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oxygenation but failed to demonstrate improvement in mortality or reduction in 
ventilator days 150, 151. 
 
4.1.6.7.   Surfactant replacement therapy 
 
Surfactant abnormalities are present in patients with ALI/ARDS related to decreased 
production of surfactant products, inactivation by alveolar proteins and proteolytic 
enzymes, and dilution by the alveolar fluid.  Anzueto et al. reported that the surfactant 
replacement did not result in any difference in hemodynamic function, oxygenation, 
mechanical ventilation-free days and survival in 725 patients with ARDS caused by 
sepsis who were prospectively randomized into surfactant versus placebo groups 152.  It 
was suggested that the absence of surfactant proteins might account for the lack of 
efficacy.  Trials are continuing evaluating surfactant proteins.  A small clinical trial 
evaluating recombinant surfactant protein C replacement in patients with ARDS noted 
an improvement in oxygenation but no survival benefit 153. 
 
4.1.6.8.   Enhance edema clearance 
 
Accumulated fluid in the alveolus could potentially worsen the gas exchange, as well as 
produce adverse pulmonary mechanics with an increased work of breathing.  Recent 
strategies have been designed to improve the edema fluid clearance either using 
aquaporins or increasing the activity of the Na/K pump 154-161.  Studies in rats 
demonstrated that a β2-adrenergic agonist can enhance the clearance of lung edema 
and improve oxygenation in the resolution phase of hydrostatic pulmonary edema 155.  
In isolated perfused rat lungs, there was also a significant increase in fluid clearance 
with administration of isoproterenol or dopamine.  In a recent study of the potential 
therapeutic value of β2-adrenergic agonist therapy for the treatment of acid induced 
lung injury in rats, they found that salmeterol, a β2-adrenergic agonist given via the 
airspaces, reduced lung edema by both attenuating lung vascular injury and 
upregulating the clearance of alveolar edema fluid 105. From a practical perspective, it 
seems that the potential benefit of β2-adrenergic therapy would be achieved with 3 to 4 
days of treatment, a time period during which a significant downregulation to the 
aerosolized agonist seems unlikely.  From a clinical perspective, aerosolized β2-agonist 
therapy has been shown to reduce the incidence of high-altitude pulmonary edema in 
subjects at-risk for developing lung injury.  A small clinical trial in the United Kingdom 
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has found that intravenous salbutamol, a β2-agonist, reduces extravascular lung water 
in patients with acute lung injury.   It may be reasonable to test the therapeutic value of 
aerosolized β2-adrenergic agonist therapy for patients with acute lung injury, 
particularly because one study demonstrated that therapeutic levels of a commonly 
used β2-agonist can be achieved in the pulmonary edema fluid in ventilated patients 
with standard aerosolization procedures 162. The evaluated the issue of intravenous 
beta-agonist (salbutamol) in patients with ALI and demonstrated a significant decrease 
in the extravascular lung water at day 7 163.  The salbutamol-treated group also had 
lower end-inspiratory plateau pressures.  This group had more supraventricular 
arrhythmias 163.  Further investigation is necessary to determine the benefit of edema 
clearance strategies in the management of ALI patients. 
 
4.1.6.9.   Corticosteroids 
 
A variety of treatment strategies have been investigated in large randomized trials with 
a predominant focus on anti-inflammatory strategies, particularly using glucocorticoids.  
However, glucocorticoids had no benefit when they given before the onset of the 
disease or early in its course 164, 165.  More recently, glucocorticoids have been used to 
treat the later, fibrosing-alveolitis phase of the disease. The use of corticosteroid 
rescue for the patients with persistent ARDS or in the fibroproliferative phase of ARDS 
was evaluated by the NIH-sponsored ARDS network.  They studied 180 patients with 
ARDS greater than or equal to 7 days into a placebo-controlled trial of 
methylprednisolone versus placebo.  The use of methylprednisolone was associated 
with early improvement in mortality, PaO2/FiO2 ratio, blood pressure, ventilator and 
ICU-free days.  An increase in white blood cell count and glucose level related to 
steroid administration occurred with a decrease in body temperature.  The steroid 
treatment was not associated with an increase in serious infection.  In fact, there was 
more pneumonia and septic shock seen in the placebo group than in the steroid-
treated group.  However, no difference was measured in the 60-day mortality or in the 
180-day outcome between two groups 166. For now, the use of rescue steroids remains 
controversial. A short course of corticosteroids could be used as rescue therapy in 
patients with severe disease that is not resolving. 
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4.1.6.10.   Anti-inflammatory and anticoagulant factors 
 
Ibuprofen, a non-steroidal anti-inflammatory drug, failed to improve the outcome of 
critically ill patients with sepsis or septic shock and failed to prevent the development of 
ARDS in a prospective, randomized, placebo-controlled, multicenter clinical trial 167 
 
There is evidence that, like sepsis, ALI/ARDS is a procoagulant, antifibrinolytic state.  A 
number of clinical trials evaluated the potential benefit of anticoagulant agents such as 
antithrombin III, activated protein C, and the tissue factor pathway inhibitor (TFPI) to 
prevent or treat the microthrombosis of the microcirculatory bed that occurs in sepsis 
and could result in ALI/ARDS as an early manifestation of MODS/MOF.  To date, this 
strategy has not been found to decrease the development of or improve the outcome of 
ALI/ARDS 168-170. 
 
Toxic oxygen radicals from the activated inflammatory cells are increased in the lungs 
of patients with ARDS.  The abundant production of toxic oxygen radicals may 
overwhelm the ability of the endogenous oxygen radical scavengers, superoxide 
dismutase (SOD), catalase, and the glutathione reductase cycle.  The administration of 
antioxidants such as N-acetylcysteine, procysteine, vitamine E, β-carotene, and vitamin 
C have been evaluated in the prevention and/or management of patients with ARDS.  
No survival benefit was seen associated with the administration of N-acetylcysteine or 
procysteine versus placebo in patients with ALI/ARDS 171 
 
Two published trials have demonstrated a significant reduction in the development of 
ARDS in surgical patients when ketoconazole, an imidazole thromboxane A2 
synthetase inhibitor, was administered to an at-risk population of patients.  When 
ketoconazole was used in patients with established ARDS, there was no benefit on 
survival 172.  More studies are needed to know the real effect of this drug on prevention 
of ALI/ARDS in at-risk patients 172. 
 
4.1.6.11.   Keratinocyte growth factor 
 
Keratinocyte grow factor (KGF) is a potent epithelial mitogen produced and secreted by 
stromal cells.  Epithelial cells express the KGF receptor and are the main target of this 
growth factor.  KGF is an important mediator of epithelial-mesenchymal interactions 
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and epithelial repair in multiple organ systems, including the skin, intestine, and 
bladder.  In animal models, pretreatment with KGF ameliorates experimentally induced 
acute lung injury 173, 174.  This protective effect was due to an improvement of the 
alveolar epithelial repair by increasing the proliferation and migration of alveolar type II, 
probably through stimulation of the epidermal growth factor receptor 175. Also, KGF 
seems to increase in the clearance rate of alveolar fluid 176, induce antioxidants 
effects177 and reduce lung endothelial injury 178. 
 
4.1.6.12.   Complications 
 
Complications are common in any critically ill patient population.  Support care and 
vigilance in both preventing and diagnosing common complications such as pulmonary 
embolism, acute myocardial infarction, gastrointestinal bleeding and nosocomial 
infection.   
 
4.1.6.12.1.   Barotrauma 
 
Barotrauma occurs when air dissects out the airways or alveolar space into 
surrounding tissues, leading to pneumothorax, pneumomediastinum, pneumatocele or 
subcutaneous emphysema.  The exact incidence of pulmonary barotrauma is unclear 
but appears to be declining.  In the NIH ARDS Network trial, approximately 10% of 
patients developed some form of barotrauma regardless of whether they were in the 6 
or 12 mL/kg tidal volume arm.  Furthermore, PEEP level was the only factor that 
predicted the development of barotrauma in a multivariate analysis 33.  Pneumothorax 
can be life threatening particularly if it is under tension, and immediate diagnosis and 
tube thoracostomy is essential.  Pneumomediastinum and subcutaneous emphysema 
can be painful but, other than analgesia, do not require specific therapy.  Air embolus is 
a potentially fatal complication that has been reported occasionally in patients with 
ALI/ARDS and usually occurs in conjugation with other evidence of pulmonary 
barotrauma, many times simultaneously 179. 
 
4.1.6.12.2.   Nosocomial pneumonia 
 
The estimate incidence of nosocomial pneumonia is 15 to 60% of patients.  Autopsy 
studies of patients dying with ALI/ARDS show a high incidence of unexpected 
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pneumonia 61, 180, 181.  The adequacy and timeliness of initial empirical therapy are 
important determinants of outcome.  Knowledge of local resistance patterns is crucial, 
and a high index of suspicion is required. 
 
4.1.6.12.3.   Multiple organ dysfunction syndrome 
 
A frequent complication of an exaggerated proinflammatory state in the setting of 
sepsis, systemic inflammatory response syndrome (SIRS) and ARDS is the 
development of organ systemic dysfunction.  This dysfunction may involve single or 
multiple organs.  The dysfunction of two or more organs is considered as multiple 
organ dysfunction syndrome (MODS), and it is the most common cause of death in the 
noncoronary intensive care units.  Organ dysfunction may result from the underlying 
cause of ALI/ARDS, such as sepsis, or occur independently, probably from an 
excessive systemic inflammatory response.  Multiple combinations of direct lung injury, 
ischemic injury, circulatory humoral or inflammatory mediators, translocation of 
endotoxin and/or colonic bacteria, altered rheologic properties of the blood cells, or the 
iatrogenic effects of the therapy administered may interact in the eventual production of 
MODS 182-184. 
 
4.1.6.12.4.   Neuromuscular weakness 
 
Patients with ALI/ARDS are at high risk for developing prolonged muscle weakness 
that persists after resolution of pulmonary infiltrates and can complicate weaning from 
mechanical ventilation and rehabilitation.  One study suggests that neuromuscular 
abnormalities are persistent in many survivors of critical illness, even when studied up 
to 5 years after ICU discharge.  Prolonged muscle weakness is more common in 
critically ill patients who are treated with glucocorticoids.  In other studies, 
neuromuscular blockade has also been implicated 97, 185. 
 
 
4.1.7.   PROGNOSIS 
 
Prior to the 1990s, mortality in clinical trials of patients with ALI/ARDS was 40% to 
60%.  The risk of in-hospital mortality was highest in those with sepsis (43%), 
intermediate in those with pneumonia (36%) or aspiration (37%) and lowest in those 
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with multiple trauma (11%).  Reported mortality from ALI/ARDS appears to be 
gradually declining.  The low tidal volume strategy was effective at reducing mortality 
across all causes of ALI/ARDS (31% in the 6 mL/kg tidal volume arm and 40% in the 
12 mL/kg tidal volume arm).  Factors that are associated independently with mortality 
from ALI/ARDS include age, septic and septic shock, acute physiology score, multiple 
organ failures, immunosuppression and chronic liver disease 4, 5, 10, 25.  Young trauma 
patients have the best outcomes 186.  Mortality is also associated with other underlying 
diseases such as HIV infection or cancer.  Patients with a higher severity of illness 
score are more likely to develop ALI/ARDS and die of lung injury.  Surprisingly, initial 
indexes of oxygenation and ventilation, including the PaO2/FiO2 ratio, PEEP and 
plateau pressure or gas exchange (PaCO2 and VE40) and the lung injury score do not 
predict outcome 4, 5, 10.  However, the failure of pulmonary function to improve during 
the first week of treatment is a negative prognosis factor 6, 187.  An elevated dead space 
fraction has also been shown to be an independent risk for death 188.  In cases of 
ARDS, death is usually caused by progressive multisystem organ failure rather than 
respiratory deterioration 189. 
 
Usually, survivors start to recover within two weeks of the onset of ARDS 189, however, 
they frequently have long-term functional disability.  Interestingly, pulmonary function 
returns to normal or near normal in survivors.  It has been reported in a one-year 
follow-up study of 109 survivors of ARDS, that lung volumes and spirometry returned to 
normal within 6 to 12 months, despite the severe injury to the lung 98, 190.   However, 
carbon monoxide diffusing capacity was persistently low at 12 months, largely due to 
muscle wasting and weakness rather than pulmonary function abnormalities.  Residual 
impairment of pulmonary mechanisms may include mild restriction, obstruction, 
impairment of the diffusing capacity of carbon monoxide, or gas-exchange 
abnormalities with exercises, but these abnormalities are usually asymptomatic 191-193.  
Severe disease and prolonged mechanical ventilation predict patients at highest risk for 
persistent pulmonary function alterations 98, 194.  Neuropsychologic testing may reveal 
significant deficits in patients who had more severe and protracted hypoxemia 195.  
Neuropsychiatric problems and neuromuscular weakness are now known to occur 
frequently and are the major limitation for these patients to regain their daily activities 
35, 97, 195, 196.  Patients who survived from ALI/ARDS have been reported to have both 
reduced health-related quality of life and reduced pulmonary disease-specific health-
related quality of life 35, 98, 196. 
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4.1.8.   FUTURE CONSIDERATIONS 
 
During the past 30 years, there has been considerable progress in standardizing the 
evaluation and management of this disease worldwide.  A better understanding of the 
pathophysiology has produced management strategies that have translated into 
evidence-based improvement in outcome.  Experimental studies are being conducted 
to evaluate the role of epithelial growth factors and beta-adrenergic agonists in 
reducing lung injury and hastening repair.  The growing knowledge of molecular biology 
and the elaborate mechanisms that govern an individual’s response to injury, repair 
and cell death will likely have a major role in the management of patients with 
ALI/ARDS.  Investigation into the role of gene mutations and gene polymorphisms has 
given insight into possible genetic susceptibility for the development and outcome of 
ARDS.  Individuals with increased risk for ALI and ARDS development will probably be 
identified on the basis of their genetic profile.  It is possible that in the future we may 
potentially modify the genetic makeup or the biologic response of a susceptible 
individual by inserting selected genes or modifying the transcription or function of 
various regulatory proteins 197. Proteomic technologies have the potential to identify 
each protein expressed in isolated cells or in complex tissues such as injured lung and 
also to determine posttranslational modifications, protein-protein interactions, and other 
critical features that define phenotype and regulate cellular function.  Proteomic 
approaches can provide physiologic relevance that is not inherent in measuring 
transcript levels and profiles in ALI/ARDS 198, 199.  Proteomic analysis of clinical samples 
may be useful in establishing molecular patterns that are characteristic of individual 
diseases or disease stages. 
Another approach for the future treatment of ALI/ARDS could involve stem cells to 
replace dying lung cells.  A similar strategy has been proposed for brain, heart, and 
liver diseases.  The inflammatory response includes release of cells from bone marrow, 
such as mature and immature neutrophils and stem cells.  Elegant bone marrow 
reconstitution studies have demonstrated that these stem cells have the potential to 
differentiate into endothelial, mesenchymal, and epithelial cells 200-202.  The proliferative 
potential of fully differentiated capillary endothelial cells and epithelial type I cells is 
very poor in the lungs.  The potential for stem cells to help in the repair of injured lung 
tissue has not been explored and requires a better understanding of stem cell release, 
targeting, proliferation, and differentiation in lung tissue.  Supplementing this release by 
intravenous infusion of donor bone marrow-derived stem cells might be useful in 
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ALI/ARDS, as the pulmonary microvasculature would be the first capillary bed that 
these cells would encounter, enhancing their entrapment and accumulation.  Newly 
implanted endothelial cells may help restore the lung capillary network after ALI, 
although considerable work will be needed to develop approaches for delivery of viable 
cells to injured areas of the lung 203, 204.   
As more strategies and drugs are developed, there is hope that control of this once 
fatal disease will be possible.  For now, treating the inciting cause, avoiding ventilator-
induced injury, managing fluids judiciously, and providing supportive care remain the 
cornerstones of management. 
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4.2.   PATHOGENESIS OF ALI/ARDS 
 
4.2.1.   GENERAL DESCRIPTION OF THE PATHOLOGICAL FEATURES OF 
ALI/ARDS 
 
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are 
syndromes with a spectrum of increasing severity of lung injury defined by physiologic 
and radiographic criteria in which widespread damage to cells and structures of the 
alveolar capillary membrane occurs within hours to days of a predisposing insult.  This 
syndrome is characterized by the influx of protein-rich edematous fluid into the 
airspaces due to increased permeability of the alveolar-capillary barrier.  The cells of 
the alveolar-capillary membrane together with cells of the innate immune and 
hemostatic systems are targets of damage and effectors of injury in ALI/ARDS 38.  The 
numbers and morphologic phenotypes of these cells are altered in development of 
ALI/ARDS and its progression or resolution 114.   
 
The first stage, the exudative phase, is an acute inflammatory response accompanied 
by a marked influx of neutrophils, and epithelial and endothelial cell injury.  The 
resulting death of epithelial type I cells invites a breakdown in the gas exchange and 
barrier function of the lung and is associated with the flooding of airspaces with protein-
rich edematous fluid with deposition of dense hyaline membranes.  Injury to type II 
epithelial cells reduces surfactant production and impairs the removal of edematous 
fluid from the alveolar space and favor alveolar collapse.  Endothelial injury leads to a 
widening of cellular junctions and capillary membrane disruption, producing capillary 
leakage and edema.  The proliferative phase is characterized by type II cell 
proliferation with relining of the denuded basement membrane.  This is accompanied 
by ingrowth of mesenchymal cells, such as fibroblasts, into granulation tissue, followed 
by the deposition of collagen and the migration of epithelial cells over the surface of 
organizing granulation tissue.  Some patients have an uncomplicated course and the 
disorder rapidly resolves; however, insufficient repair leads to the fibrotic phase, which 
is identified by the deposition of excess collagen and extracellular matrices mainly in 
the alveolar wall 38, 114. 
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4.2.1.1.   Lung epithelial injury 
The important role of the alveolar epithelial barrier in the pathogenesis and resolution 
of ALI/ARDS has been increasingly appreciated, including its role in the production of 
surface-active material to maintain alveolar stability as well as in the resolution of 
alveolar edema 107.  The classic ultrastructural studies of Baclofen and Weibel show 
that epithelial damage was more prominent than endothelial damage in patients who 
died with ARDS 85, 205.  As the epithelium is exposed to the external environment, it is a 
target for injury and infection.  However, our understanding of the responses of the 
alveolar epithelium to injury remains incomplete. 
Disruption of alveolar epithelial integrity is a major contributor to increased permeability 
and alveolar flooding with protein-rich edema fluid, a hallmark of ALI/ARDS 82, 107, 110.  
The formation and the resolution of protein-rich pulmonary edema is determined by 
several mechanisms, including lung vascular pressure, lung endothelial and epithelial 
permeability to protein, and the capacity of the alveolar epithelium to effectively remove 
alveolar edema fluid and the alveolar proteins.  The level of alveolar fluid clearance 
(AFC) impairment has significant prognosis value in determining morbidity and 
mortality.  Increased alveolar epithelial and endothelial protein permeability, another 
significant characteristic of ALI/ARDS, can influence the resolution of pulmonary 
edema.  Loss of the epithelial barrier can also lead to septic shock in patients with 
bacterial pneumonia 206.  The alveolar epithelium not only plays a role in the 
pathogenesis but also in the resolution of acute respiratory distress syndrome (ARDS) 
82, 107, 206.  If the alveolar epithelium damage is severe, disorganized or insufficient 
epithelial repair may lead to fibrosis 112. 
 
4.2.1.1.1.   General features and functions of the alveolar epithelium 
 
The alveolar epithelium not only exerts a barrier function, but also regulates the water 
and solute content of the fluid lining the epithelium at the air–liquid interface.  
Regulation of this fluid layer constitutes an essential component of both homeostatic 
gas exchange and host defense against infection 207, 208.   Under normal conditions, the 
epithelial barrier is much less permeable than the endothelial barrier 107.  The normal 
alveolar epithelium is composed of two types of cells.  Flat type I epithelial cells make 
up 90 percent of the alveolar surface area and are easily injured 209.  They serve 
primarily a barrier function, but are metabolically active, participating in host defense, 
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alveolar remodeling and antioxidant functions 210, 211.  Cuboidal type II epithelial cells 
are smaller, make up the remaining 10 % of the alveolar surface area and are more 
resistant to injury.  They are readily recognized by their characteristic lamellar 
inclusions.  These inclusions are the predominant intracellular storage form of surface 
active material.  Physiologic functions of type II cells include: 1) synthesis, storage, and 
secretion of surface active material; 2) differentiation into alveolar type I cells after 
injury; 3) hyperplasia and adaptation after lung injury; 4) secretion of non-surfactant 
proteins; 5) transport of fluid and electrolytes from the alveolar space into the 
interstitium, and 6) immune functions 1, 156, 205, 212, 213.  The loss of epithelial integrity and 
injury to type I cells disrupts normal epithelial fluid transport, impairing the removal of 
edema fluid from the alveolar space 207, 208.  Injury to type II cells reduces the 
production and turnover of surfactant, contributing to the characteristic surfactant 
abnormalities 212, 214, 215.   
  
4.2.1.1.2.   Alveolar epithelium, protein permeability and alveolar protein clearance in 
ALI 
 
Increased protein permeability is well documented in ARDS.  Alveolar epithelial lining 
fluid obtained from normal subjects contains a spectrum of soluble proteins derived 
from plasma 216-220.  Although many of these proteins are quantitatively proportioned as 
in plasma, very large molecules such as IgM and α2-macroglobulin are much more 
sparsely distributed to the alveolar surface 219.  In contrast to the normal lung, 
increased protein permeability in ARDS is associated with loss of this size restriction so 
that all plasma proteins are distributed equally between plasma and alveolar epithelial 
lining fluid.  The large proteins IgM and α2-macroglobulin were found in ARDS BALF at 
>90 times the concentrations of normal or cardiac edema fluid, indicating that normal 
size selectivity is preserved in cardiac edema but is destroyed by the alveolar-capillary 
injury of ARDS 108.  Patients dying with acute lung injury and the acute respiratory 
distress syndrome (ARDS) have large quantities of insoluble protein in their air spaces, 
and patients who die with lung injury after ARDS have three times as much protein in 
their alveoli as survivors 217, 221, 222.  The alveolar protein clearance is also an important 
function of the alveolar epithelium to maintain an adequate air-fluid interface.  The 
alveolar epithelium is a tight epithelium and is the primary barrier restricting passage of 
solutes and water into or out of the alveolar space.  The mechanism for the alveolar 
epithelium to clear molecules as large as serum proteins from the air space is not 
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totally understood.  Given that the rate of transalveolar protein flux is slow and no 
paracellular passage of large proteins has been observed through the epithelium, it is 
likely that the proteins are cleared by transcellular pinocytotis 223.  Disruption of the 
alveolar epithelium is associated with a decrease in the alveolar protein clearance 
which also impairs the resolution of the lung edema in ALI/ARDS.  Clearance of serum 
proteins from the alveolar space is an important process in recovery from pulmonary 
edema.  Albumin and immunoglobulin G (IgG) are present in pulmonary edema fluid in 
concentrations that are 40–65% of plasma levels in hydrostatic pulmonary edema and 
75–95% in lung injury pulmonary edema.   Protein concentrations rise even higher 
during the recovery phase from alveolar edema because the salt and water fraction of 
edema fluid is cleared much faster than albumin and IgG 88, 224-228.  High protein 
concentrations, in turn, increase protein osmotic pressures which slows alveolar fluid 
clearance.  Alveolar liquid clearance slowed from 8%/h in the first 4 h to 3%/h at the 
end of this period.  In addition to limiting liquid clearance, highly concentrated alveolar 
protein may precipitate, necessitating clearance of insoluble as well as soluble protein.  
The inability to clear alveolar protein results in the accumulation of fluid and 
macromolecules in the alveolar space and severe gas exchange impairment.  
Therefore, it may play a role in poor outcomes after pulmonary edema 225.   
 
4.2.1.1.3.   Alveolar epithelium and alveolar fluid clearance in ALI 
 
The classic studies of Matthay and Wiener-Kronish showed that the normal alveolar 
epithelium can concentrate protein-containing solutions in the airspaces, because 
electrolytes and water are transported out of the alveolar spaces more rapidly than 
proteins.  Most patients with ALI/ARDS are thought to have altered fluid clearance from 
the alveolar space.  The alveolar fluid clearance is a dynamic balance between fluid 
formation and clearance across the alveolar epithelium with alveolar liquid volume 
regulated by a balance between physical and biochemical forces.  Edema fluid 
clearance from the lung occurs when sodium undergoes vectorial transport from the 
alveoli into the underlying interstitium.  This transport is thought to be primarily a 
function of alveolar type II cells.  Transport occurs when sodium enters the cell through 
the amiloride-sensitive Na channel (ENaC) and is pumped out of the cell by Na/K-
ATPases located on the basolateral surface of the epithelial cells 156.  This enzymatic 
process of sodium transport is manipulable; the Na channel inhibitor amiloride blocks 
fluid clearance, whereas the ATPase can be stimulated by β-agonists, increasing 
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sodium transport and therefore trans-epithelial fluid movement 90, 226, 229-232.  Chloride is 
secreted to preserve electrical neutrality and likely moves through the CFTR present in 
type I cells 233.  Water follows the osmotic gradient generated by Naþ transport.  The 
specific pathway for water movement across the epithelium is controversial: water may 
travel through specialized water transporting proteins called aquaporins 234; however, in 
transgenic mice where aquaporins have been deleted, alveolar liquid clearance is 
unaffected 88, 235. 
 
To assess the efficacy of edema fluid clearance from the lung, serial measurements of 
edema fluid protein concentration must be made.  Using this technique, Matthay et al. 
measured the rate of fluid clearance from the airspaces of the lung in sequential 
samples of undiluted edema fluid obtained from patients with ARDS 236, 237 92.  A greater 
capacity to remove alveolar edema fluid early in the course of lung injury was 
associated with a better outcome.  They also completed a larger study of 79 patients 
with ALI in which they collected pulmonary edema fluid sampled sequentially within the 
first 4 h after intubation.  In this study, they demonstrated by measuring the alveolar 
fluid clearance that 56% of the 79 patients studied with ALI had impaired alveolar fluid 
clearance compared to control patients with hydrostatic pulmonary edema 92.  Overall, 
the mean alveolar fluid clearance rate was 6% per hour.   Furthermore, they also 
showed that in patients with ARDS, the ability to concentrate alveolar fluid proteins in 
the first hours after the lung injury is a good prognostic sign, whereas patients with 
unchanging alveolar fluid protein concentrations have a significantly higher mortality 92, 
237.   The results confirm that a decrease in the capacity of the alveolar epithelial barrier 
to remove alveolar edema fluid is an important determinant of a poor outcome 92. 
 
4.2.1.1.4.   Other roles of the alveolar epithelium in ALI 
 
One of the most important events for the resolution of ALI/ARDS is the reestablishment 
of the alveolar epithelium integrity.  It is clear that alveolar epithelial type II cells re-
populate the injured alveolar barrier in ALI, however, more information is needed about 
the intracellular signaling pathways that are activated or differential mechanisms of 
gene expression during injury, proliferation, and differentiation.  The cellular denudation 
of the alveolar epithelium seems to precede and promote activation of fibroblasts which 
results in the development of fibrosis 87, 238-241.  In addition, current lines of evidence 
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show that epithelial cells produce cytokines 242, 243, although the mechanisms and the 
consequent effects are not clear.   
4.2.1.2.   Lung endothelial injury 
The responses of lung endothelial cells are also altered in ALI/ARDS, triggered by 
sepsis, trauma, and other systemic conditions, but the mechanisms are incompletely 
defined.  The lung endothelium, in concert with the epithelial barrier, mediates the initial 
change in permeability and is also critical for repair and remodeling of the alveolar 
capillary membrane.  The cells lining the intima of blood vessels comprise an 
endothelial cell monolayer that functions as a semipermeable barrier, controlling the 
exchange of macromolecules and fluids between the blood and interstitial space.  This 
tenet is based on experimental data that demonstrate that under basal conditions, the 
endothelium functions as a barrier to fluid exchange 244, while at the same time it 
actively translocates diverse macromolecules such as albumin 245, insulin, transferrin 
246, ceruloplasmin 247, LDL 248, angiotensin 249, and orosomucoid 250. 
Endothelial heterogeneity may be a factor in the lung's responses to pathologic stimuli 
251.  In rodent lungs, each short segment of lung capillary possesses a few functionally 
distinct endothelial cells (the pacemaker cells).  These cells appear to regulate 
endothelial calcium within the capillary segment by generating intercellular calcium 
waves, and they may be the sites of inflammatory initiation in the capillary 252.  The 
endothelial cytoskeleton has been identified as a critical regulator of vascular barrier 
integrity 253.  It has been suggested that the endothelial barrier is regulated by a 
balance between barrier-disrupting cellular contractile forces and barrier-protective 
cell–cell and cell–matrix forces 254.  These competing forces exert their opposing 
effects via manipulation of the actin-based endothelial cytoskeleton and associated 
endothelial regulatory proteins.  Endothelial cells generate tension via actin and myosin 
fibers, and changes in tension/relaxation of these fibers can be accomplished by 
regulation of the phosphorylation of myosin light chain (MLC) catalyzed by the 
Ca2+/calmodulin (CaM)-dependent enzyme myosin light chain kinase (MLCK) 255.  
Endothelial proteins, such as thrombin and activated protein C (APC), play an 
important role on the vascular permeability in lung injury.  APC is a vascular endothelial 
protein which interacts with other coagulation proteins such as thrombin.  Whereas 
thrombin alters the endothelial integrity and consequently increases the endothelial 
permeability in cultured human pulmonary endothelial cells; the pre- or post-exposure 
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to physiologic concentrations of APC significantly attenuates the increase in endothelial 
permeability mediated by thrombin 256.  More needs to be learned about the diversity of 
endothelial cells, particularly regarding how they regulate the onset of lung 
inflammation.   
 
It is noteworthy that although the most obvious initial manifestations may be respiratory 
in nature, ALI/ARDS are part of a systemic process involving microvascular dysfunction 
of diverse organs including the heart, kidneys, gut, liver, muscle and the brain 184.  
Activation of endothelial cells resulting in activation of multiple pathways occurs in both 
pulmonary and systemic endothelium 257.  We have an incomplete picture of the 
molecular mechanisms that govern the responses of pulmonary endothelial cells, their 
interaction with alveolar epithelium, and the responses of the systemic endothelium in 
ALI/ARDS.   
 
 
4.2.2.   PATHOLOGICAL MECHANISMS 
 
4.2.2.1.   Cell death in ALI/ARDS 
 
Cell death has been demonstrated in the lung and other organs during the 
pathogenesis of ALI/ARDS 96, 258.   The two major pathways of cell death, necrosis and 
apoptosis, have been described in patients who died with ARDS 85.  These types of cell 
death have different morphological and biochemical characteristics. 
 
4.2.2.1.1.   Description of two modes of cell death: necrosis and apoptosis 
 
Necrosis begins with an impairment of the cell’s ability to maintain homeostasis, 
leading to an influx of water and extracellular ions.  Intracellular organelles, most 
notably the mitochondria, and the entire cell swell and rupture (cell lysis).  Due to the 
ultimate breakdown of the plasma membrane, the cytoplasmic contents, including 
lysosomal enzymes, are released into the extracellular space leading to an intense 
inflammatory response that, in turn, can extend the tissue damage.  Apoptosis, in 
contrast, is a controlled form of cell death, in which the cell is an active participant in its 
own demise (“cellular suicide”).  This active process is gene-directed and usually 
requires protein synthesis.  Apoptosis is important in the normal development of tissues 
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and in the remodeling of tissues that occurs during normal repair processes.   Cells 
undergoing apoptosis show characteristic morphological and biochemical features.  
The morphological features include cytoskeletal rearrangement, chromatin 
aggregation, nuclear and cytoplasmic condensation, cell shrinkage, plasma membrane 
blebbing, and formation of apoptotic bodies (partition of cytoplasm and nucleus into 
membrane bound-vesicles in which organelles are initially intact).  In vivo, these 
apoptotic bodies are rapidly recognized and phagocytized by either macrophages or 
adjacent epithelial cells, so intracellular products are not spilled into the extracellular 
space.   Biochemically, activation of specific intracellular serine rich proteases 
(caspases) leads to DNA cleavage, which is quite different from the random DNA 
degradation observed in necrosis 241, 258-261. 
 
Necrosis is a degenerative phenomenon that follows irreversible injury.  Necrosis 
occurs when cells are exposed to extreme conditions such as hyperthermia, trauma or 
severe hypoxia, which may result in damage to the plasma membrane 259, 262.  In the 
lung, necrosis caused by hypoxia is less common because of the dual pulmonary 
circulations and the ventilated alveolar spaces 241.  Other agents like complement, lytic 
viruses and some bacterial exotoxins (toxins released by Pseudomonas species, 
Escherichia coli or Staphylococcus aureus) can cause direct lysis of the epithelial cells 
in the lung 263, 264.  Mechanical forces created by shear stress or overdistension may 
also cause direct disruption of epithelial membranes, particularly in injured lungs in 
which heterogeneous alveolar flooding leads to marked heterogeneity in regional 
compliance 264, 265.  Apoptosis signaling pathways are activated in response to receptor-
ligand interactions (e.g., tumor necrosis factor-receptor family), environmental factors 
(such as ultraviolet light and changes in oxidation/reduction potential), and internal 
factors encoded in the genome (“programmed cell death”).  Inappropriate activation or 
inhibition of these pathways can lead to disease, either because cells have prolonged 
survival (malignant transformation) or because they die prematurely and produce 
structural changes in the tissue (e.g., apoptosis of lung epithelial cells) 241, 258. 
 
4.2.2.1.2.   Apoptosis of alveolar epithelial cells in ALI 
 
The lung is a complex organ which includes many different types of cells; including 
endothelial cells, epithelial cells, fibroblasts, and inflammatory cells 266-268.  Apoptosis 
can either ameliorate or exacerbate lung injury, depending upon the cell type. 
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Excessive apoptosis might contribute to injury of both the alveolar epithelial and 
endothelial barriers.  In patients with sepsis, apoptosis has been postulated to be a 
major mechanism of end-organ damage and has been demonstrated in the intestinal 
epithelium and the spleen of patients dying from sepsis 269-271.  By contrast, inadequate 
apoptosis might impair the resolution of type II pneumocyte hyperplasia or the removal 
of activated inflammatory cells, leading to an inadequate repair and prolonged 
inflammation 241, 258.  The alveolar epithelium of patients who die from lung injury 
contains cells that exhibit morphological and biochemical features of apoptosis such as 
DNA fragmentation 272, and upregulation of the intracellular pro-apoptotic pathway 
(Bax, a Bcl-2) 273.  Evidence of extensive alveolar epithelial cell apoptosis has been 
described in murine models of pulmonary fibrosis and lipopolysaccharide-induced lung 
injury 274-277.  Apoptosis of alveolar epithelial cells is detectable in mice as early as 6 
hours after intratracheal administration of lipopolysaccharide 277.  Apoptotic pathways 
are modulated by cytokines and other inflammatory products.  At inflammatory sites in 
the lungs, neutrophil apoptosis is delayed and epithelial apoptosis is enhanced 95, 96, 278, 
279.  Because apoptosis is a regulated event, new therapeutic interventions that inhibit 
key steps in the apoptosis pathways hold promise for limiting some types of injury 
responses in the lungs 267, 280. 
 
Apoptosis can be initiated by activation of a family of death receptors (extrinsic 
pathway) or by direct mitochondrial damage (intrinsic pathway). Death receptors 
include Fas (CD95) and tumor necrosis factor receptors (TNF-I and -II) on the cell 
surface, which are triggered by protein ligands either on the surface of effector cells, or 
in the soluble phase of extracellular fluids.  Activation of these membrane receptor 
proteins mediates apoptosis via activation of intracellular caspases, resulting in the 
cleavage of nuclear DNA.  The cognate Fas Ligand (FasL) is a membrane protein that 
can be shed from cell membranes by metalloproteinases (MMP-7 and MMP-3) and 
accumulates in extracellular fluids as a soluble ligand (sFasL).  Studies of human lung 
tissue have shown that Fas is present on proliferating type II pneumocytes, as well as 
airway epithelial cells 280-283.  Activation of membrane Fas caused apoptosis of murine 
type II cells in vivo.  The bronchoalveolar lavage fluid was found to contain sFasL 
before and after the onset of ARDS, but the sFasL was biologically active only at the 
onset of ARDS 284.  Other receptor-mediated apoptosis pathways also exit.  In this line, 
Uhal et al. have found that angiotensin peptides (angiotensin I to angiotensin II) 
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produced by fibroblasts from fibrotic human lungs initiated apoptosis of alveolar 
epithelial cells via the angiotensin II receptor 268, 285.  In ARDS the concentration of 
angiotensin converting enzyme, which catalyzes the conversion of angiotensin I to 
angiotensin II, is increased in BAL fluid 286.  On the other hand, surfactant protein A 
(SP-A), the primary protein present in pulmonary surfactant, is an inhibitor of type II 
apoptosis in vivo 287, 288.  This is important because, in patients with early ARDS, the 
concentration of SP-A is decreased in BAL fluid 214.  The lower concentration of SP-A 
would favor apoptosis of type II cells in these patients.  Therefore, in early ARDS a 
combination of three factors favors alveolar epithelial apoptosis: increased 
concentrations of soluble Fas ligand; increased concentrations of angiotensin-
converting enzyme and angiotensin II; and decreased concentrations of SP-A 289. 
 
Apoptosis can also be initiated by direct mitochondrial damage 290.  Either hyperoxia or 
hypoxia can induce apoptosis of pulmonary epithelial cells in experimental systems, 
and both are relevant in patients with ALI who are ventilated with a high FiO2, yet at the 
same time may have regions of tissue hypoxia where alveolar collapse has occurred.  
Hyperoxia induced apoptosis of primary rat alveolar epithelial cells in vitro by activating 
the pro-apoptotic protein (Bax) at the mitochondrial membrane 291.  This leads to the 
release of mitochondrial cytochrome C, which binds to Apaf-1 and activates caspase 9, 
and subsequently caspase 3, followed by DNA fragmentation and apoptotic cell death.  
In contrast, exposure of rat type II cells to graded hypoxia suppresses proliferation and 
causes apoptosis by a mechanism that involves activation of hypoxia inducible factor 
(HIF-1α), and the hypoxia response element (HRE) in nuclear DNA 241, 292. 
 
One of the consequences of apoptosis is loss of cellular attachment to the underlying 
basement membrane.  This could result in the exposure of the underlying alveolar 
epithelial basement membrane to inflammatory products in the alveolar spaces, such 
as oxidants, proteinases, and inflammatory factors.  Destruction of the alveolar walls 
and activation of fibroblast proliferation and collagen production, which is known to 
occur at the onset of ALI in humans, could lead to fibrosis during the repair process 83.  
Current studies are attempting to identify the mechanisms that link apoptosis with acute 
and chronic fibrosis in the lungs 238, 241, 293-298. 
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4.2.2.1.3.   Apoptosis of PMN in ALI 
 
Polymorphonuclear leukocytes (PMN) undergo apoptosis, and macrophages can 
remove apoptotic PMN by phagocytosis 96, 299-304.  However, inflammation appears to 
blunt apoptosis of PMN cells in vitro and in vivo studies 304-310.  Despite the large 
content of PMN infiltrating the lung tissue in acute lung injury, G. Matute-Bello and T.R. 
Martin (mentor group) found that there are fewer apoptotic PMN in bronchoalveolar 
lavage (BAL) fluid of patients either with acute respiratory distress syndrome (ARDS) or 
at risk of ARDS 96, 282, 284, 289.  Furthermore, BAL from ARDS patients decreases 
apoptosis and prolongs survival in vitro of normal human PMN, due to the presence of 
anti-apoptotic soluble factors, such as the proinflammatory cytokines granulocyte 
colony-stimulating factor and granulocyte/macrophage colony-stimulating factor 95, and 
possibly IL-8 and IL-2 96, 311-313.  These observations suggest that reduction of PMN 
apoptosis may prolong inflammatory responses and predispose the patients to ARDS 
after acute lung injury 314-316.  Interestingly, apoptotic PMN are taken up rapidly by 
activated alveolar lung macrophages, which indicates that two processes are likely to 
be occurring simultaneously: PMN apoptosis is delayed in the airspaces, and apoptotic 
PMN are taken up very rapidly by activated macrophages 96, 258, 278, 289. 
 
4.2.2.2.   Inflammation 
 
Acute lung injury (ALI) and its more severe form, the acute respiratory distress 
syndrome (ARDS), reflect severe injury leading to dysfunction of the barrier properties 
of the pulmonary endothelium and epithelium as a consequence of an unregulated 
acute inflammatory response 85, 317.  ALI/ARDS is characterized by an acute 
inflammatory process in the airspaces and lung parenchyma.  With initiation of 
inflammation there is increased leukocyte production and rapid recruitment to the 
inflamed site 82.  There is also activation of mediator cascades including the production 
of cytokines, chemokines, acute phase proteins, free radicals, complement, 
coagulation pathway components, and focal upregulation of adhesion molecule 
expression.  During the early phase of ALI, a variety of inflammatory mediators are 
released into the distal air spaces that can initiate and amplify the inflammatory 
response 38, 129, 317-321.  For example, cytokines such TNF-α, IL-1, and IL-8, are 
produced locally in the lung by alveolar macrophages, epithelial cells, and fibroblasts, 
and have been involved in epithelial and endothelial cell injury 82, 322-324.  Other 
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proinflammatory mediators, including endotoxin (LPS), vascular endothelial growth 
factor (VEGF), high mobility group-1 protein, and thrombin, are also implicated in the 
pathogenesis of ALI/ARDS.  To regulate the pro-inflammatory response, there is also 
activation of “antiinflammatory” responses including glucocorticoids, cytokines 
(interleukin (IL)-4, IL-10 and IL-1 receptor antagonist (IL-1RA) and other mechanisms, 
such as shedding of adhesion molecules.  These antiinflammatory mediators limit the 
proinflammatory response in the injured lung 82, 325 326 319, 321, 327, 328.  The balance 
between pro- and anti-inflammatory factors will determine the net effect of inflammation 
in the lung. 
 
4.2.2.2.1.   Neutrophils  
 
Neutrophils are the dominant leukocytes found both in BAL fluid and in histological 
specimens from patients with ARDS 82, 96, 282, 284, 289, 329.  Some lines of evidence 
consider that an initiating event (sepsis, shock, trauma, multiple transfusions, 
pancreatitis, etc.) leads to activation of pulmonary epithelium, endothelium and 
macrophages (alveolar and interstitial) resulting in upregulation of adhesion molecules 
and production of cytokines and chemokines that induce a massive sequestration of 
neutrophils within the pulmonary microvasculature.  These cells transmigrate across 
the endothelium and epithelium into the alveolar space and release a variety of 
cytotoxic and proinflammatory compounds, including proteolytic enzymes, reactive 
oxygen species (ROS) and nitrogen species, cationic proteins, lipid mediators, and 
additional inflammatory cytokines 279, 319, 325, 326, 330-332.  This perpetuates a vicious cycle 
by recruiting additional inflammatory cells that in turn produce more cytotoxic 
mediators, ultimately leading to profound injury to the alveolo-capillary membrane and 
respiratory failure.   
 
In many animal models the degree of lung injury is reduced dramatically if neutrophil 
influx is abated, although this is not a universal finding 333, 334.  However, ARDS can 
develop in neutropenic patients 335, and neutrophils can enter the lungs of nomal 
subjects without altering epithelial permeability 336. Because some animal models of 
acute lung injury are neutrophil-independent, neutrophils are believed to be an 
important but not essential component of the injurious response 337.  Neutrophils cause 
cell damage through the production of free radicals, inflammatory mediators, and 
proteases.  Excessive quantities of neutrophil products including elastase, collagenase, 
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reactive oxygen species, and cytokines, such as tumor necrosis factor-α (TNF-α) have 
been found in patients with ARDS 279, 319, 325, 326, 330-332, 338.  Recent studies with mice 
deficient in neutrophil elastase suggest that this enzyme may be an important mediator 
of damage to the alveolar epithelium and the progression to fibrosis 339.  Adhesion 
molecules, notably β2-integrins, mediate neutrophil binding to the pulmonary 
endothelium.  Adhesion molecules also modulate activation and mediator release by 
neutrophils.  Other inflammatory cells including macrophages and, later, lymphocytes 
are involved, while platelets may exacerbate the vascular injury and endothelial cells 
themselves are capable of producing many damaging mediators of inflammation 340. 
 
4.2.2.2.2.   Inflammatory mediators 
a) Cytokines 
Evidence from several clinical studies indicates that a complex network of inflammatory 
cytokines and chemokines (chemotactic cytokines) play a major role in mediating, 
amplifying, and perpetuating the lung injury process.  Cytokines are low-molecular-
weight soluble proteins (generally < 30 kDa) that transmit signals between cells 319.  
Proinflammatory cytokines are produced locally in the lung inflammatory cells, lung 
epithelial cells or fibroblasts.  Cytokines production by extrapulmonary factors has also 
been described.  Simultaneous production of anti-inflammatory cytokines can 
potentially counteract pro-inflammatory cytokine effects and modify the intensity of the 
inflammatory process.  The cytokine balance between proinflammatory and anti-
inflammatory cytokines is crucial to understand the biological activity of cytokines in 
biological fluids 319, 327.   
The inflammatory process is driven in part by cytokines including TNF-α, IL-1β, IL-6, 
and IL-8.  All have been found in BAL fluid and plasma of patients with ARDS 322, 341, 342.  
TNF-α and IL-1β seems to be the earliest released cytokines in the lungs with acute 
lung injury.   The increase in TNF-α levels occurs very early in the clinical course of 
induced acute lung injury and may be missed by the time of presentation.  TNF-α and 
IL-1β are present in BAL fluid of patients at risk for ARDS and with established ARDS 
341, 343, 344.  The highest concentrations of TNF-α and IL-1-β occur in the BAL fluid from 
patients with sustained ARDS.  The ratios of BAL fluid to serum cytokine 
concentrations are typically elevated, suggesting a pulmonary origin 345, 346.  In animal 
models, both cytokines can produce an ARDS-like condition.  They are produced by 
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inflammatory cells and can promote neutrophil-endothelial adhesion, microvascular 
leakage, and amplify other proinflammatory responses. 
  
The pro-inflammatory cytokines IL-1β and TNF-α identified in BAL fluids from ARDS 
patients are also accompanied by high concentrations of their specific antagonists IL-1 
receptor Antagonist (IL-RA) and soluble TNF receptors (sTNFR) 129.  This prominent 
antiinflammatory response in the lungs provides a mechanism for limiting the intensity 
of the inflammatory response in the soluble phase of lung fluids before and after the 
onset of ARDS.  The balance of “anti-inflammatory” cytokines and mediators must also 
be considered.  Some studies using a bioassay that measures balance of cytokines 
with their inhibitors, determined that the proinflammatory activity in the BAL fluids from 
patients with ARDS is mainly due to IL-1β, rather than to TNF-α that is considerably 
less active than IL-1β 317, 323, 341.  Therefore, IL-1β seems to be one of the most 
biologically active cytokines in the lungs early after the onset of ALI.  In experimental 
models, IL-1β stimulates the production of a variety of chemokines (e.g.  IL-8, 
monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein-1α 
(MIP-1-α))321 involved in epithelial wound repair 323, 347 and is a potent inducer of lung 
fibrosis 348, 349.  It has been previously shown in rats that lung vascular permeability 
increases after short term exposure of IL-1α and IL-1β protein when given 
intratracheally 350, 351. 
 
b) Chemokines 
The intense neutrophilic infiltrate has led to a search for the chemotactic factors 
responsible.  Leukocyte migration is directed to a large extent by chemokines 
(chemotactic cytokines).  The two major classes include the α-chemokines, which 
recruit PMNs, and β-chemokines, which recruit monocytes and lymphocytes 342.  The α-
chemokines include IL-8, GRO (melanoma growth stimulating activity), and ENA-78 
(epithelial cell neutrophil activating factor).  The β-chemokines include the monocyte 
chemotactic peptides (MCP-1,2,3,4) and RANTES (regulated on activation, T-cell 
expressed and secreted).  IL-8, GRO, and ENA-78 are detectable in the BAL fluid of 
patients at risk for ARDS and during the course of established ARDS.  Alveolar 
macrophages are a major source of chemokines in the airspaces, and produce IL-8, 
GRO-related peptides, and ENA-78.  The α- and β-chemokines are present in the lungs 
of patients with ARDS.  IL-8, GRO, ENA-78, and MCP-1 all have been found in BAL 
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fluid of patients at-risk for and with established ARDS 346, 352.  Although other potent 
leukocyte chemoattractants also exist, including the complement component C5a and 
the low-molecular-weight lipids leukotriene B4 and platelet activating factor, the 
neutrophil chemotactic activity in BAL fluid is due predominantly to IL-8, and not to C5a 
346, 353.  Correlations between IL-8 and total PMN in BAL fluid is poor at the onset of 
ARDS, however, it actually grows stronger with time in patients with persistent ARDS 
346, 353.  Other chemokines in ARDS BAL fluid also are likely to contribute to PMN 
recruitment such as GRO and ENA-78.  Despite the fact that the concentrations of 
GRO and ENA-78 exceed the concentration of IL-8 in BAL fluid throughout most of the 
course of ARDS 346, 352, IL-8 was the dominant PMN chemoattractant in the fluids 
studied.  GRO and ENA-78 may then account for IL-8 independent neutrophil adhesion 
in ARDS.  MCP-1, which regulates monocyte recruitment, is detectable in ARDS BAL 
fluid at the onset of ARDS and persists in the lungs of patients with sustained ARDS 
346.  These neutrophil chemotactic cytokines are also balanced by the presence of 
counter-ligands such as α2-macroglobulin, the Duffy antigen chemokine binding 
protein, natural neutralizing antibodies, and the anti-inflammatory cytokine IL-10 in the 
lung milieu.  The macrophage migration inhibitory factor (MIF) was identified in BAL 
fluid from patients studied on the first day of ARDS 354, and increases in the lungs of 
patients with sustained ARDS 321.  Activated alveolar macrophages of patients with 
ARDS seem to produce this cytokine.  MIF may sustain inflammation in the alveolar 
spaces, although the role of MIF in the lungs of patients with ARDS is unclear.   
Molar concentration ratios of pro- and anti-inflammatory molecular pairs in BAL fluid 
provide insight into the inflammatory balance in individual patients, and measurement 
of the net inflammatory activity in the lungs of patients with ARDS is an important step 
in the pathogenesis of this syndrome.  Low concentrations of IL-10 and IL-1RA in BAL 
fluid from patients with ARDS were found to be associated with increased mortality, 
suggesting an important role for anti-inflammatory mediators in counter balancing the 
pro-inflammatory response 355.  Therefore, it is possible that ARDS represents the 
failure of anti-inflammatory cytokine responses in susceptible individuals as much as 
the activation of pro-inflammatory networks. 
 
c) Other mediators  
The toll-like receptors of innate immune cells and endothelial cells, which recognize 
pathogen-associated molecular patterns in LPS and other microbial factors, are 
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another group of factors that are critical to inflammation and injury.  Toll-like receptors 
are linked by intracellular signal transduction cascades to activation of the nuclear 
factor-κB (NF-κB) family of transcription factors and induction of tumor necrosis factor 
alpha and other NF-κB dependent gene products.  Their engagement is central to host 
defense and sepsis, septic shock, and their complications including ALI/ARDS 356. 
Bacterial lipopolysaccharide (LPS) is a component of the gram-negative cell wall that 
activates innate immunity 357.  Most experimental models of ARDS have used LPS to 
trigger inflammatory responses by interacting with specific host proteins that initiate 
cytokine production.  During the acute phase of ALI, concentrations of the 
lipopolysaccharide-binding protein (LBP) and sCD14 in plasma and bronchoalveolar 
lavage fluid rise by more than ten-fold in patients with acute lung injury 358.  LBP 
enhances several LPS-stimulated responses that could contribute to ARDS, including 
the regulation of CD18, the adherence of neutrophils to endothelium, and the 
production of cytokines (e.g., TNF-α from alveolar macrophages).  The LPYLBP 
complex interacts with CD14 to trigger intracellular responses and the development of 
lung injury.  The increased levels of LBP and CD14 in BAL fluid from patients with 
ARDS, are significantly related to total protein and polymorphonuclear neutrophil 
concentrations, markers of increased alveolar-capillary membrane permeability and 
inflammation, respectively 359.   LPS can also induce tolerance to inflammatory insults.  
Exposure to a sublethal dose of LPS is associated with relative hyporesponsiveness to 
subsequent exposure.   The extent to which endotoxin tolerance could modulate the 
development of ARDS in individuals at risk remains unclear but represents an exciting 
therapeutic prospect.  Finally, although LPS is implicated as an important agent in the 
induction of ARDS and is present in the plasma of many patients with sepsis 
complicated by lung injury, its precise source remains unknown 357. 
 
4.2.2.3.   Metalloproteinases 
 
The response to acute lung injury is characterized by a series of events, including 
inflammation and extracellular matrix (ECM) revision, which can result in loss of the 
normal alveolar architecture.   Throughout this process, ECM components are 
deposited, removed, or remodeled, enabling cell migration, neovascularization, and 
restructuring of the alveolar-capillary interface.  These MMPs are thought to make 
important contributions to the inflammatory response 360-365.  These proteolytic enzymes 
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have important functions in normal developmental processes, such as lung branching 
morphogenesis.  On the other hand, patients with acute respiratory distress syndrome 
(ARDS), asthma or fibrosis lung diseases express increased levels of MMPs, 
suggesting their participation in the response to lung injury 30, 366.  In pathological 
conditions, MMPs are involved in inflammatory processes, tissue injury and repair, 
remodeling, and host defense against pathogens 367-369.  Some of the known targets of 
MMPs in the lung include extracellular matrix (ECM) molecules, growth factors, 
chemokines, proteinases, and cell surface proteins, such as adhesion molecules and 
TNF family ligands.  The proteolytic activities of MMPs must be tightly controlled to 
restrict inflammation and ECM revision to areas of lung damage and to avoid 
destruction of healthy tissue.  An important mechanism of MMP regulation is provided 
by the tissue inhibitors of metalloproteinases (TIMPs), which block MMP proteolytic 
activity.  Four homologous TIMPs have been well characterized: TIMP-1,-2, -3, and -4 
370, 371.  The functional significance of the interactions between MMPs and their 
substrates in bronchoalveolar fluid and in the lung parenchyma is a novel concept that 
is currently being explored, but remains poorly understood. 
 
The MMP-2, MMP-7, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 have 
been demonstrated in pulmonary epithelium in patients with asthma, ARDS, and cystic 
fibrosis 372-374.  In patients with ARDS, MMP-9 (92 kDa-gelatinase B) and MMP-2 (72 
kDa-gelatinase A) are also elevated in the BAL fluid, and the number of neutrophils 
present in the BAL fluid correlates with the increase in MMP-9 375, 376.  In addition, the 
elevated levels of MMP-9 and MMP-2 in the BAL fluid of these patients correlate 
directly with an increase in the concentration of degradation products from type IV 
collagen within the basement membrane.  Fligiel et al. detected high levels of MMP-2, 
MMP-8 (neutrophil collagenase), MMP-9, and TIMP-1 (metalloproteinase innhibitor-1) 
in all the BAL fluid of all patients with ALI/ARDS included in the study, whereas MMP-1 
(interstitial collagenase) and/or MMP-3 (stromelysin-1) were detected only in a small 
subset of patients.  In these patients with elevated levels of MMP-3 and/or MMP-1, the 
severity of illness and overall mortality rate were higher than in the group in which only 
MMP-2, MMP-8, and MMP-9 were detected 370. 
 
In the lung, MMPs are produced by a wide variety of cell types, including type II 
epithelial cells, airway epithelial cells, endothelium, fibroblasts, and alveolar 
macrophages.  MMPs derived by migrating neutrophils could also play pathogenic 
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roles in acute lung disease.  MMP-8, generated by neutrophils, has been identified in 
BAL fluid of adult and neonatal patients with ARDS.  In these studies, elevated MMP-8 
was associated with the presence of large numbers of neutrophils in lung tissue 377-379.  
Gibbs et al., however, determined that alveolar macrophages isolated from injured 
lungs produced the same spectrum of MMPs as seen in the BAL fluid from patients 
with ARDS.  These studies suggest that alveolar macrophages can be the main source 
of MMPs in the lung under pathological conditions, and that MMPs can play an active 
role in the development of lung injury 380, 381.   
 
In animal models of inflammatory lung diseases induced by IgG-containing immune 
complexes 382 or LPS 381, administration of TIMP-2 via intratracheal instillation resulted 
in a reduction of lung injury associated with a significant reduction of both the 
neutrophil influx to the alveolar space and the protein permeability index of the lung.  
One mechanism involves a direct role for MMPs in neutrophil recruitment.  The 
presence of exogenous MMP inhibitor in the alveolar space may limit neutrophil influx 
in a variety of possible ways.  The presence of the inhibitor may prevent damage to the 
basement membrane, which is necessary for neutrophil transmigration across the 
vessel wall.  Such an effect might also account for the reduction in protein permeability.  
Another possibility is that the proteolytic enzymes might be directly responsible for 
injury to the resident epithelial cells and endothelial cells.  Injury to resident cells in the 
alveolar unit is a pathogenic feature of acute inflammatory lung injury.  Cellular injury 
has been directly attributed to proteolytic enzymes alone or the combinations of 
oxidants and proteolytic enzymes 380, 381, 383.  In a mouse model of Bleomycin-induced 
lung injury, TIMP-1 deficiency amplifies acute lung injury with increased pulmonary 
neutrophilia, hemorrhage, and vascular permeability.  These experimental models of 
lung injury suggest an important role of MMPs in the development of acute lung injury 
by promoting leukocyte influx and alteration of the vascular permeability at sites of 
inflammation 381, 382, 384, 385. 
 
Within the MMP family, however, matrilysin (MMP-7) is the only known member that 
lacks the hemopexin domain thought to be important in interactions with TIMPs, 
whereby it is believed to be less sensitive to the inhibitory action of these proteins 386.  
In addition to its activity on basement membrane and extracellular matrix components, 
matrilysin (MMP-7) has been reported to cleave a variety of secreted and cell-surface 
proteins 387.  These cell-surface substrates include the transmembrane precursor to 
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TNF-α, and FasL.  Cleavage of FasL by matrilysin results in the release of active 
soluble Fas ligand (sFasL) from the cell surface 388.  Matrilysin (MMP-7) is mainly 
expressed in the cell-surface of epithelial cells.  MMP-7, unlike many MMPs, is 
expressed by non-injured, non-inflamed mucosal epithelia in most adult human tissues 
389, 390.  In the human lung, matrilysin is constitutively expressed in tracheal glands and 
in tracheobronchial epithelium, and expression is acutely up-regulated by injury or 
exposure to bacteria 391, 392.  Matrilysin is induced in alveolar epithelium in mice after 
lung injury with bleomycin, and expression increases and continues as fibrosis 
progresses 384.  This MMP has been reported to contribute to the development of 
fibrosis in the lung 393, 394.  Despite this harmful effect, matrilysin regulates neutrophil 
influx by controlling chemokine compartmentalization during the first days after injury, 
and mediates shedding of E-cadherin that is required for lung epithelium repair 395.  
Therefore, it is not clear whether MMP inhibition is beneficial or harmful and in which 
situations it would be of clinical help. 
 
4.2.2.4.   Coagulation 
 
Disruptions in the coagulation system have long been recognized to be an integral part 
of inflammation, sepsis and ALI.  Elemental to the pathophysiology of sepsis and ALI is 
a shift towards a pro-coagulant state.  Bronchoalveolar (BAL) fluid from patients with 
ALI reflects this increase in procoagulant activity with elevated levels of fibrinopeptide 
A, factor VII and d-dimer.  Concomitantly, there is a decrease in fibrinolytic activity, as 
shown by depressed BAL levels of urokinase and increased levels of the fibrinolysis 
inhibitors plasminogen activator inhibitor (PAI) and α2-antiplasmin 396, 397.  This pro-
coagulant milieu contributes to the pathophysiology of ALI by causing intra-alveolar and 
interstitial fibrin deposition which can, in turn, lead to direct endothelial contraction 398.  
Moreover, fibrin inhibits surfactant, which contributes to alveolar collapse, and 
promotes the aggregation of fibroblasts leading to increased fibrosis.  In addition, fibrin 
is also a chemotactic factor for neutrophils 399, 400.  Indeed, fibrin microthrombi are 
present at autopsy in patients with acute respiratory distress syndrome (ARDS) 49. 
 
Over the past decade, the protein C pathway has been increasingly recognized as an 
essential participant in both coagulation and inflammation, stimulating research into its 
role in sepsis and ALI.  In the landmark Prowess study, a recent multi-center clinical 
trial, activated protein C (APC) treatment resulted in a significant survival benefit in 
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patients with sepsis 168.  APC inactivates the active forms of factor Va and VIIIa which, 
in turn, blocks downstream thrombin generation.  The protein C pathway also has 
important anti-inflammatory properties; APC blocks nuclear factor-κB nuclear 
translocation and decreases TNF-α production in mice exposed to endotoxin.  
Clinically, patients with sepsis and low protein C concentrations are more likely to 
progress to shock and have a higher mortality than patients with higher levels 401, 402.  
However, in humans given endotoxin, APC infusion results in improved hemodynamics 
but has no effect on inflammatory, thrombotic or fibrinolytic markers 403, 404, suggesting 
an alternative protective mechanism.  The mechanism by which APC has a protective 
effect is not completely understood. 
 
4.2.2.5.   Oxidative stress in ALI 
 
In ALI/ARDS, neutrophil migrates into the alveolar spaces and releases a variety of 
cytotoxic and proinflammatory compounds, including reactive oxygen species (ROS) 
and nitrogen species (RNS) in addition to cytokines, proteolytic enzymes and lipid 
mediators 330, 405.  Both ROS and RNS help perpetuate the inflammatory response, and 
contribute to alveolo-capillary membrane damage and respiratory failure. 
 
Biologically important, ROS include superoxide anion radical (O2-), hydrogen peroxide 
(H2O2), hydroxyl radical (OH -), and hypochlorous acid (HOCl).  Reactive nitrogen 
species, derivatives of nitric oxide (NO) including peroxynitrate (ONOO -), have also 
been implicated in oxidation/nitration of proteins and lipids 406-411.  Reactive oxygen and 
nitrogen species can lead to cell injury by various mechanisms, including: 1) direct 
damage to DNA resulting in strand breaks and point mutations; 2) lipid peroxidation 
with formation of vasoactive and pro-inflammatory molecules such as thromboxane; 3) 
oxidation of proteins (primarily at sulfhydryl groups) that alter protein activity 412-414, 
leading to release of proteases and inactivation of antioxidant and antiprotease 
enzymes 415; and 4) alteration of transcription factors such as activator protein-1 and 
nuclear factor (NF)-κB, leading to enhanced expression of proinflammatory genes 416. 
 
To neutralize free radicals and counteract the detrimental effects of ROS generated 
during normal metabolism, cells express a number of endogenous antioxidants such as 
superoxide dismutase (SOD, which degrades O2-), catalase, and glutathione 
peroxidase (GSH, which inactivates H2O2 and hydroperoxides, and is particularly 
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abundant in the lung)  405.  However, these antioxidants are rapidly overwhelmed during 
an acute inflammatory response.  In the context of ALI/ARDS, there are many potential 
sources of ROS, including itinerant and resident leukocytes (neutrophils, monocytes, 
and macrophages), parenchymal cells (endothelial and epithelial cells, fibroblasts, and 
myocytes), circulating oxidant-generating enzymes (xanthine oxidase), and inhaled 
gases with high concentrations of oxygen that are often used during mechanical 
ventilation.  Patients with ARDS have increased levels of H2O2 in exhaled breath 
condensate 417-419.  Moreover, bronchoalveolar lavage fluid from these patients contains 
an excess of oxidatively modified proteins in combination with a relative deficiency in 
antioxidant molecules such as glutathione 420-423.  Thus, although there is a complex 
antioxidant defense system, in ALI/ARDS there is extensive overproduction of ROS to 
the extent that endogenous antioxidants are overwhelmed, permitting oxidative cell 
damage.  Experimental models also support the role of oxidants and oxidative injury in 
the pathogenesis of ALI/ ARDS 159, 332, 409, 417, 424. 
 
4.2.2.5.1.   Source of oxidants in the lung 
 
Activated neutrophils and macrophages, in the bronchoalveolar space are generally 
considered to be the most potential sources of ROS 425 such as superoxide anion, 
hydrogen peroxidase, hydroxyl radicals, and hypochlorous acid (HOCl), which are 
highly toxic to extracellular microorganisms and tissues 332.  The BAL fluids of ARDS 
patients and at-risk patients contain a variety of pro-inflammatory compounds, including 
lipopolysaccharide (LPS), cytokines, chemokines, complement fragments, clotting 
fragments, and lipid mediators, which are capable of priming and/or activating 
neutrophils to generate ROS.  Leukocytes express three enzyme systems, the NADPH 
oxidase 426, nitric oxide synthases (NOS) 427 and myeloperoxidase (MPO), which can 
generate reactive species in substantial amounts 428, 429.  The large numbers of 
activated neutrophils in the lung in ALI/ARDS has focused attention on these 
phagocytes as a major source of ROS 428.  In addition, it has been described that 
fibroblasts, endothelial, epithelial, and smooth muscle cells have also phagocytic 
functions and express oxidases capable of generating physiologically important 
amounts of ROS 419, 430-432.  Other sources of ROS include mitochondrial electron 
transport chain 433, cytochrome P450 434, and xanthine oxidase 435.  Finally, inhaled 
oxidants, including high concentrations of oxygen, used in mechanical ventilation can 
contribute to formation of ROS 332. 
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4.2.2.5.2.   Potential targets of oxidants in ALI/ARDS 
 
Numerous changes that occur during the evolution of ALI are the consequences of 
oxidative stress that leads to cellular damage.  The delicate balance between oxidant 
and anti-oxidant systems is very important in maintaining the normal function and 
structure of the lung. 
 
a) Oxidation of cellular components 
 
Various cellular components can be subject to oxidative modifications including 
membrane, cytosolic, and nuclear lipids and proteins.  Also nucleic acid can be 
modified by oxidation.  Cellular membranes and especially plasma membranes are 
primary targets of ROS.  The fatty acid side chains of membrane phospholipids 
undergo peroxidation under oxidative stress 436.  Membrane fluidity is dependent on 
lipid composition of the plasma membrane, and alterations in this composition, 
including those by oxidation, profoundly influence diverse aspects of membrane 
function.  In the context of acute inflammation, oxidation of components of the 
endothelial or epithelial plasma membrane could facilitate neutrophil recruitment into 
the lung by compromising the barrier function of these cells, thereby allowing leakage 
of chemokines and other chemoattractant molecules into the vascular space.  
Additionally, oxidant exposure can lead to enhanced leukocyte adhesion either by 
direct oxidative modification of components of the endothelial plasma membrane 
generating lipid mediators or by “inside-out” signaling leading to enhanced surface 
expression and affinity of adhesion molecules 437.  Cytosolic and nuclear events 
initiated by oxidants might also contribute to inflammatory injury and be amenable to 
pharmacologic intervention.  For example, elevation of cytokines and chemokines is a 
common feature in the lung of patients with ALI/ARDS, and it is primarily regulated by 
NF-κB, a DNA-binding factor that stimulates transcription of many different cytokines 
involved in acute inflammation.  There is evidence that NF-κB is activated in the 
context of ALI/ ARDS.  Oxidation of IκB, the inhibitor factor of NF-κB, results in 
dissociation of IκB from NF-κB, which allows the free NF-κB to translocate to the 
nucleus 438-440.  Attempts to attenuate lung injury have focused on modulation of the 
signaling pathways leading to increased inflammatory cytokine/chemokine production, 
and on restoration of the oxidant/antioxidant balance to limit the degree of oxidative cell 
damage 332, 441.   
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b) Oxidation of extracellular proteins 
 
Accumulation of oxidized proteins occurs in many diseases such as Alzheimer’s 
disease, arteriosclerosis, amyotrophic lateral sclerosis, muscular dystrophy or 
rheumatoid arthritis.  In the lung, the increased production of ROS leads to an oxidative 
modification of proteins in the alveolar space in patients with ALI 423, 442, 443.  A.G. Lenz 
et al. determined that oxidatively modified proteins clearly accumulate in BAL fluid of 
ARDS patients, and to a minor extent in at-risk patients 423.  Oxidative modification of 
proteins is an early event in oxidative damage to endothelial cells, which suggests that 
oxidative modification of proteins is not only a marker for oxidative stress but a causal 
factor in oxidative injury 443, 444.  In this sense, the presence of oxidized pulmonary 
proteins may be important in the pathogenesis of ARDS.  Carbonyl formation in the 
amino acid side-chains of proteins is one of the consequences of oxidation and 
appears to be the first change occurring with low amounts of oxidant.  Increase in 
carbonyl groups has been detected in the proteins accumulated in the BAL fluid of 
patients with ARDS.  The formation of these carbonyl groups has been used as a 
marker of oxidative stress damage in multiple tissues included the lungs.  However, 
carbonyl groups cause loss of function in the affected proteins and also lead to protein 
degradation contributing to protein-turn-over 423, 444, 445.  In patients with ARDS, there is 
a correlation of oxidized proteins with the number of neutrophils and myeloperoxidase 
suggesting an important role of neutrophils in this oxidation process.   In fact, carbonyls 
are generated on proteins by myeloperoxidase-derived hypochlorous acid, a reaction 
that takes place mainly in neutrophils 408, 423, 429, 446, 447.   
 
4.2.2.6.   Fibrosing alveolitis 
 
After the acute phase of acute lung injury and the acute respiratory distress syndrome, 
some patients have an uncomplicated course and rapid resolution of the disorder 237.  
Others have progression to fibrotic lung injury, and such injury can be observed 
histologically as early as five to seven days after the onset of the disorder 85, 109, 110.  
The alveolar space becomes filled with mesenchymal cells and their products, along 
with new blood vessels 400.   The finding of fibrosing alveolitis on histologic analysis 
correlates with an increased risk of death, 448 and patients who die of the condition 
have a marked accumulation of collagen and fibronectin in the lung at autopsy 113. 
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Recent evidence suggests that there is a much greater overlap of the inflammatory and 
fibroproliferative phases than previously thought 5, and many mediators are common to 
both processes.  The process of fibrosing alveolitis apparently begins early in the 
course of the disorder and may be promoted by early proinflammatory mediators such 
as interleukin-1 449-452.  Levels of procollagen III peptide, a precursor of collagen 
synthesis, are elevated in the alveolar compartment very early in the course of the 
illness 83, 84.  High concentrations of PCPIII in BAL are associated with an increased risk 
of death, suggesting more severe lung injury 84.  Transforming growth factor-alpha 
(TGF-α) increases fibroblast collagen production and may contribute to the fibrosis that 
occurs in patients with sustained ARDS 98.  TGF-α is detectable in BAL for prolonged 
periods after the onset of ARDS, and high concentrations of TGF-α in BAL on day 7 
are associated with an increased risk of death in patients with sustained ARDS 453.  
TGF-α also stimulates epithelial cell proliferation in vitro 454.  Other growth factors that 
stimulate epithelial cell proliferation, including keratinocyte growth factor and 
hepatocyte growth factor, have been detected in ARDS BAL 455.  Myofibroblast cells 
also show an early increase in the alveolar walls, and BAL fluid from ARDS patients 
within 48 hours of diagnosis is intensely mitogenic for fibroblasts 41, 456.   This all 
suggests that the fibrosis characteristic of ARDS may not be a late event but is 
switched on at a very early stage.  This is particularly important as it offers the 
possibility for early directed treatments against fibrosis 457. 
 
4.2.2.7.   Mechanical forces and ALI 
 
Mechanical ventilation with high volumes and pressures, and high inspired oxygen can 
cause structural and functional alterations in uninjured lungs, as well as enhance the 
damages in the injured lungs 130-133, 458.   Volutrauma is the overdistension of injured 
and normal alveoli.  Alveolar overdistension is believed to degrade surfactant, disrupt 
epithelial and endothelial cell barriers, and increase cytokine levels and inflammatory 
cells in the lung.  Elevated ventilating pressures (barotrauma) also contribute to 
hydrostatic alveolar flooding 458-460.   More recently, cyclic opening and closing of 
atelectatic alveoli during mechanical ventilation have been shown to cause lung injury 
independently of alveolar overdistention, by shearing of epithelial and endothelial cell 
layers 458, 459.   Alveolar overdistention coupled with the repeated collapse and 
reopening of alveoli can initiate a cascade of proinflammatory cytokines 135, 461.  The 
use of high FIO2 concentration has been associated with pathologic changes in the 
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lung such as edema, alveolar thickening, and fibrinous exudate 462, 463.  These issues 
have led to a number of clinical trials of protective ventilatory strategies to reduce 
alveolar overdistention and increase the recruitment of atelectatic alveoli 33. 
 
The effect of the mechanical stresses applied to the lung may extend far beyond the 
thoracic structures to systemic organs.  Recent studies have demonstrated that 
mechanical ventilation can release mediators 464, 465 that may translocate into the 
systemic circulation 135.  This may contribute to the high prevalence of multiple organ 
failure in patients with ALI/ARDS.  This hypothesis was strengthened by the low tidal 
volume study that demonstrated a systemic component in ALI/ARDS that was altered 
by the ventilatory strategy 33.  Injurious ventilatory strategies can lead to loss of 
compartmentalization in the lung and may cause translocation of mediators, endotoxin, 
and bacteria from the lung to the systemic circulation 138, 466.  Examination of the 
physiological, biological, and genetic basis of stress-induced injury to the lung in health 
and disease is thus a fertile area of future research. 
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4.3.   RELEVANCE OF THE FAS/FAS LIGAND SYSTEM IN ALI/ARDS 
 
Many lines of evidence indicates that the Fas/Fas Ligand (Fas/FasL) system plays an 
essential role in the pathogenesis of ALI/ARDS by inducing apoptosis and activation of 
inflammatory pathways in the early phase 274, 282, 284, 289, 467-473, but it also has an 
important role in lung repair and fibrosis 293, 295, 296, 474-477. 
 
 
4.3.1.   MOLECULAR BASIS OF THE FAS/FAS LIGAND SYSTEM 
  
The Fas/Fas Ligand (Fas/FasL) system is comprised of the cell membrane surface 
receptor Fas (CD95) and its natural ligand, namely Fas ligand 281, 478.  Fas (CD95) is a 
45-kd type I membrane receptor, a member of the tumor necrosis factor family of cell 
surface receptors 281, 479, 480.   FasL (CD95L), a 37-kd type II membrane glycoprotein, is 
also a member of the tumor necrosis factor family of cytokines 478.  Fas and FasL exist 
in both membrane-bound and soluble forms 481, 482.  The soluble form of FasL (sFasL) 
can result from enzymatic cleavage of membrane bound FasL by enzymes such as 
metalloproteinase-7 (MMP7, matrilysin) and metalloproteinase-3 (MMP-3) 482-488, or 
from rapid release by activated monocytes and monocyte-derived macrophages 471, 489-
491.   Both the membrane-bound and the soluble forms of FasL are capable of inducing 
apoptosis of susceptible cells, and inflammation 282, 284.  Apoptosis and inflammation 
are induced when membrane-bound or soluble FasL binds to Fas-bearing cells 492-495.  
In contrast, soluble Fas can inhibit apoptosis by binding to either membrane-bound 
FasL or soluble FasL, thereby preventing FasL from interacting with membrane-bound 
Fas receptors 496.   
 
In normal lungs, Fas is expressed in myeloid cells, including neutrophils and alveolar 
macrophages, and also in nonmyeloid cells, including airway and alveolar epithelial 
cells and fibroblasts 283, 491, 497-502.  Expression in pulmonary endothelial cells has been 
reported to be minimal or absent 501, 503.  FasL protein is expressed in the cell 
membrane and cytoplasm of surface airways epithelial cells (throughout the trachea, 
bronchi and bronchioles), and in some alveolar type II cells.  Monocytes 498, fibroblasts, 
neutrophils 304, 491, and lymphocytes 504-506 also express FasL protein on their surfaces.  
Fas and FasL proteins are co-localized in airway epithelial cells obtained from resected 
human lungs 502, particularly in columnar and basal cells of bronchial epithelium 468.  
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This coexpression of receptor and ligand is uncommon for mammalian cells in normal 
conditions; it has been described only for corneal epithelium, crypt cells in ulcerative 
colitis 507, and two hematopoietic cells, neutrophils 491, and T cells 505, 508. 
 
Fas/FasL interactions have demonstrated a role in immune cell homeostasis.  The 
dysregulation of the Fas apoptotic pathway contributes to several autoimmune 
diseases 508, 509.  However, little is known about the role of these apoptotic molecules in 
epithelial cells 502.  Neo- or overexpression of Fas was detected in the airway 
epithelium of lung inflammatory illnesses such as asthma and chronic bronchitis, as 
well as in the alveolar epithelium of patients with ALI/ARDS in which pro-apoptotic 
pathways are upregulated.  It is now apparent that activation of Fas is likely to have an 
important role in mediating both apoptosis and inflammation in the lung epithelium.  On 
the other hand, the expression of FasL in the lung epithelium may function to prevent 
infiltration of Fas-bearing inflammatory cells (e.g., eosinophils) into the epithelial layer.  
In that case, the FasL expression in the epithelium may confer immune privilege and 
protect it from the activated cell immune response as has been suggested for testis 510, 
brain 511, and placenta 512, 513. 
 
4.3.1.1.   The Fas/FasL system and the molecular mechanisms of apoptosis 
 
Apoptosis is a form of regulated cell death in which activation of specific intracellular 
serine rich proteases (caspases) leads 
to DNA cleavage and cell death.  
Apoptosis is an essential feature of 
development, and provides a 
mechanism for tissue remodeling.  
Apoptosis occurs in response to 
activation of specific cell membrane 
receptors, termed “death receptors”, as 
well as in response to the release of 
mitochondrial products such as cytochrome c 514, 515 (Figure 4.1, adapted from T.R. 
Martin 241).  The death receptor family includes the TNF receptors I and II, and the Fas 
receptor (CD95), which is activated either by Fas ligand (FasL) on the surface of 
cytotoxic lymphocytes, or by a soluble form of FasL (sFasL), which can be cleaved 
from cell membranes by the action of specific serine proteinases, such as matrix 
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metalloproteinases 7 and 3 (MMP-7, MMP-3) 482-488.  Soluble FasL is also released 
from activated blood monocytes, but it does not appear to be released from activated 
alveolar macrophages 471, 489-491.   
 
Apoptosis is initiated by the engagement and co-aggregation of FasL with the Fas 
receptor on the cell surface followed by a series of intracellular molecular interactions 
that coordinate the activation of caspases and cell death (Fig. 4.1) 516-519.  Fas is 
expressed on the surface of cells as pre-associated homotrimers and, upon FasL 
binding, undergoes a conformational change to reveal its cytoplasmic death domain 
(DD), which favors homotypic interactions with other DD-containing proteins.  
Additional interactions mediated through the ‘death effector domain’ (DED) of FADD 
with DED domains of procaspase-8 and procaspase-10 assemble the death-inducing 
signaling complex (DISC) 520.  Efficient DISC assembly provides a molecular scaffold 
which concentrates cysteine proteases in a manner that promotes autoproteolytic 
cleavage of caspase-8 and subsequent activation of the apoptotic pathway.  Activated 
caspase-8 initiates the extrinsic pathway of apoptosis by converting inactive effector 
procaspases-3, -6, and -7 into active enzymes via transproteolysis (in type I cells), and 
also can activate the intrinsic pathway of apoptosis via cleavage of bcl-2 interacting 
domain (Bid) to generate truncated Bid that translocates to the mitochondria and 
induces the release of cytochrome c.   Released cytochrome c activates caspace-9 that 
binds to Apaf-1 and activates caspase-3 (in type II cells) 519, 521, 522.  Executioner 
caspases cleave various vital cellular substrates including cleavage of nuclear DNA 
that leads to cell death.  The DNA cleavage is detectable as a “laddering” effect of DNA 
fragments of different molecular weights when cellular DNA is analyzed by 
electrophoresis in agarose gels.  DNA cleavage is also detectable by assays which 
identify nucleotide cleavage sites using a terminal deoxynucleotide transferase enzyme 
(TUNEL assay) 523.   Activated caspase 3, a distal enzyme in the caspase cascade, can 
be detected in cells and tissues using antibodies specific for the cleaved (activated) 
form of caspase 3. 
 
Cellular apoptosis is tightly regulated by several different inhibitory proteins, so that cell 
death can be controlled at the appropriate times.  These inhibitory proteins of apoptosis 
(IAP) directly bind and inhibit caspases 3, 6, 7, and 9 524-526.  The mitochondrial 
pathway is inhibited by the Bcl-2 family of proteins, which block activation of caspases 
by cytochrome c 525-527.  A FLICE-like inhibitor protein (FLIP) competitively inhibits the 
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binding of caspase-8 to the Fas/FADD membrane complex and blocks the Fas 
signaling pathway 515, 528, 529 .  Apoptosis leads to the loss of polarization of the cell 
membrane followed by the expression of phosphatidylserine on the outer leaflet of the 
lipid bilayer, which can be detectable using the binding of the fluorescent indicator 
annexin V 530.  Apoptotic cells are phagocited via recognition of the phosphatidylserine 
on the cell membrane surface 531. 
 
Resolution of neutrophil mediated inflammation is achieved, in part, through induction 
of neutrophil apoptosis.  This constitutively expressed program can be induced by 
ligation of the Fas receptor.  However, it has been shown that activated neutrophils are 
resistant to pro-apoptotic signals resulting from Fas ligation 305, 532.  This resistance is 
associated with an increase in intracellular levels of reduced glutathione (GSH) 305 and 
altered caspase expression 532.  In addition, apoptosis can be delayed in neutrophils by 
the presence of inflammatory mediators such as insulin-like growth factor-1 (IGF1), 
interferon-δ (IFNG) and granulocyte–macrophage colony-stimulating factor (GM-CSF) 
95.  This indicates that apoptosis of neutrophils are delayed at the site of inflammation. 
 
In epithelial cells, one of the consequences of apoptosis is loss of cellular attachment 
to the underlying basement membrane.  In the alveolar epithelium, this could result in 
the exposure of the underlying alveolar epithelial basement membrane to inflammatory 
products present in the alveolar spaces, such as oxidants, proteinases, and other 
elements of the inflammatory milieu.  Destruction of the alveolar walls is also 
associated with the activation of fibroblast proliferation and collagen production, which 
could lead to fibrosis during the repair process in ALI. Delay in neutrophil apoptosis by 
the presence of inflammatory mediators such as insulin-like growth factor-1 (IGF1), 
interferon-δ (IFNγ) and granulocyte–macrophage colony-stimulating factor (GM-CSF) 
could also perpetuate the injury 83, 304, 473. 
 
4.3.1.2.   Fas/FasL and the molecular mechanisms of inflammation 
 
Apoptosis has been traditionally considered a “silent” process of cell death.  However, 
accumulating evidence indicates that apoptosis can also activate inflammatory 
responses.  The Fas/FasL system triggers activation of a series of cysteine proteases 
(caspases), which leads to apoptosis.  In addition, studies performed in vitro have 
established that activation of the Fas/FasL system can also lead to activation of 
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proinflammatory pathways including those triggered by translocation of NF-κB and 
ERK/AP-1 533, and those associated with activation of the IL-1β converting enzyme 
(ICE, Caspase-1) 534, 535.  The intracellular signaling through the Fas pathway is 
regulated by the intracellular caspase-8 homolog FLICE-like inhibitory protein (cFLIP).  
Binding of cFLIP to the DISC can inactivate caspase-8 and shift the Fas apoptotic 
pathway to non-apoptotic signaling.  FLIP interacts with TRAF1/RIP and with 
TRAF2/Raf-1, leading to NF-κB and ERK/AP-1 activation, respectively 515, 533, 536.  
Activation of the transcription factors NF-κB and AP-1 533, 536, instead of inducing 
apoptosis, leads to the production of proinflammatory cytokines, including neutrophil 
chemoattractant and factors involved in cell proliferation such as IL-2, which facilitates 
proliferation of T cells.  Apoptosis and inflammation are not mutually exclusive; on the 
contrary, they seem to be intimately linked.  This is particularly evident in the dual roles 
of some caspases (including caspase-1) in the execution of both apoptosis and the 
processing and secretion of pro-inflammatory cytokines (including IL-1β and IL-18).  
Notably, FADD and caspase-8, important molecules for the Fas/FasL system-induced 
apoptosis, also mediate NF-κB activation upon Fas ligation.  Moreover, inactivation of 
caspase-8 has been associated to an increase in NF-κB activation induced by sFasL 
537.  Therefore, the branch point of the Fas signal transduction pathways leading to 
apoptosis and NF-κB activation has been suggested to be downstream of caspase-8.  
However, molecular details underlying proinflammatory signaling induced by FasL are 
not completely understood. 
 
In general, FasL induces inflammation by exerting a direct effect on inflammatory cells.  
In this sense, FasL promotes neutrophil infiltration 538 and activates macrophages.  
When human macrophages are activated by soluble FasL (sFasL) or the agonistic 
antibody CH11 in vitro, they do not become apoptotic, but instead release 
proinflammatory cytokines such as TNF-α and IL-8 associated with nuclear 
translocation of NF-κB 499.  In addition, soluble FasL (sFasL) activates NF-κB and 
ERK1/2 in serum-starved fibroblasts, leading to IL-6 and IL-8 secretion in the complete 
absence of cell death 537.  Interestingly, new evidence indicates that Fas/FasL 
mediated-inflammation is not restricted to inflammatory cells.  In fact, a variety of cells 
including epithelial cells can also secrete cytokines and chemokines upon Fas ligation.  
In vitro studies showed that Fas ligation in bronchiolar and alveolar epithelial cells 
induces the secretion of the neutrophil chemoattractant IL-8 through NF-κB activation 
in combination with activation of pro-apoptotic pathways 539.  In human kidney cells 
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(HEK293 cells), FasL induces cell-autonomous NF-κB activation and IL-8 production 
without inducing detectable apoptosis 540.  Vascular smooth muscle cells upregulated a 
number of cytokines and chemokines in response to Fas ligation, including IL-8, IL-1α, 
MCP-1, GRO-1 and IL-6.   Therefore, locally excessive FasL-mediated apoptosis is not 
a 'silent' process but it can promote secretion of proinflammatory cytokines and 
recruitment of inflammatory cells.  This double function may facilitate cytokine-
mediated recruitment of inflammatory phagocytes to clear apoptotic bodies from areas 
of excessive apoptosis, but cytokines and active phagocytic cells have also been 
directly implicated in the generation of local tissue damage 469, 473. 
 
 
4.3.2.   RELEVANCE OF FAS/FAS LIGAND SYSTEM IN ALI 
 
4.3.2.1.   Clinical studies 
 
Albertine et al. found that, in the lungs of patients with ALI or ARDS, both Fas and FasL 
are co-expressed by alveolar epithelium and distal airway as well as by inflammatory 
cells (neutrophils and macrophages/monocytes) located in the air spaces 468.  The local 
up-regulation of Fas/FasL is greater in the lungs of patients who died, and is 
associated with greater apoptosis of cells in the alveolar wall 468.   S. Hashimoto et al. 
also found up-regulation of mRNA for a number of molecules associated with 
apoptosis, including Fas and FasL, in the cellular component of the BAL fluid from 
patients with septic ARDS 467.   
 
G.  Matute-Bello and T.R.  Matin (mentors) first found that soluble Fas ligand is present 
in the BAL fluid in humans with early ARDS, and reaches higher concentrations in the 
lung fluids from patients who die.  The soluble Fas ligand present in the lung fluids from 
patients with ARDS is biologically active and can induce apoptosis in normal human 
distal lung epithelial cells 284.  Albertine et al. confirmed these findings by detecting 
higher concentrations of soluble FasL in the undiluted pulmonary edema fluid of 
patients with ALI or ARDS compared to control patients with hydrostatic pulmonary 
edema.  In addition, the concentration of soluble FasL was significantly higher in the 
pulmonary edema fluid of patients with ALI or ARDS compared to simultaneous plasma 
samples, indicating local production in the alveolar compartment 468. 
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Matute-Bello and Martin also demonstrated that cells recovered from the airspaces of 
patients with ARDS release sFasL (40), which increased after stimulation with 
lipopolysaccharide (LPS) 284.  This can be particularly relevant since LPS is also 
present in the BAL fluid of many patients with ARDS 357, 358.   A separate group 
determined that FasL mRNA was increased in the cellular component of BAL fluid 
retrieved from patients with early septic ARDS 468.  These results show that sFasL is 
produced or released locally in the airspace compartment.  The alveolar macrophages 
are a possible source, since cells of the human monocyte/macrophage lineage contain 
FasL and release it when activated by phytohemagglutinin, immune complexes, or 
superantigen 471, 490, 541.  A second possibility could be that sFasL increases in the 
circulation as part of the systemic inflammatory response, and then moves into the 
airspaces when endothelial and epithelial permeability increases.  Indeed, sFasL 
concentration was not only elevated in the BAL fluid but also in serum of patients with 
ARDS and other pulmonary inflammatory diseases, such as idiopathic pulmonary 
fibrosis 295, bronchiolitis obliterans-organizing pneumonia 240, hypersensitivity 
pneumonitis, and pneumococcal pneumonia 542.  In addition, plasma sFasL was 
increased in patients with ARDS who underwent ventilation with a conventional 
strategy compared with the lung protective strategy, and it was associated with the 
development of renal dysfunction 543.  Elevated concentrations of sFasL have also 
been found in serum of patients with cardiopulmonary arrest 544 and chronic renal 
failure 545.  Thus, it is possible that both locally shed sFasL and systemic influx of 
circulating sFasL account for the increased concentrations that were detected in BAL 
fluid from patients with ARDS.  The elevated concentrations of sFasL in either BALF or 
serum were associated with an increase in the progression to multiple organ failure and 
mortality in ARDS 284, 546, 547. 
 
Taken together, these findings demonstrate that the Fas/FasL system is upregulated in 
the lungs of patients with acute lung injury and that sFasL is released into the 
airspaces in vivo during lung injury as a biologically active molecule capable of 
inducing apoptosis in Fas-susceptible target cells of the lungs.  Altogether, these 
studies suggest that the Fas/FasL system is likely to have a role in the pathogenesis of 
the distal lung epithelial injury seen in ALI or ARDS.   
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4.3.2.2.   Animal studies 
 
Animal studies have provided evidence supporting a key role for the Fas/FasL system 
in lung disease.  Fas is detectable on airway epithelial cell (Clara cells) and alveolar 
type II cells in rodents 280, 283, 502, and the expression of Fas in epithelial cells increases 
in response to inflammatory mediators such as lipopolysaccharide (LPS) 274.   We have 
shown that activation of the Fas/FasL system by either a Fas-activating mAb or 
recombinant human sFasL causes ALI and lung epithelial apoptosis in mice and rabbits 
548, 549.  Fine et al. also found that activation of Fas caused apoptosis of murine alveolar 
type II cells in vivo 283.   In a murine model of LPS-induced lung injury, the functional 
Fas/FasL system is required for the alveolar wall permeability changes and 
inflammation, as Fas-deficient mice had significantly less lung injury 274.  Fas- and Fas 
ligand–deficient mice showed marked protection from lung inflammation and apoptosis 
and decreased severity of lung injury in models of ALI mediated by sepsis after cecal 
ligation and puncture 550.  Other studies also showed that Fas-deficient mice had 
significantly reduced mortality from hypoxia-induced lung injury during Legionella 
pneumonia 551 or after challenge with intrapulmonary deposition of the IgG immune 
complexes 472.  In addition, activation of the Fas/FasL system has also been associated 
with development of distant organ failures (e.g. renal dysfunction) in models of injurious 
mechanical ventilation 543.  Thus, a growing body of evidence from studies of humans 
and animal models links activation of the Fas/FasL system with lung injury.  However, 
how activation of Fas/FasL contributes to the development of injury in the lungs is 
currently unknown. 
 
 
4.3.3.   MECHANISMS OF LUNG INJURY BY THE FAS/FAS LIGAND SYSTEM 
 
4.3.3.1.   Fas/FasL system and apoptosis in alveolar epithelial cells in ALI 
 
Damage to alveolar epithelial cells is one of the earliest events that occur in the 
development of ALI/ARDS in humans, and the severity of epithelial damage is 
associated with morbidity and mortality 18, 38, 106, 241, 258, 552.  The actual mechanisms 
leading to alveolar epithelial damage remain unclear, but are likely to involve a 
combination of necrosis and apoptosis.  Necrosis of alveolar epithelial cells has been 
found in the lungs of patients who died with ALI/ARDS, and is thought to be caused 
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directly by mechanical factors, local ischemia, or bacterial products in the airspaces 85, 
110, 259, 553.  Apoptotic cells have also been found in the alveolar wall of these patients.  
Activation of Fas in the cell membrane is one of the most potent mechanisms to induce 
cellular death by apoptosis 241, 258, 284, 468, 470, 554, 555. 
 
4.3.3.1.1.   Clinical studies 
 
Open lung biopsies performed on ARDS patients reveal apoptosis in Type II 
pneumocytes 110, 272.  The alveolar epithelium from humans with diffuse alveolar 
damage shows increased expression of the apoptotic promoter Bax, a homolog of Bcl-
2 273.  Albertine et al. also reported increase in markers of apoptosis (terminal dUTP 
nick-end labeling, capase 3, Bax, and P53) in the alveolar wall of patients who died 
with ALI or ARDS as compared with patients who died without pulmonary disease.   In 
addition, both Fas and FasL have been shown to be co-expressed by epithelial cells in 
the alveolar wall, as well as, inflammatory cells located in the airspaces, and to a 
greater extent in patients who died with ALI or ARDS compared with those dying 
without pulmonary disease.  The local up-regulation of the Fas/FasL system occurred 
in the alveolar epithelium and was associated with greater apoptosis and worse clinical 
outcome in patients with ALI/ARDS 468.   
 
T.R. Martin’s group found that human distal lung epithelial cells are sensitive to sFasL-
induced apoptosis, whereas proximal lung epithelial cells are relatively insensitive 497.  
These studies raise the possibility that there is a gradient of Fas sensitivity in the lungs, 
with the proximal airways relatively insensitive to sFasL and increasing sensitivity 
moving distally in the airways and into the alveolar space.  The mechanisms for the 
differential sensitivity of proximal and distal pneumocytes to sFasL remain unclear, as 
both types of cells express membrane Fas and contain similar patterns of steady-state 
mRNAs for the Fas pathway intermediate proteins.  These findings are important since 
epithelial damage occurs primarily in distal airway and alveolar epithelium in 
ALI/ARDS, whereas sFasL is present throughout the airspaces 497.  Altogether, these 
findings show that in humans with ALI or ARDS, the Fas/FasL system-induced 
apoptosis seems to be an important mechanism in alveolar epithelial injury 468, 556.  
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4.3.3.1.2.   Experimental studies 
 
In animal models, T.R. Martin’s group found that intratracheal instillation of 
recombinant human sFasL causes lung injury and epithelial apoptosis in the lung of 
rabbits 549, , and that activation of Fas using an activating monoclonal antibody (Jo-2), 
causes injury and epithelial apoptosis in the lungs of mice 555 .  Rabbit and mouse 
alveolar type II cells are sensitive to Fas activation either by human sFasL (in rabbit 
pneumocytes) or by a specific monoclonal antibody, which clusters membrane Fas (in 
murine pneumocytes) 549, 555.  Furthermore, the absence of a functional Fas–FasL 
system in mice or the administration of Fas-blocking antibodies decrease the severity 
of ALI and diminishes epithelial cell apoptosis and pulmonary inflammation 282, 284, 472, 
555.  These collective data suggest that the Fas/FasL pathway may play an important 
role in apoptosis of alveolar epithelial cells and disruption of the alveolar-epithelial 
barrier in ALI.   
 
4.3.3.1.3.   Modulatory factors of Fas-mediated apoptosis in alveolar epithelial cells 
 
Several factors modulate Fas-mediated apoptosis of alveolar epithelial cells.  
Surfactant protein A (SP-A), the primary protein present in pulmonary surfactant, is an 
inhibitor of type II apoptosis in vivo 287, 288.  This is important because in patients with 
early ARDS, the concentration of SP-A is decreased in BAL fluid 214.  The lower 
concentration of SP-A would favor apoptosis of Type II cells in these patients.   Another 
important modulator of Fas ligand in the lungs is angiotensin II.  Epithelial cells interact 
with angiotensin II via the angiotensin receptor subtype AT1, and this interaction is 
required for Fas-mediated apoptosis of alveolar epithelial cells in vitro 268.  Fas ligand 
and angiotensin II can induce apoptosis in cell lines derived from Type II cells 268, 285.   
In ARDS the concentration of angiotensin-converting enzyme, which catabolizes the 
conversion of angiotensin I to angiotensin II, is increased in BAL fluid 286.  Therefore, in 
early ARDS a combination of three factors favors alveolar epithelial apoptosis: 
increased concentrations of soluble Fas ligand; decreased concentrations of SP-A; and 
increased concentrations of angiotensin-converting enzyme and angiotensin II.  
Together, these studies suggest that the Fas/FasL system may mediate, in part, the 
injury to distal lung epithelial cells that occurs in patients with ALI or ARDS. 
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4.3.3.2.   Fas/FasL system and inflammation in ALI 
 
It was recently suggested that Fas (CD95) signaling can have apoptotic or pro-
inflammatory functions, and that the resultant effects strongly depend on the cellular 
microenvironment 469.  The role of the proinflammatory function of the Fas/FasL system 
in the pathogenesis of lung injury remains unclear.  In experimental studies, activation 
of the Fas/FasL system in the lungs consistently leads to activation of inflammatory 
responses characterized by cytokine release and neutrophil recruitment into the lungs 
499, 557-559.  Wortinger et al. found that instillation of recombinant FasL into the lung 
induces production of KC and MIP-2 and the recruitment of neutrophils into the lung in 
animal models 560.  Furthermore, G. Matute-Bello and T.R. Martin (mentor group) 
reported that Fas activation in vivo resulted in acute lung epithelial injury, lung 
inflammation, and recruitment of neutrophils 282, 548, 549, 555 and that Fas also modulated 
LPS-induced lung inflammation 274, 561.  The relevance of the proinflammatory function 
of the Fas/FasL system was confirmed in studies by Neff et al. who demonstrated that 
mice deficient in Fas have an impaired neutrophilic response and less production of KC 
and MIP-2 in response to inhaled LPS 472, 562.  In addition, silencing of Fas in the lungs 
protected against lung inflammation in models of hemorrhagic shock and septic shock 
followed by cecal ligation and puncture 563.  Furthermore, blockade of the Fas/FasL 
system by specific pharmacological inhibitors or Fas mutation (lpr mice) resulted in 
reduced neutrophil counts in the bronchoalveolar lavage (BAL) fluid and lower 
concentrations of TNF-α and MIP-2 at 48 h after intratracheal instillation of S. 
pneumoniae 564.  Together, these studies suggest that the Fas/FasL system may play 
an important role not only in apoptosis but also in the development of an inflammatory 
response in the lungs following exposure to LPS, live bacteria, and sepsis. 
 
In in vitro experiments, Fas ligation of human monocyte-derived macrophages resulted 
in the release of pro-inflammatory factors such as TNF-α and IL-8. Murine alveolar 
macrophages release KC and MIP-2 in response to human recombinant soluble FasL 
490, 499. Activated monocytes and macrophages by Fas ligation did not become 
apoptotic.  In contrast, A.M. Hohlbaum et al. determined that stimulation of peritoneal 
neutrophils released pro-inflammatory factors (MIP-2), and at the same time, these 
cells underwent cell manifestations of apoptosis 565.  In addition, the apoptotic death of 
this cell population in the peritoneum preceded neutrophil inflammation, whereas the 
soluble form of FasL (sFasL) did not induce apoptosis as mentioned above.  
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Interestingly, bronchiolar epithelial cells undergo apoptosis and also secrete IL-8 by 
activation of nuclear factor-kappa B (NK-κΒ) in response to Fas ligation in vitro 539.  
Current studies determined that the murine alveolar epithelial cell line MLE-12 releases 
the neutrophil chemoattractant KC, MIP-2 and MCP-1 in response to Fas activation in 
vitro 566, which was abrogated by inhibiting ERK1/2 signaling 550, 567.  Therefore, it could 
be possible that FasL signaling induces inflammatory apoptosis in epithelial cells and 
alveolar macrophages, with concomitant cytokine and chemokine release leading to 
neutrophil infiltration, which in turn may amplify the inflammatory cascade in lung injury.   
 
Activation of pro-inflammatory pathways in both lung epithelial cells and macrophages 
by Fas ligation raises the question of whether the neutrophilic inflammatory response 
mediated by Fas in lungs is due to direct activation of alveolar macrophages or instead 
is secondary to an initial effect on lung epithelial cells.  To answer this question, T.R. 
Martin’s group used chimeric mice lacking Fas in either myeloid or non-myeloid cells 
555.  They determined that mice expressing Fas only in their myeloid cells (alveolar 
macrophages) showed little response to Fas activation, whereas the mice expressing 
Fas in their non-myeloid cells (lung epithelium) showed evidence of both inflammation 
and apoptosis, suggesting that alveolar macrophages are not required for the 
development of Fas-induced lung inflammation in mice 555.  This was also confirmed in 
macrophage-depleted mice which developed a neutrophilic inflammatory response 
following Fas activation in vivo, suggesting that other cell type(s) in the lung can 
promote inflammation 566.  In this sense, the alveolar epithelium may be an important 
source of pro-inflammatory cytokines during the early phase of lung injury 555, 566, 568-573.  
To support this notion, some studies have shown that primary human alveolar Type II 
cells stimulated with LPS release chemokines (MCP-1, GRO, and IL-8) 571.  Altogether, 
these results suggest that the lung neutrophilic inflammatory response to Fas activation 
is not primarily dependent on alveolar macrophages and may depend instead on 
cytokine release by alveolar epithelial cells.   Also, it may be possible that this 
inflammatory response is favored by secondary activation of inflammatory cells in 
response to phagocytosis of apoptotic epithelial cells. 
 
4.3.3.3.   Fas/FasL system and protein permeability 
 
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are 
characterized by increased protein permeability across the pulmonary microvascular 
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endothelium and alveolar epithelium 1, 210.  The main structural manifestation of 
increased protein permeability is the disruption of alveolar epithelial cells 85, 108, 237, 574.  
The mechanisms by which the alveolar epithelium is injured in humans with ALI or 
ARDS are not totally clear.   Nevertheless, some studies indicate that Fas-mediated 
apoptosis is one of the mechanisms involved in alveolar epithelial damage and 
consequently in the alteration of the alveolar protein permeability epithelial apoptosis 
284, 468, 555. 
 
In animal models, G. Matute-Bello and T.R. Martin also determined that Fas-mediated 
lung injury requires expression of Fas expression on nonmyeloid cells including lung 
epithelial cells, and is associated with apoptosis of cells of the alveolar walls, increased 
alveolar permeability, and moderate neutrophilic inflammation in the absence of 
cytokine expression (MIP-2, KC).  These findings suggest that the alveolar epithelium 
is the primary target of Fas-mediated acute lung injury 555.  Furthermore, the 
neutrophilic response in the mice expressing Fas in myeloid cells (alveolar 
macrophages/monocytes and neutrophils) was small and was not associated with 
permeability changes.  This suggests that in those animal models of lung injury 
mediated by Fas activation, the increase in protein permeability is due to Fas-mediated 
injury in the epithelium, rather than by inducing an inflammatory response.   
 
4.3.3.4.   Fas/FasL system and pulmonary fibrosis 
 
The control of cell number is determined by a balance between cell proliferation and 
cell death.  Apoptosis, then, may have a role in human diseases in two different ways.  
Increased apoptosis in the early phase of ALI, particularly in alveolar epithelial cells, 
may contribute to respiratory failure.  However, apoptosis can also have a beneficial 
role in lung repair in the proliferative and chronic phase of ALI when the elimination of 
proliferating mesenchymal and inflammatory cells from the alveolar air space and the 
alveolar walls are required 575, 576.  Excessive alveolar epithelial cell death could 
overwhelm the necessary elimination of proliferating mesenchymal and inflammatory 
cells after the early phase of lung injury.  This could prolong the inflammatory response 
576, 577 and interfere with re-epithelization, which leads to overgrowth of lung fibroblasts 
and development of lung fibrosis 238, 576.   
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4.3.3.4.1.   Fibrosis in ALI 
 
The early inflammatory response in ALI/ARDS, which is maximal during the first three 
days, is then followed by a fibroproliferative response 38 1, 210.   The fibroproliferative 
response is thought to occur late in the course of ALI/ARDS, but autopsy studies have 
shown histopathological evidence of fibroproliferation as early as day 5 with evidence 
of collagen production in the lungs even on the first day of ALI/ARDS 83, 112, 400, 578, 579.  
The development of a fibroproliferative response has been repeatedly identified as an 
independent poor prognostic factor in ALI/ARDS 84, 448, 580. 
 
4.3.3.4.2.   Lung fibrosis and apoptosis of lung epithelial cells  
 
A prominent feature of lung fibrosis is the proliferation and accumulation of 
mesenchymal cells, which include abnormal fibroblast populations that emerge in the 
interstitium but may migrate into the alveolar spaces 581-584, and endothelial cells that 
proliferate during the neovascularization of nascent fibrotic foci 575, 576.  Apoptosis has 
been identified as an important mechanism to remove excess cells to recover from lung 
fibrosis.  On the other hand, apoptosis of epithelial cells has been reported to 
contribute directly to the pathogenesis of lung fibrosis.  Epithelial apoptosis occurs in 
regions of the heaviest myofibroblast activity and collagen accumulation in patients with 
idiopathic pulmonary fibrosis (IPF) or chronic hypersensitivity pneumonitis.  Apoptosis 
can damage the lung epithelium, which has important antifibrotic functions, including: 
1) constitutive synthesis of inhibitors of lung fibroblast proliferation such as 
prostaglandin E2; 2) the synthesis of urokinase-type plasminogen activator and the 
degradation of fibrin exuded from damaged capillaries; 3) the provision of a physical 
barrier that protects underlying interstitial cells from mitogens that are released by 
activated alveolar macrophages 239, 241, 294, 582, 583, 585.  Therefore, apoptosis results in 
loss of the alveolar epithelial cells and their normal antifibrotic functions, which may 
directly promote proliferation of lung fibroblasts and collagen deposition 241, 294, 296, 582, 
583, 586, 587. 
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4.3.3.4.3.   Lung Fibrosis and Fas/FasL system 
 
a) Clinical studies 
 
In the lung tissue from patients with idiopathic pulmonary fibrosis, the expression of 
Fas and FasL proteins was upregulated in bronchiolar and alveolar epithelial cells and 
in infiltrating lymphocytes or granulocytes, respectively indicating a potential role of the 
Fas/FasL system in the development of lung fibrosis.  The Fas-FasL pathway has been 
shown to contribute to severe epithelial damage and seems to be a predisposing factor 
for fibroblast proliferation in ARDS 240, 295.   The soluble FasL released into the air 
spaces is biologically active and induces apoptosis of epithelial cells during acute lung 
injury 284.  Alveolar epithelial damage in humans with ALI or ARDS is in part associated 
with the local upregulation of the Fas-FasL pathway and activation of the apoptotic 
cascade in epithelial cells 468.  The Fas/FasL system is also upregulated in lung 
epithelial cells and infiltrating inflammatory cells in lung tissues from patients with 
idiopathic pulmonary fibrosis (IPF) 240, 295.  In these patients, the expression of FasL is 
increased in myofibroblasts.  The BAL fluid from patients with ARDS or IPF could 
induce apoptosis in small airway epithelial cells which are sensitive to the Fas-FasL 
pathway 284, 295, 476.  FasL molecules are reported to be expressed on α-smooth muscle 
actin positive cells in mice with bleomycin-induced pulmonary fibrosis, and in humans 
with IPF 469, 473, 476.  Inhibiting this pathway may be one of the novel treatment strategies 
against lung injury and fibrosis.   
 
b) Experimental studies 
 
Activation of Fas receptor in the lungs is associated with apoptosis of bronchial and 
alveolar epithelial cells and acute lung inflammation followed by delayed fibrosis in 
mice 238, 241, 296.  Also, the induction of lung fibrosis by intratracheal instillation of 
bleomycin is associated with the up-regulation of Fas on the epithelium associated to 
epithelial apoptosis that preceded the accumulation of collagens 293, 295.   Blockade of 
the Fas receptor by administration of a Fas-soluble form of Fas antigen and anti-FasL 
antibody prevented the development of bleomycin-induced fibrosis, and Fas- and FasL-
deficient mice were resistant to the induction of pulmonary fibrosis 295, 588.  This 
suggests that Fas-induced apoptosis plays an essential role in the development of the 
fibrotic response 295, 469, 473.   G. Matute-Bello showed that in mouse lungs, repeated 
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activation of Fas resulted in apoptosis of bronchial and alveolar epithelial cells, but not 
fibroblasts, which subsequently led to pulmonary fibrosis in mice 238.  These results 
imply that the resistance of fibroblasts to Fas-mediated apoptosis may be associated 
with the pathophysiology of pulmonary fibrosis.  In animal models of bleomycin-induced 
lung fibrosis there is an increase of FasL in myofibroblasts as occurs in the lungs of 
patients with IPF.  It has been determined that FasL-expressing myofibroblasts may act 
as effector cells to induce Fas-dependent epithelial cell apoptosis during lung fibrosis.  
This indicates that myofibroblasts may prolong the epithelial cell apoptosis, which could 
impair the re-epithelialization in lung fibrosis.  Several other studies have indicated the 
existence of “cross-talk” between lung epithelium and myofibroblasts, which may be 
involved in the development of lung fibrosis 589.  Epithelial cells overlying fibroblastic 
foci were found to be apoptotic 590, and fibroblasts isolated from fibrotic human or rat 
lungs were shown to produce factors capable of inducing epithelial cell apoptosis 589. 
 
Fas ligation over time induces not only apoptosis but also inflammatory responses and 
pro-fibrotic factors such as TGF-β.  Fas activation in the lungs has previously been 
shown to upregulate TGF-β expression, and several studies have suggested that TGF-
β plays an important role in the development of fibrotic responses in mice 591.  More 
recently, a study by G. Matute-Bello found that activation of the Fas receptor pathway 
in the lungs is associated with up-regulation of metalloproteinase-12 (MMP-12) in 
alveolar macrophages 296, 365, 592 and that deficiency in MMP-12 protected from Fas-
mediated fibrosis.  It has been found in in vitro studies that MMP-12 has a wide variety 
of potential substrates, including type IV collagen, fibronectin, laminin, and gelatin, as 
well as non-matrix proteins such as α1-antitrypsin and latent TNF-α 593.  The 
mechanism by which MMP-12 has a role in Fas-mediated lung fibrosis is not yet clear.  
One possibility is that Fas dependent apoptosis of alveolar epithelial cells exposes the 
alveolar basement membrane and allows MMP-12 and other metalloproteinases to 
degrade the matrix, triggering a fibroproliferative response 296. 
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4.3.4.   CONTROL OF THE BIOLOGICAL ACTIVITY OF sFasL 
 
4.3.4.1.   FasL structure 
 
FasL protein is expressed in two distinct forms: 1) a membrane form on the cell surface 
or stored in intracellular microvesicles (mFasL), which are excreted into the intercellular 
milieu in response to various physiologic stimuli; and 2) a soluble form (sFasL) 
generated by the cleavage of membrane FasL by matrix metalloproteinases expressed 
on the cell surface 482-488 or released by activated monocytes 471, 489-491.    
 
The membrane FasL is a 40 kDa type II protein that acts locally through cell-to-cell 
contact.  The cell membrane form of FasL comprises cytoplasmic, transmembrane and 
extracellular regions.  As with other members of TNF family, the extracellular domain of 
FasL can be cleaved by matrix metalloproteinases into a 26-29 kDa soluble form 
(sFasL).  The extracellular domain is composed of the stalk region (103-136 aa) at the 
NH2-terminus (closer to the cell membrane) and the TNF homology domain (137-
281aa) at the COOH-terminus.  It has been identified a self assembly (SA) region 
spanning aa 137 to 183 of the FasL ectodomain.  The oligomerization of mFasL seems 
to be essentially dependent on the SA region and is required for activation of Fas and 
intracellular signalling.  Membrane-bound FasL presumably exhibits its biological 
activity as a homotrimeric complex.  The TNF homology domain (THD) expresses the 
highest similarity to related proteins, but also mediates highly specific binding to the 
cysteine-rich domains of the Fas receptor 594-596.  The cleavage site of FasL is outside 
the regions that are required for multimerization and receptor binding.  That means that 
sFasL carries both domains and theoretically could have the capacity to form multimers 
and bind to Fas.  In fact, human sFasL has also been shown to form trimers in in vitro 
studies. 
 
4.3.4.2.   Functional activity of sFasL 
 
There is substantial controversy in the literature over the physiological role of sFasL.  
Some studies found that sFasL in solution was less effective than membrane FasL in 
inducing apoptosis, and that sFasL inhibited the cytotoxicity mediated by membrane 
FasL 482, 597, 598.  Thus, it has been proposed that sFasL might function to protect 
healthy bystander cells bearing FasL, such as cytotoxic T cells 565.  In some studies, 
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neither human nor murine sFasL could induce apoptosis in cultured lymphocytes, 
hepatocytes, or colon carcinoma cells 565.  On the other hand, human sFasL induced 
hepatic failure in mice that  had been pretreated with bacteria, whereas mice deficient 
in Fas receptor (lpr mice) were not affected 599, indicating that human sFasL induced 
liver damage by Fas activation.  T.R. Martin’s group demonstrated that intratracheal 
instillation of human sFasL induced lung injury in rabbits.  In accordance with that, 
sFasL is also pro-apoptotic in vitro against Helicobacter pylori-infected gastric epithelial 
cells, mouse hepatocytes and lymphoma cells among others.  Furthermore, two 
separate groups also found that neutrophils undergoing apoptosis release sFasL 
capable of inducing cell death of lung epithelial cells 577 and Jurkat cells 491.  On the 
other hand, it has been suggested that sFasL can activate inflammatory responses 
rather than apoptosis.  Human sFasL can recruit human and mouse PMN in vitro 538, 600 
and reduces neutrophil adhesion to endothelial cells 601, 602.  Therefore, it seems that 
sFasL can have proapoptotic, antiapoptotic, and neutrophil recruitment functions 
depending on the nature of other contextual mediators in the microenvironment 554, 597, 
600, 603-606. 
 
The difference between the membranous and the soluble FasL in activating apoptosis 
is not completely understood.  The receptor Fas needs to co-aggregate into high 
molecular weight clusters in order to transmit the intracellular death signal 518, 519.  
Some studies suggest that the membrane-bound FasL has capability to form trimers 
and larger aggregates on the cell surface that facilitates the formation of the receptor 
Fas clusters which results in oligomerization of a cytoplasmic death domain (DISC) 
and, consequently, intracellular death signalling 518, 519, 521, 607, 608.   Although sFasL exits 
as a homotrimer and binds to Fas, some studies show that it is ineffective in forming 
Fas clusters necessary to activate apoptotic signal, but is capable of activating non-
apoptotic signals 519, 540, 554, 605, 609, 610.  Thus, the transduction of the apoptotic signal by 
membranous FasL can be blocked in the presence of sFasL and the observed overall 
effect is inhibition of apoptosis 597, 598, 611.  Another possibility for the differences in the 
activity between membranous and soluble forms of FasL is that accessory molecules 
may act to enhance the activity of membrane FasL.  S. Sieg et al. determined that the 
expression of ICAM-1 on the cell surface with FasL enhances the capacity of FasL to 
induce apoptosis 612.  The sFasL, however, can induce apoptosis following association 
or aggregation with extracellular matrix proteins 613, 614 when cells overexpress Fas on 
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their surface 481, 598 or when engineered to form tetramers and higher order structures 
615-617. 
 
The discrepancies among studies may be due to the presence of accessory molecules 
that may enhance the function of sFasL, the type of tissues and cells used to test 
cytotoxicity and the environmental conditions.  In addition, these differences may be 
explained by the different methods to generate sFasL and the use of sFasL from 
distinct species (human vs mouse) and with different N-terminal sequences. 
   
4.3.4.2.1.   Cleavage sites 
 
Different cleavage sites have been identified in the extracellular domain of FasL where 
several matrix metalloproteinases (MMPs) can act to generate sFasL483, 484, 487, 488, 597, 
618.  The multiple forms of sFasL that have been used so far had different N-terminal 
sequences, which may represent alternative proteolytic cleavage products.  Tanaka el 
al. reported that natural cleave short form of mouse sFasL (amino acids 127–279) was 
not cytotoxic 482. In contrast, Berg and Suda showed that a recombinant protein 
corresponding to the entire extracellular domain of mouse FasL (amino acids 101–279) 
induced apoptosis 619, 620. 
 
Recent studies have shown that matrix metalloproteinase 7 and 3 (MMP7-3) cleave 
FasL in certain cell types 488.  In contrast to the previously described sFasL fragments, 
the soluble protein generated by MMP7 cleavage has pro-apoptotic activity in vitro in 
prostate epithelial cells and in vivo 487, 621.  Therefore, it is possible that differential 
proteolysis of FasL could yield soluble forms with unique biological activities.  This 
could explain in part the discrepancies related to the function of sFasL 488.   
 
Three different cleavage sites in FasL have been reported for MMP-7: 1) ELAELR 
present in the stalk region close to the cell membrane, 2) SL, upstream to the previous 
one, also present in the stalk region, and 3) ELR, the closest to the C-terminus, present 
in the trimerization domain within the TNF domain.   It is possible that processing at the 
ELAELR site occurs first, followed by a secondary cleavage at the C-terminally located 
SL sites in both murine and human FasL 488.  In other studies, cleaved sFasL at the 
trimerization domain created a sFasL molecule that was no longer active 622.  
Therefore, it is possible that the existence of different cleavage sites of FasL may yield 
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a variety of soluble forms with different biological activities, which also implies that 
MMPs such as MMP-7 could be a mechanism to regulate the activity of FasL in vivo. 
 
4.3.4.2.2.   Aggregation 
 
Numerous proteins can form multimers composed of two or more polypeptide chains 
which may be alike (homo-multimers protein) or different (hetero-multimers protein).  
The degree of multimerization has been proposed to tightly control the biological 
activity of some proteins by diminishing or enhancing their activity.  Also, it has been 
observed that multimeric proteins normally are more resistant to degradation 623, 624. 
 
As mentioned before, the membrane-bound FasL has the capability to form aggregates 
of higher molecular weight while binding to receptor Fas 625.  Formation of high 
molecular weight Fas-FasL complexes results in oligomerization of a cytoplasmic death 
domain (DISC) and, consequently, intracellular death signal transmission 522, 626.  Some 
studies have found that human sFasL also forms trimers but that these trimers cannot 
initiate the apoptosis signal 611.  Two separate groups artificially aggregated human 
sFasL units upon addition of cross-linking antibodies and observed that this larger 
molecule of sFasL restored its cytotoxic activity in in vivo and in vitro models 597, 615.  P. 
Schneider et al. compared the effect on mouse liver of this cross-linked aggregated 
sFasL to its non-aggregated form.  The cross-linked sFasL induced lethal liver 
hemorrhages and apoptosis in hepatocytes, whereas the non-aggregated sFasL 
treated hepatocytes had a normal morphology 597.  Moreover, Holler et al. showed that 
both trimeric or hexameric sFasL bound to Fas, but only the hexameric forms were 
highly cytotoxic and competent to signal apoptosis via formation of death-inducing 
signaling complex 615.  They suggested that a minimal multimerization into hexamers of 
sFasL is required to trigger the intracellular death signal.   
 
It has been reported that a substitution of F275 to L275 in human FasL mice leads to 
an inadequate oligomerization of FasL molecule along with a significant loss of activity 
622, 627.  However, substitution of amino acid residues located at the binding site resulted 
in a deficiency in Fas-FasL binding and a significant loss of cytotoxicity but its capacity 
to multimerize was preserved.  This suggests that both multimerization and adequate 
binding of FasL to its receptor are needed in order to preserve its cytotoxic activity. 
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4.3.4.2.3.   Level of Fas expression in the cell membrane and type of cell 
 
It also has been proposed that the activity of sFasL is target-cell specific.  Some cells 
have different sensitivities to the soluble and the membrane-bound forms of sFasL.  
Although sFasL has less capability to induce apoptosis than the membrane-bound 
FasL, some cells can be killed by sFasL under certain circumstances.  For example, 
mouse W4 and hFasL/ WR19L cells that overexpress Fas could be efficiently killed by 
natural cleaved human sFasL 483, 492.  In contrast, human Jurkat cells or mouse primary 
hepatocytes that express a moderate level of Fas endogenously were resistant to 
human sFasL but were efficiently killed by membrane-bound FasL 281, 597, 612, 622.  
Therefore, the levels of the receptor Fas expressed in the cell surface can explain in 
part the differences in the sensitivity to sFasL.   Also the use of tumor cells verus non-
tumor cells, lymphoid cells vs epithelial cells, and transformed cells vs primary cells 
that display different behaviors can also account for the different activity of sFasL found 
in the literature. 
 
4.3.4.2.4.   Species-specific differences 
 
Species-specific differences have been detected in the activity of sFasL.   Some 
studies show that mouse sFasL is less cytotoxic than human sFasL in vitro 619.  In our 
preliminary animal experiments, we confirmed that intratracheal instillation of mouse 
sFasL into mouse lungs was poorly cytotoxic, whereas instillation of human sFasL 
resulted in the development of lung injury in vivo. 
 
4.3.4.2.5.   Accessory molecules 
 
Association of proteins to other molecules is a general phenomenon that controls 
protein activity.  For instance, immunoglobulins associate with many proteins in the 
lungs, which leads to important changes in activity those proteins.  In particular, the cell 
adhesion molecule ICAM-1 has been shown to enhance the activity of FasL in vitro, 
which raises the possibility that sFasL activity might be also regulated by associations 
with other molecules in the lungs 612.   In addition, membrane-bound FasL has been 
found to bind to fibronectin (FN) and vitronectin, two prototypic cell-adhesive 
glycoproteins of the extracellular matrix (ECM), and the resulting ECM-anchored FasL 
retains its cytotoxic potential 613, 614.   The soluble form of FasL can also bind to these 
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extracellular matrix products, resulting in the recovery of cytotoxic activity.  The sFasL 
can induce apoptosis when it is anchored to the extracellular matrix to form oligomers 
613, 614.   In contrast, if sFasL is released in a milieu where the formation of oligomers is 
unattainable, it may exert an antiapoptotic effect by competing with the membranous 
form for binding to Fas 598, 603, 625, 628.   Therefore, sFasL may have either apoptotic or 
antiapoptotic attributes depending on the characteristics of the extracellular matrix.    
 
4.3.4.2.6.   Glycosylation 
 
Glycosylation occurs in many proteins at the end of the protein synthesis process in the 
Golgi apparatus.  Although this phenomenon can alter the bioactivity of some 
molecules, FasL bioactivity does not seem to be affected.  Human FasL contains within 
its ectodomain three N-glycosylation sites (Asn-184, Asn-250, Asn-260) which appear 
to be required for efficient intracellular posttranscriptional trafficking and secretion of 
sFasL protein outside the cell.  Amino acid replacement at these N-glycosylation sites 
significantly reduces FasL protein production but does not interfere in its activity.  This 
is supported by the fact that the three amino acids involved in glycosylation are located 
far from the interface area between FasL and Fas, so the capacity of FasL to bind to 
Fas seems to be preserved 594, 595, 629. 
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Acute Lung Injury (ALI) and its severe form, the Acute Respiratory Distress Syndrome 
(ARDS), are a frequent complication and cause of mortality in critically ill patients.  A 
major feature of ALI that influences its severity and outcome is the development of 
alveolar epithelial cell injury, in which apoptosis is known to play a significant role. 
 
Activation of the Fas receptor/Fas ligand system is thought to be a major mechanism 
responsible for apoptosis of alveolar epithelial cells in humans with ALI and animal 
models of acute lung injury.  FasL exists in membrane and soluble forms, both of which 
can bind and cluster the Fas receptor on the cell surface of target cells, initiating 
intracellular apoptotic and inflammatory signals.   The soluble form of FasL can be 
generated from the cleavage of the membrane FasL by the proteolytic action of 
metalloproteinases (MMPs).  This soluble FasL (sFasL) is known to increase in lung 
edema fluid of patients before and after ALI/ARDS, but only the sFasL present in the 
BAL fluid from patients with established ALI/ARDS induces apoptosis in human distal 
lung epithelial cells in vitro.  This observation suggests the existence of mechanisms 
that modulate the bioactivity of sFasL in vivo. 
 
The mechanisms responsible for the biological activity of sFasL in vivo are not 
completely understood.  Three cleavage sites have been identified in the extracellular 
domain of the membrane FasL that give rise to variants of sFasL with different N-
terminal sequences and different biological activities.  Several lines of evidence 
suggest that the degree of aggregation is also an important determinant of the 
biological activity of sFasL.  Oxidation of certain amino acid residues, such as 
methionine, has been shown to modify the degree of aggregation and bioactivity of 
some proteins.   The alveolar environment in patients with ALI contains abundant 
oxidants.  The generation of reactive oxygen species by activated neutrophils in the 
lungs may lead to structural and functional modifications of many proteins, including 
sFasL. 
 
R. Herrero                                                                         HYPOTHESIS AND OBJECTIVES 
 
82 
 
 
HYPOTHESES 
 
In the present work, we investigated the following hypotheses: 
 
 
1. The biological activity of sFasL in vivo depends on the extent of proteolytic 
cleavage, and the corresponding length of the N-terminal sequence. 
 
2. The oxidation of methionine residues in sFasL promotes aggregation of sFasL 
and modifies its bioactivity in the lungs of patients with ARDS. 
 
 
 
OBJECTIVES 
 
 
1. To identify the intrinsic structural determinants that modulate the biological activity 
of human sFasL: 
 
 
a. To determine whether the presence of the stalk region at the N-terminus of 
sFasL influences its biological activity in vivo, and 
b. To determine whether metalloproteinases can modulate the biological activity of 
sFasL by releasing the stalk region. 
 
 
2. To  identify the mechanisms that modify the structure and the activity of human 
sFasL in the airspaces of patients with ARDS: 
 
 
a. To determine whether neutrophil-derived oxidants facilitate the aggregation and 
modify the biological activity of sFasL, and 
b. To determine the molecular mechanisms and the key amino acids involved in 
the structural and functional modifications of sFasL under oxidative conditions. 
 
  
 
 
 
 
 
 
 
6. – MATERIAL AND METHODS 
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6.1.   REAGENTS 
 
Commercial variants of recombinant human and mouse sFasL 
Three commercial forms of recombinant human sFasL (rh-sFasL) were used in this 
project.  The rh-sFasL from Axxora-Alexis Co.  (Alexis SuperFasL, Cat# 522-020-3005) 
was used to develop the animal model of human sFasL-mediated lung injury in mouse 
lungs.  Another form of rh-sFasL from Peprotech Inc.  (Cat# 310-03) was used in in 
vitro models of rh-sFasL incubated in ARDS BAL fluid, or exposed to oxidative and 
reducing conditions.  These two rh-sFasL proteins corresponded to the whole 
extracellular domain of FasL.  In addition to these proteins, a short form of rh-sFasL 
from R&D Systems (Cat# 126-FL/CF) was used in in vitro experiments to determine the 
level of aggregation of all variants of human sFasL.  A short form of a commercial 
recombinant mouse sFasL from R&D Systems (Cat# 526-SAC/CF) was also used to 
study the effect of oxidation in multimerization of sFasL. 
 
Mice: C57BL/6 (wild-type) and MRL/MpJ-Faslpr/2J (lpr Fas-deficient mice) with a 
C57BL/6 background were obtained from Jackson Laboratories (Bar Harbor, ME).   
Cultured cells: Jurkat cells (human T cell lymphoblast-like cell, clone E6-1) were 
purchased from ATCC.  HEK293 cells (Human Embryonic kidney cells, FreeStyle 293 
R97007) were purchased from Invitrogen. 
 
Antibodies (Ab) for human proteins: 
For western-blotting of human FasL: Goat anti-human FasL polyclonal Ab (Peprotech 
Inc., Cat# 500-P184G), HRP conjugated rabbit anti-goat Ab (KPL, Cat# 141306), 
mouse anti-human FasL monoclonal Ab (BD Biosciences, Cat# 556387), HRP 
conjugated AffiniPure F(ab’)2 fragment donkey anti-mouse Ab (Jackson 
ImmunoResearch Cat# 715-036-151). 
For ELISA: Human sFas ligand ELISA Kit (Cat#5255 MBL Nagoya Japan). 
For FasL purification: mouse anti-human FasL monoclonal Ab (R&D Systems, 
MAB126, 0.5 ml/vial). 
 
Antibodies (Ab) for mouse proteins: 
For western-blotting: Rat anti-mouse FasL Ab (R&D Systems, Cat# MAB5262), HRP 
conjugated goat anti-rat Ab (Amersham, Cat# NA 935V). 
For ELISA: Mouse Fas Ligand DuoSet ELISA (R&D Systems, Cat# DY526). 
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For FasL purification: Rat anti-mouse FasL Ab (R&D Systems, Cat# MAB5262).     
For immunohistochemistry of caspase-3: Rabbit anti-cleaved caspase-3 polyclonal Ab 
(Cell Signaling, Cat# 9661S), goat anti-rabbit biotinylated Ab (Zymed®, Cat# 65-6140). 
 
Enzymes: Myeloperoxidase (MPO-Sigma-Aldrich, Cat# M6908), Catalase (Sigma-
Aldrich, Cat# C-3515), Human metalloproteinase-7 (MMP-7). Calbiochem, Cat# 
444270) 
 
Other reagents: L-methionine (Sigma-Aldrich, Cat# M5308), hypochlorous acid 
(HOCl-Fisher Scientific, Cat# SS290-1), hydrogen peroxidase (H2O2) (Sigma-Aldrich, 
Cat# 095K3774), dimethyl sulfide (Sigma-Aldrich, Cat# 41624), hydrochloric acid (J.T.  
Baker Inc., Cat# 9535-33), iodoacetamide (IAM) (Sigma-Aldrich, Cat# I1149), 
phosphate buffer saline (PBS 10X) (Invitrogen Corporation).  Tween-20 (Sigma-
Aldrich), bovine serum albumin (BSA) (Spectrum Chemical), peroxi-Block (Zymed, 
Cat# 50-2015), Alamar Blue (BioSource, Cat# AL-01-100), Dako Serum-Free Protein 
Block (Dako, Cat# X0909), Avidin-Biotin Complex-HP (ABC-HP) (VECTOR Labs., Cat# 
PK-6101), diaminobenzidine substrate (Zymed, Cat# 00-2014) and methyl green 
(Trevigen, Cat# 4800-30-18).  The rest of the reagents used in this project were 
purchased from Sigma-Aldrich. 
 
 
6.2.   EXPRESSION OF HUMAN AND MOUSE sFASL 
 
6.2.1.   CLONING OF sFASL 
 
Human and mouse of sFasL cDNA sequences were amplified by using a standard 
PCR technique with DNA polymerase (Easy-A High-Fidelity PCR Cloning Enzyme 
Cat#600400 Strategene).  The sequences of PCR primers used for amplification of 
human and mouse cDNA were as follows: 
 
Cloning Human sFasL: 
 
Short human sFasL: 
5’-AAGCAAATAGGCCACCCCAG-3’ Forward 
5’-AGTTTCACCGATGGCTCAGG-3’ Backward 
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Long human sFasL: 
5’-CAGCTCTTCCACCTACAGAAGGAGC-3’  
5’-GTCCCCAAAACATCTCTCTTG-3’ Backward 
 
Cloning Mouse sFasL: 
 
Short mouse sFasL: 
5’-CCCAGTACACCCTCTGAAAAAAAAGAGCCG-3’ Forward 
5’-GGGGGCTCATGATGCAGGCATTAAGGACC-3’ Backward 
Long mouse sFasL: 
5’-CAGCTCTTCCACCTGCAG-3’ Forward 
5’-AGACAATATTCCTGGTGCCC-3’ Backward 
 
The PCR conditions were: 95°C, 2 min, then 95°C, 40 sec, 55°C, 30 sec, 72°C, 1 min, 
for 35 cycles, and 72°C, 7 min.  The PCR products were visualized in agarose gels 
containing ethidium bromide, excised from the gel and then extracted from the gel 
using Amicon Ultrafree-DA (Cat# 42600 Millipore).  The purified cDNA was ligated into 
pSecTag/FRT/V5-His-TOPO vector in pSecTag/FRT/V5-His-TOPO Expression Kit 
(Cat# K6025-01 Invitrogen) according to the manufacturer’s instructions.  
 
For cloning reaction, the recombinant vectors containing human or mouse sFasL cDNA 
were transformed by heat shock into competent TOP10 E. coli.  The transformed 
bacteria were plated on LB agar plates containing ampicillin.  The optimal cell 
transformation was screened by PCR amplification. Then, the sequences of the cloned 
pSecTag/cDNA-sFasL plasmids were confirmed by BigDye Terminator v3.1 Cycle 
Sequencing Kit (Cat# 4337454 Applied Biosystems). 
The large scaled endotoxin-free plasmids were isolated from bacteria by using 
EndoFree Plasmid Maxi Kit (Cat#040506 Qiagen Inc.) for the transfection.   
 
6.2.2.   SITE-DIRECTED MUTAGENESIS 
 
The wild-type mouse sFasL cDNA was mutated by site-directed mutagenesis in order 
to generate a mutant mouse sFasL encoding the same number of methionine residues 
and in the same location as those in human sFasL.  Point-mutations in a total of 5 
codons in the plasmid encoding wild-type mouse sFasL cDNA were performed by 
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using QuikChange II site-directed mutagenesis kit (Cat# 200523, Stratagene) and the 
following mutagenic primers: 
 
91 codon: 
5’-GTATCCTGAGGATCTGGTGATGATGGAGGAGAAGATGATG-3’ Forward 
5’-CATCATCTTCTCCTCCATCATCACCAGATCCTCAGGATAC-3’ Backward 
105 codon: 
5’-CTGCACTACTGGACAGATGTGGGCCCACAGCAGCCACCTG-3’ Forward 
5’-CAGGTGGCTGCTGTGGGCCCACATCTGTCCAGTAGTGCAG-3’ Backward 
96 and 97 codons: 
5’-GCTAATGGAGGAGAAGATGATGAACTACTGCACTACTGG-3’ Forward 
5’-CCAGTAGTGCAGTAGTTCATCATCTTCTCCTCCATTAGC-3’ Backward 
25 codon: 
5’-GAACCCCCACTCAAGGTCCATGCCTCTGGAATGGGAAGAC-3’ Forward 
5’-GTCTTCCCATTCCAGAGGCATGGACCTTGAGTGGGGGTTC-3’ Backward 
 
The plasmids containing the WT or the Mutant sFasL cDNA were transformed into 
XL1-Blue supercompetent cells (E. coli dam+, Stratagene) by heat shock. The 
transformed cells were spread on LB-agar plates containing 100 μg/mL ampicillin.  To 
verify the transformation efficiency, some cultured cell colonies were directly inoculated 
into a PCR cocktail for DNA amplification and visualized by agarose gel 
electrophoresis. The plasmids were isolated from the same verified colonies with 
Wizard Plus SV Minipreps DNA Purification System (Promega, Cat# A1330).  The 
isolated plasmids were processed for sequencing using BigDye Terminator v3.1 Cycle 
Sequencing Kit to verify that the selected colonies contained the desired mutations. 
 
6.2.3.   DNA TRANSFECTION INTO MAMMALIAN CELLS 
 
Human Embryonic kidney (HEK) cells were cultured in FreeStyle 293 expression 
medium (Gibco) without serum in a humidified 8% CO2 incubator at 37ºC, while 
shaking.  The plasmids pSecTag/cDNA-sFasL coding the mouse or human sFasL (250 
mg) were incorporated to liposomes (293fectin, Invitrogen) in Opti-MEM I (Invitrogen) 
for 30 min at room temparature.  HEK cells (1x106 cells/mL) were transiently 
transfected using the liposomes containing the plasmid pSecTag/cDNA-sFasL 
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according to the manufacturer’s instructions.   The cell supernatant was harvested 3 
days or 6 days after cell transfection; then filtered and stored at –20ºC. 
 
6.2.4.   PROTEIN PURIFICATION BY IMMUNOAFFINITY COLUMN 
 
6.2.4.1.   Preparation of immunoaffinity column 
 
Mouse monoclonal antibody to human Fas Ligand (R&D Systems, Cat# MAB126) and 
rat anti-mouse Fas Ligand antibody (R&D System) at the concentration of 500 μg/mL 
were first dialyzed overnight in a slide-A-Lyzer (Pierce, Cat# 66425) against 1000 mL 
of coupling buffer at 4°C while stirring.   The column (Hi Trap NHS-activated HP 1 ml 
column Cat# 17-0716-01 GE Healthcare Piscataway NJ) was washed with pre-chilled 1 
mM HCl (10 mL x 3 times at 5 mL/min).   Then, the dialyzed anti-FasL antibody was 
injected into the column at 5 mL/min.   The column was then left standing for 30 min at 
room temperature, following by three series of washes using buffer A and B 
alternatively and according to manufacture’s instructions.   Dulbecco’s PBS was used 
for the last wash and the column was stored at 4°C.  The compositions of coupling 
buffer and wash A and B buffers are described below: 
 
− Coupling buffer: 0.2 M NaHCO3 and 0.5 M NaCl, pH 8.3 
− Buffer A: 0.5 M Ethanolamine and 0.5 M NaCl, pH 8.3 
− Buffer B: 0.1 M Sodium Acetate and 0.5 M NaCl, pH 4.0 
 
6.2.4.2.   Protein purification by immunoaffinity column 
 
The immunoaffinity column was washed first with an elution buffer (0.1 M glycine and 
1M NaCl buffer pH2.5) for 10 min followed by PBS using the Pharmacia Peristaltic 
Pump.  The supernatant collected from the transfected HEK123 cells was filterred 
through a 0.45 μm pore filter.  The transfected HEK cell supernatant containing the 
variants of human or mouse sFasL was applied through the column and the flow 
through was collected.  The column was thoroughly washed with PBS.  The protein 
bound to the column was eluted with the elution buffer and collected in separate 
fraction tubes containing 100 μl of 1 M phosphate buffer pH 7.4.  After washing the 
column again with PBS, it was filled with 5 mL of 0.02% NaN3 PBS and stored at 4ºC.  
The concentrations of human and mouse variants of sFasL protein were determined by 
ELISA (Cat# 5255 MBL Nagiya Japan or R&D Systems) in each fraction.  Fractions 
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with the highest concentrations of sFasL were pooled and the final concentrations of 
sFasL were determined again by ELISA.  The purified proteins in solution were stored 
at –20ºC. 
 
6.2.4.3.  Dialysis of purified sFasL proteins 
 
One of the purposes of this study was to explore the level of multimerization of sFasL 
proteins under oxidative conditions.  We observed that the presence of glycine in the 
purified sFasL elution prevented protein oxidation.  In order to reduce the content of 
glycine, the sFasL protein eluated were dialyzed several times in dialysis cassettes 
(Slide-A-Lyzer, 10,000 MWCO, Pierce) against PBS 1X, pH 7.4 at 4ºC. 
 
 
6.3.   CONCENTRATIONS OF sFASL MEASURED BY ELISA 
 
6.3.1.  ELISA OF HUMAN sFASL 
 
Human sFasL was measured by the MBL ELISA kit (cat# 5255), which includes 
microwells coated with anti-human FasL antibody.  The samples and the standards 
were diluted 1:2 with assay diluent, and added to the antibody coated microwells.  After 
60 min of incubation, the well contents were discarded and the wells were washed 
several times.  Next, the wells were incubated with conjugated solution containing the 
peroxidase conjugated anti-human FasL monoclonal antibody for 60 min.  After several 
washes, the wells were incubated with substrate solution for 30 min.  Then, the 
reaction was stopped and the absorbance of each well was read at 450 nm.  All the 
steps were performed at room temperature.  The low detection limit of human FasL 
ELISA was 75 pg/mL.  
 
6.3.2.  ELISA OF MOUSE sFASL 
 
Mouse sFasL was measured by the R&D Systems ELISA kit (cat# DY526).  A 96-well 
plate was coated with the corresponding capture anti-mouse FasL antibody overnight 
at room temperature.  The capture antibody was aspirated and the wells were washed 
three times with 0.05% Tween-20 in PBS.  The wells were blocked with 1% BSA 
diluted in PBS for 1 hour, and washed three times.  Samples containing mouse, human 
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sFasL or standards were added and incubated for 2 hours followed by another 
aspiration/wash step.  Next, the corresponding detection anti-mouse FasL biotinylated 
antibody was applied to the wells for 2 hours.  The wells were washed three times and 
then incubated with streptavidin-HRP solution for 20 min, washed three more times and 
developed with TMB substrate solution for another 20 min on the dark.  The reaction 
was stopped by the addition of 1M phosphoric acid.  The optical density was 
determined immediately following this procedure by using a microplate reader set to 
450 nm.  All of the procedures were performed at room temperature.  The low detection 
limit of mouse FasL ELISA was 15 pg/mL. 
 
 
6.4.  EXPERIMENTAL PROTOCOL IN ANIMAL MODELS 
 
6.4.1.   ANIMAL PROTOCOL 
 
The animal protocols were approved by the Animal Care Committee of the Veterans 
Administration Puget Sound Health Care System (Seattle, WA).   Male mice weighing 
25–30 g were anesthetized with inhaled 2-5% isoflurane, and then placed on an 
inclined surface.  The larynx was visualized and intubated with a gavage tube attached 
to a 1.0-mL syringe containing 100 μl of water.  Intubation of the trachea was verified 
by movement of the water bubble with the animal’s respiratory efforts.  After 
endotracheal intubation was confirmed, one single dose of 25 ng/g of human sFasL 
(LPS-free) was instilled into the lung.  After instillation, the gavage tube was removed, 
and the mice were returned to their cages, allowed to recover from anesthesia, and 
provided with free access to food and water.  The mice were monitored throughout the 
study.  Our time-points, depending on the experiments, were 6 hours and 16 hours 
after intratracheal instillation. 
 
The mice were euthanised at 6 or 16 hours post-instillatiton or at any time if they 
developed weight loss >15% of the original body weight, had evidence of respiratory 
distress, or at least three of the following: 1) dehydration (evaluated by skin tenting), 2) 
lethargy and decreased movement, 3) pale eyes, 4) loose stools, 5) nasal and/or ocular 
discharge, or 6) neuromuscular signs (uncoordination or seizures). 
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6.4.2.   SAMPLING 
 
Sixteen hours after intratracheal instillation, the mice were killed with an intraperitoneal 
injection of pentobarbital (120 mg/kg) and exsanguinated by closed intracardiac 
puncture at 16 hours post-instillation.  The thorax was opened and the trachea 
cannulated and secured. 
 
Snap freezing of left lung:  The left hilum was clamped and sutured with 2-0 silk suture, 
then, the left lung was removed and flash frozen in liquid nitrogen. 
 
Bronchoalveolar lavage (BAL):  After removing the left lung, bronchoalveolar lavage 
(BAL) was performed in the right lung by instillation of 0.9% NaCl containing 0.6 
mmol/L ethylenediaminetetraacetic acid (EDTA) in four separate 0.5 mL aliquots.  The 
BAL fluid was recovered by gentle suction and placed on ice for immediate processing.   
 
Fixation:  Immediately after the BAL procedure, the right lung was fixed by inflation with 
4% paraformaldehyde at a transpulmonary pressure of 15 cmH2O, and immersed into 
the same fixative overnight at 4ºC.  Next day, lungs were processed for paraffin-
embedding.   
 
6.4.3.    EXPERIMENTAL DESIGN 
 
6.4.3.1.  Dose-response of human sFasL in the lungs of mice 
 
We developed a preliminary experiment to determine the most efficient dose of 
recombinant human sFasL to induce lung injury in mice at an early time-point.  Male 
C57BL/6 mice were challenged with one intratracheal instillation of recombinant human 
sFasL (rh-sFasL) at different doses diluted in sterile phosphate-buffer: 0.3 ng/g (n= 5), 
1 ng/g (n=5), 3 ng/g (n= 8), 8.3 ng/g (n=4), 25 ng/g (n=4).  The mice were euthanized 
at 6 hours post-instillation.  The administration of rh-sFasL at the dose of 25 ng/g 
induced the maximal response in PMN recruitment in the lungs.  
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Figure 6.1.  PMN recruitment in mouse lung treated with different concentrations 
of human sFasL. Mice received one intratracheal instillation of different doses of 
recombinant human sFasL (SuperFasL, Alexis Co.): 0.3 ng/g (n= 5), 1 ng/g (n=5), 3 
ng/g (n= 8), 8.3 ng/g (n=4), 25 ng/g (n=4). The number of PMN was determined in the 
BAL fluid collected from these mice at 6 hours after intratracheal instillation. Results 
shown in scattered dots. Each dot represents one mouse.  X axis represents the doses 
expressed in log10 numbers. 
 
6.4.3.2.  Human sFasL induces lung injury through Fas activation in mice 
 
We first developed a mouse experiment to determine whether human sFasL is 
cytotoxic in the lungs of mice through Fas activation.  Two strains of mice were used: 
male C57BL/6, which express Fas (wild-type mice), and lpr mice, which are natural 
mutants deficient in Fas on a C57BL/6 background (MRL/MpJ-Faslpr/2J).  All the mice 
were obtained from the Jackson Laboratories (Bar Harbor, ME).  We studied the 
following groups: 
 
I. Group control Normal:  C57BL/6 mice expressing Fas (wild-type mice) received 
no intratracheal instillation (n=5) 
II. Group control PBS:  C57BL/6 mice expressing Fas (wild-type mice) received one 
intratracheal instillation of PBS only.  (n=12) 
III. Group WT-human sFasL:  C57BL/6 mice expressing Fas (wild-type mice) 
received one intratracheal instillation of human sFasL (25 ng/g) (n=10) 
IV. Group of lpr-human sFasL:  lpr mice deficient in Fas received one intratracheal 
instillation of human sFasL (25 ng/g) (n=10) 
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All the mice were euthanized 16 hours after intratracheal instillation.  The degree of 
lung injury was evaluated by the presence of: 1) structural alterations of the alveolar 
wall, 2) cell death, and 3) alveolar-capillary barrier dysfunction. 
 
6.4.3.3.  Comparison of the activity of variants of human sFasL in mice 
 
Male C57BL/6 mice expressing Fas were used to compare the activity of two variants 
of human sFasL with different N-terminal (Long and Short human sFasL) in mouse 
lungs in vivo.  These mice were obtained from Jackson Laboratories (Bar Harbor, ME).  
We studied the following groups: 
 
I. Group control Normal:  C57BL/6 mice expressing Fas received no intratracheal 
instillation (n=3) 
II. Group control PBS:  C57BL/6 mice expressing Fas received one intratracheal 
instillation of PBS only.  (n=7) 
I. Group Human Long-sFasL:  C57BL/6 mice expressing Fas received one 
intratracheal instillation of human Long-sFasL (25 ng/g) (n=5) 
II. Group of Human Short-sFasL:  C57BL/6 mice expressing Fas received one 
intratracheal instillation of human Short-sFasL (25 ng/g) (n=5) 
 
All the mice were euthanized 16 hours after intratracheal instillation.  The degree of 
lung injury was evaluated by the presence of: 1) structural alterations of the alveolar 
wall, 2) cell death, and 3) alveolar-capillary barrier dysfunction. 
 
 
6.5.   HISTOLOGICAL METHODS AND IMMUNOHISTOCHEMISTRY 
 
6.5.1  HEMATOXILIN AND EOSIN STAINING OF MURINE LUNG 
 
Lung sections were stained with hematoxylin and eosin for light microscopy.  Multiple 
tissue sections derived from C57BL/6 wild-type or lpr mice were deparaffinized in 
xylene for 20 min, then rehydrated in graded ethanol solutions to PBS.  Staining was 
performed with Harris hematoxylin, then eosin Y.  The sections were rinsed with H2O, 
dehydrated in graded ethanol solutions, immersed in xylene, and mounted in 
Permount. 
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6.5.2.  CASPASE-3 IMMUNOHISTOCHEMISTRY 
 
The sections were deparaffinized by heating at 57°C for 60 min and rehydrated by 
washing twice in xylene for 5 min, twice in 100% ethanol for 3 min, twice in 95% 
ethanol for 3 min, and once in deionized H2O for 5 min.  The slides were then washed 
three times in PBS for 5 min and treated with 0.3% Triton X-100 for 30 min at room 
temperature.  After washing in PBS three times for 5 min, endogenous peroxidases 
were blocked with Peroxo-Block (Zymed) for 2 min at room temperature.  The slides 
were rinsed twice with PBS for 5 min, and the samples were treated with citrate buffer 
(Vector Laboratories) in a microwave for 15 min at medium setting.  The slides were 
cooled to room temperature for 10 min, rinsed twice with PBS for 5 min, and blocked 
with Dako Serum-Free Protein Block (Dako, Catalog # X0909) for 30 min at room 
temperature.  The tissues were then labeled with rabbit anti-cleaved caspase-3 
polyclonal Ab (Cell Signaling) overnight at 4°C in a moist chamber.  After washing in 
PBS three times, the tissues were labeled with biotinylated goat anti-rabbit biotinylated 
Ab (Zymed) for 40 min at room temperature and washed in PBS three times.  The 
slides were then labeled with avidin-biotin complex-HP (ABC-HP, VECTOR Labs) for 
30 min at room temperature, rinsed three times with PBS, and developed in a moist 
chamber with diaminobenzidine substrate (Zymed) for 10 min.  The slides were rinsed 
with running deionized H2O for 5 min, counterstained with 1% methyl green (Trevigen) 
for 6 min.  The slides were dehydrated with ethanol, incubated in xylene for 5 min, and 
mounted with Permount.   
 
 
6.6.  MEASUREMENTS IN MOUSE LUNG TISSUE 
 
6.6.1.  LUNG TISSUE HOMOGENIZATION 
 
The left lung was weighed and then homogenized in 1.0 mL of sterile distilled H2O 
using a hand-held homogenizer.  Each lung homogenate was divided into aliquots for 
cytokine, caspase-3 activity and myeloperoxidase (MPO) measurements.  For cytokine 
and caspase-3 activity measurements, the homogenate aliquot was mixed with a lysis 
buffer containing 0.5% Triton X-100, 150 mM NaCl, 15 mM Tris, 1 mM CaCl2, and 1 
mM MgCl2 (pH 7.40), incubated for 30 min at 4ºC, and then centrifuged at 10,000 x g 
for 20 min.  The supernatants were stored at -80 ºC.  For MPO measurements, the 
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homogenate aliquot was vigorously mixed with 50 mM potassium phosphate (pH6.0) 
with 5% hexadecyltrimethyl ammonium bromide (Sigma-Aldrich) and 5 mM EDTA.  The 
mixture was sonicated and spun at 12,000 x g for 15 min at 25 ºC, and the supernatant 
was stored at -80 ºC. 
 
6.6.2.  CYTOKINE EXPRESSION BY ELISA 
 
The cytokines IL-1β, IL-4, IL-6, IL-10, IL-12, KC, MIP-2, MCP-1, TNF-α and IFN-δ were 
measured in lung homogenates using Fluorokine MultiAnalyte Profiling kits (R&D 
Systems.) for a multiplex fluorescent bead assay (Luminex, Austin, TX).  After dilution 
of the samples, the sensitivities of these immunoassays were 37,9 pg/mL for IL-1β, 
11.25 pg/mL for IL-4, 10,53 pg/mL for IL-6, 7.47 pg/mL for IL-10, 23,83 pg/mL for IL-12, 
13.08 pg/mL for KC, 6.69 pg/mL for MIP-2 , 54.15 pg/mL for MCP-1, 6.82 pg/mL for 
TNF-α and 22.19 pg/mL for INF-δ.   
 
6.6.3.   ENZYMATIC ASSAYS 
 
6.6.3.1.  Myeloperoxidase activity 
 
Neutrophil infiltration of the lung was evaluated by measuring myeloperoxidase (MPO) 
activity in the sypernatant of lung homogenates.  Myeloperoxidase activity was 
measured in lung homogenates using the Amplex Red fluorometric assay, following 
instructions from the manufacturer (Molecular Probes, Eugene, OR).  The supernatant 
was mixed 1:15 with assay buffer and read at 490 nm.  MPO units were calculated as 
the change in absorbance over time.  The assay buffer consisted of 100 mM potassium 
phosphate, pH 6.0, 0.083 mL H202 (Sigma; 30% stock diluted 1:100), and 0.834 mL o-
dianisidine hydrochloride (Sigma; 10 mg/mL).  MPO activity was calculated as the 
change in absorbance over time measured by an espectrophotometer, as described 
previously. 
 
6.6.3.2.  Caspase-3 activity 
 
Caspase-3 activity in lung homogenates was measured with the caspase-3/CPP32 
Fluorometric Assay kit (Biovision, Mountain View, CA).  Fifty-microliter aliquots of lung 
homogenate were diluted 1:2 in assay reaction buffer containing 10 mM DTT, and 
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incubated for 2 hours at 37°C with the caspase-3-specific substrate DEDV-AFC 
(50μM).   Active caspase-3 cleaves a variety of molecules that contain the amino acid 
motif DEVD.   The cleavage of this peptide releases AFC (7-amino-4-trifluoromethyl 
coumarin) that, when excitated by light at 400 nm, emits fluorescence at 505 nm.  
Caspase-3 activity is directly proportional to the fluorescence signal (505 nm) 
measured using a fluorescent microplate reader.   
 
 
6.7.  MEASUREMENTS IN MOUSE BRONCHOALVEOLAR LAVAGE (BAL) 
FLUID 
 
6.7.1.  TOTAL CELL AND DIFFERENTIAL COUNTS IN MOUSE BAL FLUID 
 
The bronchoalveolar (BAL) fluid aliquots from each mouse were pooled and processed 
immediately for total cell counts and differentials.  Total cell counts were performed 
with a hemocytometer, whereas differential counts (cytology) were performed on 
cytospin preparations stained with the Diff-quick method (Andwin Scientific, Addison, 
IL), and a minimum of 200 cells were counted.The remainder of the lavage fluid was 
spun at 200 xg for 30 minutes and the supernatant was removed aseptically and stored 
in individual aliquots at – 80ºC.   
 
6.7.2.  PERMEABILITY MEASUREMENTS 
 
The total protein concentration in BAL fluid was measured using the bicinchoninic acid 
method (BCA assay; Pierce, Rockford, IL).  The concentration of IgM in BAL Fluid was 
measured with a specific mouse immunoassay (R&D Systems).  After dilution of the 
samples, the lower limit of detection of the IgM assay was 20 ng/mL. 
 
 
6.8.  CELL CULTURE EXPERIMENTS IN JURKAT CELLS 
 
6.8.1.  INCUBATION OF JURKAT CELLS 
 
Human Jurkat cells T Lymphocytes (ATCC) were grown in RPMI-1640 medium 
supplemented with 10% fetal bovine serum at 37ºC, 5% CO2.  For the bioassay 
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experiments, Jurkat cells were seeded in Costar 96-well tissue culture plates (Corning 
Inc.) at 2x105 cells/well in serum-free media supplemented at a 50% concentration with 
serum-free media containing serial concentrations of samples containing sFasL or 
media only.  After incubation for 18 hours at 37ºC, 5% CO2, cell survival was assessed 
using Alamar Blue assay. 
 
6.8.2.  CYTOTOXICITY MEASURED BY ALAMAR BLUE ASSAY 
 
Cell viability was assessed with Alamar Blue assay (BioSource International, Camarillo 
CA) which incorporates a fluorometric/colourimetric growth indicator based on 
detection of metabolic activity.  This is an oxidative-reduction (redox) indicator that both 
fluoresces and color changes in response to reducing equivalents generated during 
cellular metabolism and cell growth.  Basically, the oxidized form of the redox indicator 
(non-fluorescent, blue) change to a reduced form (fluorescent, red) in the presence of 
live cells.  Alamar Blue reduction results in a shift in light fluorescence from 590 nm to 
530 nm. 
 
After incubation for 16 hours with conditional media, 10% of Alamar Blue was added to 
the wells.  The cells were then incubated for 4 hours at 37ºC in 5% CO2.  After 
incubation, fluorescence was measured at 530-nm excitation and 590-nm emission 
using a CytoFlour II fluorometer (PerSeptive Biosystems, Framingham, MA).   Data are 
shown as percent of survival or as percent of cell death. 
Percent of survival was calculated as follows: 
Survival (%) = (experimental fluorescence x 100)/live cell fluorescence.   
Cell death (%) = [(live cell fluorescence-experimental fluorescence)/live cell fluorescence] x100. 
Live cell fluorescence corresponds to fluorescence of cells in media only. 
 
 
6.9.  INCUBATION OF sFASL IN HUMAN BAL FLUID 
 
Exogenous recombinant human sFasL (rh-sFasL) was added to PBS or pooled BAL 
fluid samples from normal volunteers, patients at-risk or with ARDS, and was incubated 
for 90 minutes at 37ºC.  At the end of the incubation, the HOCl scavenger L-methionine 
was added to the samples.  When indicated, rh-sFasL was incorporated to the ARDS 
BAL fluid after the addition of L-methionine to prevent protein oxidation.  As control for 
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Western-blot analysis, the same volume of each BAL fluid samples without exogenous 
human sFasL protein was also incubated.  As indicated in each experiment, the 
samples (with and without exogenous sFasL) were or were not boiled for 5 min  and 
subjected to electrophoresis without reducing agents in SDS-PAGE gels.   
 
 
6.10.  OXIDATION OF sFASL 
 
6.10.1.  OXIDATION OF sFASL BY MIELOPEROXIDASE-H2O2-Cl- SYSTEM 
 
Commercial recombinant human and mouse sFasL proteins (0.06 μM) were incubated 
in 25 μL of PBS-DTPA in the presence of 100 mM NaCl and serial concentrations of 
myeloperoxidase (10, 25 and 50 nM) and H202 (2, 5, 10, and 20 μM) for 60 min at 37ºC.  
Then, the molecular weight of sFasL subspecies was determined by SDS-
electrophoresis, with or without reducing sample buffer as specified in each 
experiment, and Western-blotting. 
 
6.10.2.  OXIDATION OF sFASL BY HYPOCHLOROUS ACID (HOCl) 
 
Recombinant human and mouse sFasL, including the short wild-type form of mouse 
sFasL (WT sFasL) and the short methionine-mutated mouse sFasL (Met-sFasL) 
proteins expressed in our laboratory, were treated with serial dilutions of HOCl from 
0.06 to 30 μM for 30 min at 37ºC.  The reaction was stopped by adding 2.5 mM of free 
L-methionine.  When indicated, sFasL protein was added to the oxidising buffer once 
the oxidative reaction was terminated with free L-methionine to prevent sFasL from 
oxidation. These non-oxidized samples were used as controls.  The molecular weight 
of sFasL subspecies was determined by SDS-electrophoresis, with or without reducing 
sample buffer as specified in each experiment, and Western-blotting. 
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6.11.  REDUCTION OF sFASL 
 
6.11.1.  REDUCTION OF sFASL BY DITHIOTHREITOL (DTT) 
 
In order to determine whether disulfide bonds are involved in oxidation-mediated 
multimerization of human sFasL, we incubated a mildly oxidized recombinant human 
sFasL protein with the reducing agent dithiothreito (DTT) followed by iodoacetamide.  
Iodoacetamide is an alkylating sulfhydryl reagent commonly used to bind covalently 
with cysteine, so the protein cannot form disulfide bonds.  Briefly, a recombinant 
human sFasL (rh-sFasL, Peprotech Inc.) at the concentration of 10,000 ng/mL was 
incubated in 50 μL 1X PBS containing 5 mM of the reducing agent dithiothreitol (DTT) 
at 37ºC.  After 1 hour, 10 mM of iodoacetamide (IAM) was added to the reaction and 
was incubated at room temperature for another 30 min.  As control, rh-sFasL was 
diluted in 1X PBS without either DTT or IAM.  To stop the reaction and to reduce the 
content of DTT and IAM, the samples were diluted 1:5 in 1X PBS, and then filtered in 
albumin pre-coated centrifugal filter columns with a 3,000-kDa molecular weight cut-off 
(Microcron Ultracel YM-3, Millipore) by centrifugation at 10,000 x g for 25 min at 4ºC.  
The molecular weight of sFasL subspecies was determined by SDS-electrophoresis, 
without reducing sample buffer, and Western-blotting. 
 
6.11.2.  REDUCTION OF sFASL BY DIMETHYL SULFIDE (Me2S) 
 
In order to determine whether oxidation of methionine residues is involved in oxidation-
mediated multimerization of human sFasL, we incubated a mildly oxidized recombinant 
human sFasL with dimethyl sulfide.  Dimethyl sulfide (Me2S) specifically reduces the 
methionine sulfoxide (oxidized methionine) back to methionine sulfide (non-oxidized 
methionine) as described by Y. Shechter et al. 630.  Briefly, a recombinant human sFasL 
(rh-sFasL, Peprotech Inc.) was reduced by dissolving 400 ng of rh-sFasL in 100 μL of 
0.1 M Me2S and 10 M HCl.  The reaction was allowed to proceed at room temperature 
for reaction times ranging from 10 min to 2 hours.  To stop the reaction and reduce the 
content of Me2S and HCl, the samples were diluted 1:30 in 10X PBS, pH 7,4, and then 
filtered in albumin pre-coated centrifugal filter columns with a 3,000-kDa molecular 
weight cut-off (Microcron Ultracel YM-3, Millipore) by centrifugation at 14.000 x g for 25 
min at 4ºC.  After filtration, the samples were diluted again in 50 μL of ddH2O.  The 
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molecular weight of sFasL subspecies was determined by SDS-electrophoresis, 
without reducing sample buffer, and Western-blotting. 
 
 
6.12.  MOLECULAR WEIGHT ANALYSIS OF sFASL 
 
6.12.1.  ELECTROPHORESIS AND WESTERN-BLOTTING OF EXOGENOUS sFASL  
 
The molecular mass and the level of aggregation of sFasL proteins were determined 
under different conditions by electrophoresis in both SDS and Native gel: 
 
6.12.1.1.  Electrophoresis in SDS gel 
 
Sodium Dodecyl Sulfate Polyacrylamide polyacrylamide gel electrophoresis 
(SDS PAGE): In the SDS-PAGE, the charge shift molecule is Sodium Dodecyl Sulfate 
Polyacrylamide (SDS).  The SDS denatures proteins and binds to proteins conferring a 
net negative charge allowing the proteins to migrate towards the anode.  The SDS 
makes the proteins lose their quaternary structure and converts the oligomeric proteins 
into their constituent polypeptides.  Therefore, in SDS-PAGE the electrophoretic 
mobility of proteins depends primarily on their molecular mass. 
 
Samples of the BAL fluid or the oxidative or reducing reactions containing exogenous 
recombinant human or mouse sFasL were added to 2X sample Laemmli buffer without 
reducing agents.  Samples were either not boiled or boiled for 5 min as mentioned in 
each experiment.  The amount of human and mouse sFasL proteins loaded per well in 
the 4-20%-SDS gel (Lonza) were 10 ng and 2 ng, respectively.   
 
6.12.1.2.  Electrophoresis in native gel 
 
Native polyacrylamide gel electrophoresis (Native PAGE): The Native PAGE gel 
system is based on the Blue Native Polyacrylamide gel electrophoresis technique 
developed by Schagger and von Jagow in 1991 that uses Coomassie G-250 as a 
charge-shift molecule 631.  In Native-PAGE, the coomassie G-250 binds to proteins and 
confers a net negative charge.  In contrast to SDS, G-250 charges the proteins while 
maintaining their native state without any protein denaturation.  The G-250 is present in 
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the cathode buffer to provide a continuous flow of G-250 into the gel, and is added to 
samples containing non-ionic detergent prior to loading the samples onto the gel.  The 
gels do not contain any G-250.  “Native" or "non-denaturing" gel electrophoresis is run 
in the absence of SDS.  While in SDS-PAGE the electrophoretic mobility of proteins 
depends primarily on their molecular mass, in native PAGE the mobility depends on the 
protein's charge, the folded conformation and its hydrodynamic size.  Thus, larger 
structures like multimers have lower mobility though the gel than monomers of a 
particular protein.  Therefore, we used Native PAGE to study the structural 
conformation and aggregation (self-association) of sFasL. 
 
The samples are mixed with 4x native PAGE sample buffer and 5% G-250 sample 
additive (Invitrogen) without any reducing agent.  This mixture is then added to a pre-
cast 4-16% Bis-Tris polyacrylamide gel (NativePAGE Novex® gel Cat# BN1004BOX 
Invitrogen) that operates near to neutral pH.  The proteins are run in the gel using a 
NativePAGE running buffer with a cathode additive for the upper buffer chamber and 
without the cathode additive for the lower buffer chamber according to manufacturer’s 
instructions (NativePAGETM Novex® Bis-Tris gel system, Cat# K6025-01, Invitrogen) 
  
6.12.1.3.  Western-blotting 
 
After electrophoresis in SDS gel, the proteins were transferred to nitrocellulose 
membrane (Hybond-ECL NC) with Bjerrum-Schaffer Nielsen transfer buffer at 100 vol 
at 4ºC or room temperature as specified in each experiment.  After electrophoresis in 
native gel, the proteins were transferred to a PVDF membrane with NuPAGE transfer 
buffer (Cat# NP0006-1, Invitrogen) at 100 vol at room temperature.  The membrane 
was blocked first with 0.2% SuperBlock (Pierce) buffer and 0.05% Tween-20 at room 
temperature for 1 hour and discarded afterwards.  Then the membrane was incubated 
overnight at 4ºC with the corresponding primary antibodies diluted in 0.2% 
SuperBlock/0.05% Tween-20 buffer (see below).  After thoroughly washing with 1 x 
PBS 0.05% Tween-20, the membrane was incubated for one hour at room temperature 
with HRP conjugated secondary antibody also diluted in 0.2% SuperBlock/0.05% 
Tween-20 buffer (see below).  After 3 washes in wash buffer, peroxidase activity was 
detected by chemiluminescence using Supersignal West Femto Maximum Sensitivity 
Substrate (Super Signal West Femto, Cat# 34094 Pierce). 
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1. For human sFasL: 
— Primary antibody:  Mouse anti-human FasL antibody (BD Biosciences) diluted 
1:250 or Goat anti-human FasL antibody (Peprotech) diluted 1:500 
 
— Secondary antibody:  HRP-Donkey anti-mouse IgG (Jackson ImmunoResearch) 
diluted 1:1x105 or HRP-Rabbit anti-goat IgG (KPL) diluted 1:1x105 
 
2. For mouse sFasL detection: 
— Primary antibody:  Rat anti-mouse FasL antibody (R&D System) diluted 1:250 
— Secondary antibody:  HRP-Goat anti-rat antibody (Amersham) diluted 1:10000 
 
6.12.2.  ELECTROPHORESIS AND WESTERN-BLOTTING OF ENDOGENOUS 
HUMAN sFASL IN BAL FLUID  
 
Samples of BAL fluid from four normal volunteers, four patients at-risk for ARDS and 
four patients with established ARDS (day 3) were selected from our BAL fluid bank.  
The samples were spun at 18,000 x g for 10 min at 4ºC.  In previous experiments, we 
noticed that human albumin and IgG present in BAL fluids caused nonspecific 
background in Western blotting analysis of sFasL.  In order to remove human albumin 
and IgG, 300 μl of each BAL fluid was incubated with anti-human albumin and anti-
human IgG antibodies coupling agarose beads (ProteoSeek Antibody-Based 
Albumin/IgG Removal Kit, Cat# 89876, Pierce, Rockford IL) for 2 hours at room 
temperature.  After incubation with the beads, BAL fluid was separated from the beads 
by filtration, and albumin/IgG depleted BAL fluid was concentrated 10-fold by spinning 
at 5,000 x g for 10 min at 4ºC using a ultrafiltration device with a 5,000-kDa molecular 
weight cut-off (Ultrafree-MC Centrifugal Filter Units Millipore).  Next, each sample was 
mixed with an equal volume of 2x Laemmli SDS-PAGE sample buffer and separated in 
4-12% SDS-PAGE under non-reducing conditions.  The endogenous sFasL was 
detected by Western blotting as described above using biotinylated goat anti human 
sFasL IgG or biotinylated goat isotype control IgG with streptavidin-HRP to minimize 
the nonspecific background.  Plasma from one normal volunteer was also treated with 
an Albumin/IgG removal kit and included as control for cross-reactivity of antibodies 
with serum proteins.  As a positive control, the same albumin/IgG depleted plasma 
sample was spiked with exogenous recombinant human sFasL.  
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6.12.3.  PROTEIN ANALYSIS of sFASL BY HPLC 
 
The supernatant from HEK cells transfected with the full-length extracellular domain of 
FasL cDNA expressing plasmid or supernatant from non-transfected cells were 
concentrated 46-fold.  The supernatant proteins were separated according to the 
molecular weight using high-pressure liquid chromatography with a SynChropak GPC 
100 column (250 mm x 4.6 mm; SynChrom) at a flow rate of 2 mL/min in PBS.  The 
samples were separated into 80 fractions of 1 ml each.  The column was calibrated by 
using alcohol dehydrogenase (150 kDa), bovine serum albumin (67 kDa), ovalbumin 
(43 kDa), chymotrypsinogen A (25 kDa), and ribonuclease A (13.7 kDa). 
 
 
6.13.  MICRO-LIQUID CHROMATOGRAPHY-ELECTROSPRAY IONIZATION 
TANDEM MASS SPECTROMETRY ANALYSIS 
 
Protein samples containing human sFasL (Petrotech Inc.), previously exposed or not to 
the MPO-H2O2-Cl- reaction, were incubated and denatured in 4 mM DTT, 50 mM 
ammonium bicarbonate pH 8.0, 10% acetonitrile for 15-20 minutes at 70-80ºC.  After 
cooling to room temparature, proteins were alkylated by iodoacetamide (10mM) for 15 
min; then digested with sequencing grade modified trypsin (Promega) (1:20 wt/wt, 
trypsin/protein) overnight at 37ºC.  Digestion was halted by freezing the mixture or 
acidifying it (pH 2-3) with formic acid or trifluoroacetic acid.  The micro-liquid 
chromatography-electrospray ionization tandem mass spectrometry (μLC-ESI-MS/MS) 
analysis was performed in the positive ion mode with a Finnigan LCQ Deca ProteomeX 
ion trap mass spectrometer (Thermo Electron Corp.) coupled to a quarternary Finnigan 
Surveyor HPLC (Thermo Electron Corp.).  Tryptic peptides were separated using a 
reversed-phase capillary HPLC column (180 um x 10 cm; 5-μm particules; Biobasic 18, 
Thermo Electron Corp.) using solvent A (0,1% vol/vol formic acid in water) and solvent 
B (100% acetonitrile in 0.1% formic acid).  The peptides were eluted using the following 
linear gradient: 0-10% B over 10 min; 10-35% B over 85 min; then 35-80% B over 5 
min at a flow rate 2 μl/min.  The MS/MS analysis was performed using 35% relative 
collision energy with an activation time of 30 min. 
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6.14.  STATISTICAL ANALYSES 
 
The results of the quantitative variables were expressed as media ± SEM, or plotted in 
scattered-dot graphs showing the median. To evaluate general differences between 
three or more groups, the analysis of variance (one-way ANOVA) followed by the 
Bonferroni’s or Tukey post hoc tests was used for variables with normal distribution, or 
the Kruskal-Wallis followed by the Dunn’s test for those without a normal distribution. A 
decimal logarithm (log10) was used to reduce the heterogenity of variances when these 
were significantly different.  A p value <0.05 was considered statistically significant.  
The values of the variables were saved in an Excel sheet, and the statistical analyses 
were performed using GraphPad Prism 5.0 (GraphPad Software Inc, San Diego, CA). 
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Soluble Fas Ligand has been shown to increase in the BAL fluid of patients with 
ARDS 284, 468, and it is thought to play a role in the development of ALI from 
diverse causes. In the present studies, we have investigated the form of sFasL 
which is present in the lungs of patients with ARDS, the effects and 
mechanisms of injury of human sFasL in mouse lungs, and the structural factors 
of sFasL that determine its biological activity. 
 
 
7.1. AGGREGATION STATUS OF HUMAN sFASL IN THE LUNG OF 
PATIENTS WITH ARDS 
 
Previous studies have shown that sFasL is increased in the lung of patients with 
ARDS and is correlated with mortality 284, 468, but the aggregation status of 
sFasL in the lungs of patients with ARDS is not known. To explore this issue, 
we studied the BAL fluid obtained from four normal volunteers, four patients at-
risk for ARDS and four patients with established ARDS using SDS-PAGE gel 
electrophoresis under non-reducing conditions followed by Western blotting. As 
shown in Figure 7.1, the BAL fluid from patients with ARDS contained a band at 
50-kDa which corresponds to sFasL dimers (the molecular weight of sFasL after 
glycosylation is 25-kDa). Importantly, the 50-kDa band was not present in BAL 
fluid obtained from normal volunteers or from patients at risk (open arrow in Fig. 
7.1). The absence of this band when control antibody was used confimed that 
the 50-kDa band in ARDS BAL fluid corresponded to sFasL (goat anti-V5 lanes 
in Fig. 7.1).  It is possible that the 75-kDa and larger molecular weight bands 
represent higher aggregations of sFasL, but this could not be confirmed 
because some of these bands were also present with the control antibody, 
indicating intense cross reactivity with other high molecular weight proteins. In 
summary, the present results confirm that sFasL increases in BAL fluid from 
patients with ARDS, and that it tends to aggregate in the BAL fluid, suggesting 
that aggregation of sFasL has a pathogenic role in acute lung injury in humans. 
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Figure 7.1. Soluble FasL (sFasL) increases in BAL fluid from patients with ARDS and 
tends to aggregate forming, at least, dimers. 
IgG and albumin depleted BAL fluids from four normal volunteers, four patients at-risk for ARDS 
and four patients with established ARDS was loaded onto 4-12% SDS-PAGE gels under non-
reducing conditions. Electrophoresis and Western blotting with a goat anti-hsFasL antibody or 
its isotype antibody control (goat anti-V5 IgG) were performed. IgG and albumin depleted 
plasma from one normal volunteer (Lane P) was included to control for cross-reactivity of 
antibodies with serum proteins. As a positive control, the same depleted plasma sample was 
spiked with exogenous recombinant human sFasL (Lane F).  Each lane shows the BAL fluid of 
an individual patient and the arrows indicate molecular weight.  Monomers of hsFasL have MW 
~ 25 kDa. 
 
 
7.2. BIOLOGICAL EFFECTS OF INTRATRACHEAL INSTILLATION OF 
sFASL IN MOUSE LUNGS 
 
Previous studies from Matute-Bello and Martin (lab Mentors) showed that sFasL 
is active and induces apoptosis in Fas sensitive cells in vitro 284, but the 
relevance of sFasL for the pathogenesis of ALI in vivo is still controversial.  To 
investigate in vivo the effects of sFasL, we performed a series of experiments 
testing the effects of different types of sFasL molecules administered via 
intratracheal instillation in mice. 
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7.2.1. Intratracheal instillation of human sFasL in mice induces lung injury 
via Fas activation 
 
In order to study the effects of sFasL in an in vivo system, we first instilled 
recombinant mouse sFasL intratracheally to C57BL/6 mice, expecting that this 
would result in lung injury.  Surprisingly, intratracheal instillation of mouse sFasL 
had no effects in mouse lungs (data not shown).  Because of the poor biological 
activity of mouse sFasL, we then instilled recombinant human sFasL (rh-sFasL) 
into mouse lungs. In order to exclude the possibility that any responses to the 
human form of sFasL were due to the immune recognition of a human protein 
and not to the specific activation of Fas receptor by sFasL, we also tested a 
group of mice (lpr mice) in which the Fas receptor is not functional.  C57BL/6 
wild-type and lpr mice (n=10 per group) received a single intratracheal dose of 
human sFasL (25 ng/g) and the degree of lung injury was assessed at 16 h 
post-instillation. C57BL/6 wild-type mice that were either non-instilled (n=5) or 
intratracheally instilled with PBS (n=10) were used as negative controls for the 
experiments. To assess the degree of lung injury, we evaluated the presence of: 
i. structural alterations of the alveolar wall, ii. cell death, and iii. alveolar-capillary 
barrier dysfunction. 
 
7.2.1.1 Lung weight and structural alterations of the alveolar wall 
 
The lung wet weight was measured at the time of necropsy as an indicator of 
lung injury. Intratracheal instillation of human sFasL resulted in a significant 
increase of the lung wet weight in wild-type mice compared to normal mice and 
PBS-instillated controls. The increase of lung wet weight induced by instillation 
of human sFasL, however, was significantly attenuated in Fas-deficient lpr mice. 
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Figure 7.2. Lung wet weights of normal WT mice (Normal), and wild-type (WT) and lpr 
Fas-deficient (lpr) mice treated with PBS or recombinant human sFasL (25 ng/g) via 
intratracheal instillation. The left lung was removed and the lung wet weight was determined 
using an electronic balance (sensitivity, 0.0001 g). Each point represents an individual mouse. 
Horizontal bars represent the medians. Statistical analysis: one-way ANOVA with Bonferroni’s 
post-hoc test. (#) p<0.05 vs PBS-WT, (*) p<0.001 vs human sFasL-lpr. 
 
The effects of human sFasL instillation were also histologically evaluated in 
H&E stained sections of formalin-fixed lung tissues. In wild-type C57BL/6 mice 
(WT), human sFasL caused important lung tissue damage at 16 hours after 
intratracheal instillation that was characterized by the thickening of the alveolar 
wall, as well as by the presence of vascular congestion, alveolar hemorrhage 
and neutrophilic infiltratres.  In contrast, the lung structure of the lpr mice 
harboring an inactive Fas receptor was normal (Fig. 7.3). 
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Figure 7.3. Representative lung tissue sections stained with hematoxylin-eosin from wild-
type and Fas-deficient lpr obtained 16 hours after the intratracheal instillation of human 
sFasL (25 ng/g). The lungs from wild-type mice treated with human sFasL showed marked 
thickening of the alveolar walls, vascular congestion, neutrophil infiltration as well as deposition 
of proteinaceous material in the airspaces. The lungs from Fas-deficient lpr mice, in contrast, 
had normal appearance. 
 
7.2.1.2. Apoptotic cell death 
To determine whether the tissue changes were associated with apoptosis, we 
performed immunohistochemistry for the active (cleaved) form of caspase-3, a 
key intermediate in the Fas signaling pathway.  In wild-type mice, the 
intratracheal instillation of human sFasL resulted in a significant increase in 
activated caspase-3 immunostaining localized to the alveolar walls as well as in 
some cells in the air alveolar spaces. In contrast to wild-type mice, caspase-3 
activation was not detected in the lung tissue of Fas-deficient mice receiving 
human sFasL (Fig. 7.4) 
R. Herrero                                                                                                                 RESULTS 
 
111 
 
 
 
Figure 7.4. Immunohistochemistry of activated caspase-3 in lung tissue sections from 
wild-type and Fas-deficient lpr mice 16 hours after intratracheal instillation of human 
sFasL (25 ng/g).  The lungs from wild-type mice treated with human sFasL showed increased 
immunostaining (brown reaction product) reflecting the presence of cleaved (active) caspase-3, 
which was mainly localized to the alveolar walls but also to some cells in the airspaces.  In 
contrast, the lungs from Fas-deficient mice did not show any brown reaction product. 
 
7.2.1.3.  Alveolar-capillary protein permeability 
 
At 16 hours after the intratracheal instillation of human sFasL, wild type mice 
presented a remarkable increase in the total protein concentration in BAL fluid 
(Fig. 7.5.A.). The BAL fluid concentration of IgM, which is a protein normally 
confined to the plasma compartment due to its large size (900 kDa), was also 
significantly elevated in wild-type (WT) mice receiving human sFasL compared 
to PBS instilled mice (Fig. 7.5.B.), suggesting an alteration of the permeability of 
the alveolar epithelial barrier. The BAL fluid concentrations of total protein and 
IgM were significantly lower in Fas deficient lpr mice compared to WT mice, 
although they were still increased compared to control mice receiving PBS. 
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Figure 7.5. Concentrations of total proteins and IgM in BAL fluid of wild-type (WT) and 
Fas-deficient (lpr) mice treated with PBS or recombinant human sFasL (25 ng/g) via 
intratracheal instillation. BAL fluid was collected 16 hours later. Total proteins were measured 
by the BCA method (A), and the concentration of IgM was determined by ELISA (B).  Results 
are shown as scattered dots where each point represents an individual mouse. Horizontal bars 
represent medians. Statistical analysis: one-way ANOVA with Bonferroni’s post-hoc test. (#) vs 
human sFasL-lpr mice, (*) vs PBS-WT mice. 
 
7.2.2.  Mechanisms of sFasL-induced lung injury in mice 
 
To study the potential mechanisms by which the intratracheal administration of 
recombinant human sFasL (rh-sFasL) caused lung injury in the mouse, we 
investigated the inflammatory responses (inflammatory cell recruitment and 
cytokine expression) and quantified the activation of pro-apoptotic pathways 
(caspase-3 activity) in the lungs at 16 hours after the instillation of rh-sFasL.  
 
7.2.2.1.  Inflammatory cell recruitment 
 
Migration and activation of pro-inflammatory cells are important events in the 
pathogenesis of ALI from diverse causes.  Neutrophils (polymorphonuclear 
neutrophils; PMN) predominate in the pulmonary edema fluid and 
bronchoalveolar lavage fluid obtained from patients with ALI.  To investigate the 
inflammatory cell recruitment to the airspaces of the lungs induced by the 
instillation of human sFasL, we determined the number and type of white blood 
cells present in the BAL fluid collected from mouse lungs (Fig. 7.6). Compared 
A B
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with mice receiving an intratracheal instillation of PBS, the BAL fluid from wild-
type mice receiving human sFasL contained a significantly higher number of 
white blood cells, which were predominantly neutrophils (83%), but also 
macrophages (16%) and lymphocytes (1%).  In BAL fluid from Fas-deficient lpr 
mice, however, rh-sFasL did not induce any elevation of the number of white 
blood cells, and all the cells present were mononuclear macrophages rather 
than PMN or lymphocytes.  The instillation of human sFasL, therefore, resulted 
in significant recruitment of PMN and lymphocytes to the airspace only in wild-
type mice with a functional Fas receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6. Total number of white blood cells (A), macrophages (B), PMN (C) and 
lymphocytes (D) in BAL fluid of wild-type (WT) and Fas-deficient (lpr) mice treated with 
PBS or human sFasL (25 ng/g bw) via intratracheal instillation.  At 16 hours after the 
intratracheal administration of PBS or human sFasL, the BAL fluid was recovered from the 
mouse lungs, and it was immediately processed for total and differential cell counts using a 
A
B
C
D
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hemocytometer. The differential cell analysis was performed by Diff-Quick-stained cytospin 
preparation counting a total of 200 cells per slide in randomly selected high-powered fields 
(X1000). Administration of human sFasL into the mouse lungs caused a significant influx of 
inflammatory cells (predominantly PMN and, to a less extend, lymphocytes) into the airspace of 
wild-type mice expressing a functional Fas receptor. In contrast, no inflammatory cell 
recruitment occurred in lpr Fas-deficient mice. Each point represents one mouse.  Horizontal 
bars are medians. Statistics: ANOVA with Bonferroni’s post-hoc test.  (#) vs human sFasL-lpr 
and PBS-WT mice. 
 
 
To further confirm the rh-sFasL-induced recruitment of PMNs to the lungs, we 
measured the myeloperoxidase activity in whole lung homogenates. 
Myeloperoxidase (MPO) is a peroxidase enzyme that is abundantly present in 
neutrophils and to a lesser extent in monocytes. Thus, the MPO activity is 
frequently used as an indirect measurement of the total PMN cell content in 
tissues.   The MPO enzyme has an important role in innate host defense, 
because it catalyzes the formation of hypochlorous acid (HOCl), a powerful 
oxidant with microbicidal properties. This may be pathogenetically relevant to 
our experimental model, because free extracellular MPO in tissues can also 
lead to inflammation and tissue destruction. 
 
As shown in Figure 7.7, the intratracheal instillation of rh- sFasL resulted in an 
increase in the MPO activity in the lungs of wild-type (WT) mice as compared 
with PBS-instilled mice, but this response was not present in Fas-deficient (lpr) 
mice.  The fact that human sFasL failed to increase the MPO activity in lungs 
and PMN in the BAL fluid of Fas-deficient lpr mice indicates that human sFasL 
requires the presence of a functional Fas receptor in the cell membranes in 
order to induce the migration of PMN from the microcirculation to the airspaces 
of the lungs. 
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Figure 7.7. Myeloperoxidase activity in the lungs of wild-type (WT) and Fas-deficient (lpr) 
mice receiving an intratracheal instillation of PBS or human sFasL (25 ng/g bw). The 
myeloperoxidase (MPO) activity was measured using an enzymatic assay in total homogenates 
of lungs obtained from mice at 16 h after the intratracheal administration of PBS or human 
sFasL. Each point represents one mouse.  The horizontal bars represent medians.   Statistics: 
ANOVA with the Kruskal Wallis’ post-hoc test. (#) p < 0.05 vs WT-PBS mice, (*) p < 0.001 vs 
human sFasL-lpr mice. 
  
 
7.2.2.2. Activation of inflammatory cytokines 
 
Cytokines include a group of proteins produced by a variety of cells. Cytokines 
can mediate normal cellular processes, and they are critical mediators of both 
innate and adaptive immune responses.  Many cytokines are produced locally in 
the lungs by inflammatory cells, lung epithelial cells or fibroblasts at sites of 
injury, where these proteins initiate and amplify inflammatory responses.  The 
concentrations of the pro-inflammatory cytokines IL-1β, KC and MIP-2 were 
measured in mouse lung homogenates at 16 hours after the intratracheal 
instillation of rh-sFasL.  As shown in Figure 7.8, the concentrations of these 
three cytokines were significantly increased in the lungs of wild-type mice 
receiving rh-sFasL as compared with those receiving PBS.  In contrast, rh-
sFasL did not induce any increase of these cytokines in the lungs of Fas-
deficient lpr mice.  These results indicate that human sFasL induces the 
expression of pro-inflammatory cytokines in mouse lungs in vivo, and that such 
induction requires the presence of a functional Fas receptor.
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Figure 7.8. Human sFasL induced cytokine production in the lungs of wild-type mice 
(WT) but not in Fas-deficient mice (lpr). The concentrations of the proinflammatory cytokines 
IL-1β, KC and MIP-2 were measured in lung homogenates 16 hours after the intratracheal 
instillation of human sFasL using mouse-specific immunoassays (R&D Systems, Minneapolis, 
Minn.). The sensitivity of these immunoassays for IL-1β, KC and MIP-2 was 15.6 pg/ml.  Each 
dot represents one mouse.  The horizontal bars represent medians.   Statistics: Kruskal-Wallis 
with Dunn’s post-hoc test. (#) vs PBS-WT and human sFasL-lpr mice. 
  
7.2.2.3.  Activation of pro-apoptotic pathways 
 
Previous studies showed that apoptotic pathways are activated in the lungs of 
patients with ARDS, and suggested that apoptosis is an important determinant 
of the fate of the lung epithelium in acute lung injury/ARDS.  Activation of Fas 
mediates apoptosis via the activation of intracellular caspases which lead to the 
cleavage of nuclear DNA.  Caspase-3 is an intracellular cysteine proteinase that 
exists in an inactive form as a proenzyme.  Activation of procaspase-3 by 
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proteolytic processing is a key event required for apoptosis, and quantification 
of caspase-3 activity is commonly used as a measure of the extent of activation 
of apoptotic pathways. 
 
Using an enzymatic assay, we quantified the activity of caspase-3 in lung 
tissues from wild-type and Fas-deficient lpr mice obtained at 16 hours after the 
intratracheal instillation of human sFasL.  Wild-type mice receiving human 
sFasL had a significant increase in caspase-3 activity in the lungs, whereas 
there was no increase in caspase-3 activity in the lungs of Fas-deficient mice.  
These results indicate that human sFasL mediated the activation of caspase-3 
specifically through the activation of the Fas receptor in mouse lungs (Fig. 7.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9.  Human sFasL increases the activity of caspase-3 in the lungs of wild-type 
(WT) mice but not in Fas-deficient (lpr) mice.  The WT and lpr Fas deficient mice were 
treated with intratracheal human sFasL from Alexis Co. (25 ng/g) and euthanized 16 hours later.  
Some WT mice treated with PBS were used as negative controls.  In order to detect caspase-3 
activity, the lysates of mouse lungs were incubated with (Z-DEVD)2-Rhodamince 110 substrate.  
Active caspase-3 cleaves a variety of molecules that contain the amino acid motif DEVD. The 
cleavage of this peptide releases Rhodamince 110 that when excitated by light at 400 nm emits 
fluorescence at 505 nm.  Caspase-3 activity is directly proportional to the fluorescence signal 
(505 nm) measured using a fluorescent microplate reader.  Each dot represents one mouse.  
The horizontal bars represent medians.  Statistical analysis: one-way ANOVA with Bonferroni’s 
post-hoc test. (#) vs PBS-WT and human sFasL-lpr mice. 
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7.3. STRUCTURAL DETERMINANTS OF THE BIOLOGICAL ACTIVITY OF 
HUMAN sFASL 
 
The sFasL detectable in BAL and edema fluids from patients with early ARDS is 
biologically active, suggesting that sFasL has a role at the onset of lung injury 
284. As shown previously (Fig. 7.1.), soluble FasL released into the air spaces 
tended to form aggregates in the BAL fluid of patients with ARDS. In the 
following experiments, our goal was to determine the structural determinants 
that control in vivo the biological activity of sFasL. The recombinant human 
sFasL (rh-sFasL) protein that induced the lung injury in mice in the previous 
studies comprises a TNF homology domain at the C-terminus, which mediates 
receptor binding and contains most of the trimerization domain, and a stalk 
region at the N-terminus, whose role is not yet understood.  Therefore, we 
investigated the importance of aggregation and of the stalk region as potential 
determinants that may control the biological activity of human sFasL in the 
lungs. 
 
7.3.1.  N-terminal sequence, stalk region, and variants of sFasL 
 
The two cleavage sites found at the extracelular sequence of the FasL imply 
that at least two forms of sFasL exist in vivo, a long form consisting of the stalk 
region and the TNF homology domain, and a short form consistent only of the 
TNF homology domain.  To investigate the role of the stalk region at the N-
terminus of the sFasL protein, we studied the biological activity and the degree 
of aggregation of different variants of recombinant human sFasL that were 
commercially available as well as some variants that were expressed in our 
laboratory (see Fig. 7.10.). In particular, we studied the following variants of 
human sFasL: 
 
• Two recombinant long human sFasL proteins purchased from the Alexis and 
Peprotech companies. Both human sFasL proteins contain the same TNF 
homology [TNF(H)] sequence and stalk region but the Alexis form has a 26 
R. Herrero                                                                                                                 RESULTS 
 
119 
 
amino acid leader sequence added by the company to the N-terminal stalk 
region. The Peprotech form, however, does not contain a the extra peptide. 
• A short form of human FasL purchased from R&D Systems Co, which 
contains the TNF homology domain but lacks the stalk region, and has a 6-
hystidine tail added at the N-terminus to facilitate purification. 
• A long form of sFasL containing both the stalk and the TNF domain (aa 107-
281 of human FasL; designated KH long human sFasL), and a short form of 
sFasL containing the TNF domain and only 6 aminoacids of the stalk region 
(aa 132-281 of human FasL; designated KH short human sFasL). These two 
forms of human sFasL were cloned and expressed in our laboratory, and 
they mimic the extracellular portions of FasL that can be processed by the 
action of metalloproteinases at the two identified cleavage sites. There is a 
15 aa linker between Ig κ chain secretion signal cleavage site and cloned 
sFasL sequence. This 15 aa linker contains nonpolar amino acids (aside 
from 4 basic arginines) and lacks cysteine and methionines, so we predicted 
that it would not affect the biological activity or the comformational structure 
of the sFasL protein.  
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Variants of human sFasL (h-FasL) 
 
 
 
 
 
 
 
 
 
 
Figure 7.10.  Variants of human sFasL with different N-terminal sequences.  
The long forms of human sFasL from Peprotech and Alexis Co are all biologically active in vitro 
and in vivo in mouse lungs. Both proteins contain the stalk region, but the Alexis hsFasL also 
contains a cross-linking peptide and a FLAG tag at the N-terminus. The short form of sFasL 
from R&D System lacking the stalk region was inactive in vitro and in vivo in mouse lungs. This 
short form contains a 6-histidine residues at the N-terminus. A long and a short form of human 
sFasL were produced in our laboratory using the same expression and purification system (KH 
Long and KH short human sFasL). Both proteins had a leading 15 aa sequence contained in the 
expression vector to facilitate the expression and secretion of these proteins.  TNF(H) = TNF-
homology domain. 
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7.3.2. Level of aggregation of human sFasL variants 
 
Prior studies have suggested that aggregation is required for the biological 
activity of sFasL in vitro 615, 619, but the importance of aggregation has not been 
tested in vivo.  Interestingly, the sFasL released into the air spaces of patients 
with ARDS forms aggregates (see Fig. 7.1), suggesting that aggregation may 
be a factor that modulates the bioactivity of sFasL in vivo. To explore the 
structural factors determining the aggregation of human sFasL, we analyzed the 
degree of aggregation of the long and short forms of human sFasL (short and 
long KH human sFasL, cloned and affinity purified in our laboratory) using 
various techniques.  The amino acid sequence (primary structure) is the main 
determinant of how a protein folds on itself and self-associates.  To exclude the 
possibility that the extra 15-aa secretion peptide present at the N-terminus 
caused significant changes in the aggregation of our KH human sFasL proteins, 
we compared our forms of KH hsFasL to the commercially available long and 
short forms of human sFasL described in section 3.1, which have different 
amino acid sequences added at the N-terminus (see Fig. 7.10).   
 
7.3.2.1. Analysis by native and non-reducing SDS PAGE electrophoresis 
 
Electrophoresis in "native" or "non-denaturing" gels lacking sodium dodecyl 
sulfate (SDS) and reducing agents do not disrupt the covalent nor the non-
covalent forces in the polypeptide backbone and between polypeptide units, 
preserving the natural protein folding and the degree of aggregation of proteins.  
Under these conditions, the long human sFasL proteins appeared as bands 
between 70- and 240-kDa, and the short forms appeared between 60- and 190-
kDa (Fig. 7.11.A).  Because the molecular weight of glycosylated monomers of 
long sFasL is 25-kDa and of short sFasL is 20-kDa, those bands corresponded 
to multimers of sFasL ranging from trimers (3 units) to nonamers (9 units).  
Bands at molecular weights higher than those corresponding to nonamers were 
also detected, particularly in the commercial proteins.   
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Many proteins aggregate by means of weak non-covalent forces between 
protein units, such as ionic or hydrophobic forces.  To determine whether these 
non-covalent forces are involved in the aggregation of sFasL, we separated the 
proteins by electrophoresis in an SDS polyacrylamide gel under non-reducing 
conditions, and then analyzed the proteins by Western blotting (Fig. 7.11. B).  
The long sFasL proteins appeared as an intense band at 25-kDa and the short 
foms at 20-kDa, consistent with  monomers. Less intense bands at 50- and 75-
kDa were also observed, corresponding to dimers and trimers of sFasL, 
respectively. 
 
Altogether, these data indicate that human sFasL spontaneously multimerizes 
in aqueous solutions and that, under these conditions, trimerization is its 
minimal level of multimerization.  The data also suggest that the absence of the 
stalk region does not interfere with the propensity of sFasL to aggregate, as 
agreggation was also observed for the forms of sFasL lacking the stalk region 
(R&D short h-sFasL and KH short h-sFasL).  After treatment with SDS, most of 
the human sFasL aggregates were changed into monomers and, in less extend, 
into dimers and trimers, indicating that high multimerization of human sFasL is 
due primarily to non-covalent forces.  Covalent links between molecular units, 
however, may be involved in the formation of SDS-resistant dimers and trimers 
of sFasL.   
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Figure 7.11. Aggregation of variants of human sFasL with different N-terminal sequences. 
Commercial and our homemade long and short forms of human sFasL were separated in non-
reduced conditions by electrophoresis either in native (A) or SDS PAGE gels (B). Molecular 
weight of the proteins was determined by Western blot analysis using a polyclonal goat anti-
human sFasL that recognizes both long and short sequences of human sFasL protein. In native 
gel, all variants of human sFasL regardless the presence or absence of the stalk region formed 
spontaneously trimers and larger multimers. In SDS gel, however, these variants of human 
sFasL were dissociated mainly to monomers.   
 
 
7.3.2.2. Analysis by HPLC 
 
Some proteins oxidize spontaneously during purification and storage, 
particularly those dissolved in aqueous solution without carrier proteins, and 
oxidation is a mechanism that induces protein aggregation. It was possible, 
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therefore, that the aggregation that we detected of our purified variants of 
human sFasL was induced by their oxidation and not by the intrinsic structural 
properties of the proteins.  To minimize the potential effect of oxidation, we 
further analyzed the degree of aggregation of non-purified sFasL protein 
present in a protein-enriched solution.  To achieve this, the non-purified long 
human sFasL present in the supernatant of HEK cells (in which sFasL cDNA 
coding the extracellular domain was transfected) was separated by size-
exclusion chromatography, then each fraction was analyzed by the dot blotting 
(Fig 7.12.). The fractions containing more amount of sFasL protein, as 
confirmed by dot-blot analysis, corresponded to a molecular weight ranging 
form 52 kDa to larger than 158 kDa.  This indicated that human sFasL forms 
aggregates ranging from dimers to aggregates larger than hexamers. By 
electrophoresis in SDS/PAGE gel, only one band was present at 25-kDa 
corresponding to monomers of human sFasL. These data indicate that the long 
human sFasL protein also forms aggregates in a protein-rich extracellular 
environment. These aggregates completely dissociated into monomers by SDS, 
suggesting that non-covalent forces were totally responsible for the aggregation 
of sFasL under these conditions. 
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HPLC of HEK cell supernatant containing human sFasL (KH long human 
sFasL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   (KH long human sFasL) 
 
 
 
 
 
 
 
 
 
Figure 7.12.  Analysis of HEK cell supernatants containing long sFasL using HPLC.   
A) Cell supernatant from HEK cells transfected with cDNA encoding the extracellular portion of 
FasL was concentrated and proteins were separated by size exclusion HPLC at a flow rate of 2 
ml/min in PBS (A). The supernatant sample was separated into 80 fractions of 1 mL each. The 
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column was calibrated using alcohol dehydrogenase (158 kDa), bovine serum albumin (67 
kDa), ovalbumin (43 kDa), chymotrypsinogen A (25 kDa) and ribonuclease A (13.7 kDa) as 
showed in the black line. Separation of the KEH cell supernatant containing the sFasL is 
represented in the blue line. Molecular weights are also indicated. B) Dot-blot analysis of KH 
long human sFasL fractionated by HPLC. Although the KH long human sFasL was elutated from 
fraction 35 to 60, most of the protein was eluated between fractions 36 and 40 indicating that 
this long human sFasL aggregates mainly into trimers and larger molecular weights. C) The KH 
long human sFasL present in the HEK cell supernatant was totally dissociated to monomers 
when separated in electrophoresis in SDS PAGE gel in non-reducing conditions.   
 
 
7.3.3. Role of the stalk region for the biological activity of human sFasL 
 
The presence of two cleavage sites for the proteolytic action of matrix 
metalloproteinase 7 (MMP7, also known as matrilysin) at the extracellular 
sequence of FasL implies 488 that two forms of sFasL may exist in vivo. These 
forms of sFasL have two different predicted lengths and N-terminal sequences: 
i. a long sFasL containing the stalk region plus the TNF homology domain (if 
cleaved at the preferential cleavage site), and ii. a short sFasL comprising only 
the TNF domain (if cleaved at the alternative cleavage site).  
 
We hypothesized that the long human sFaL, which contains the stalk region, 
was more active than its short form, and that MMP-7 could down-regulate the 
activity of long sFasL by releasing its stalk region.  To test these hypotheses, 
we tested the biological activity of the long and short forms of human sFasL that 
we expressed in our lab (KH short and long human sFasL; Fig. 7.10) using the 
mouse in vivo model in which we previously demonstrated that human sFasL 
caused lung injury via Fas receptor activation.  We also tested the cytotoxic 
activity of the two forms of human sFasL in human JKT cells, which are known 
to express Fas receptor in their cell membranes.  Finally, the long human sFasL 
was treated with MMP-7 and the activity of the resultant product was tested in 
human JKT cells. With these experiments, we intended to give insight into the 
role of the stalk region on the biological activity of human sFasL.   
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7.3.3.1. Stalk region and bioactivity of human sFasL: In vivo studies in mouse 
lungs 
 
In order to determine the role of the stalk region in the biological activity of 
sFasL in vivo, C57BL/6 mice (10 per group) were treated with a single 
intratracheal instillation (25 ng/g) of short or long human sFasL (KH short and 
long human sFasL).  We assessed the degree of lung injury at 16 h post-
instillation by measuring the lung wet weight, and by evaluating the presence of 
structural alterations of the alveolar wall and of alveolar-capillary barrier 
dysfunction. Organs from C57BL/6 wild-type mice (n=10) treated with 
intratracheal instillation of PBS were collected as controls for the in vivo 
experiments. 
 
7.3.3.1.1. Lung injury induced by long or short human sFasL 
 
7.3.3.1.1.1. Lung weight and structural alterations of the alveolar wall 
 
As an indicator of lung injury, the total wet weight of the lungs was measured. 
Compared to PBS, instillation of long human sFasL resulted in a significant 
increase in the wet weight of the mouse lungs, but such increase was not 
observed in the mice treated with short human sFasL (Fig.7.13). This suggested 
that the long form of human sFasL had a higher potential than its short form to 
cause lung damage.  
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Figure 7.13. Lung wet weight of mice treated with a short and long form of human sFasL 
(25 ng/g) via intratracheal instillation. The left lungs were removed and the lung wet weight 
determined using an electronic balance (sensitivity, 0.0001 g). The lung wet weight of mice 
treated with the long form of human sFasL was significant higher as compared to PBS treated 
mice, whereas this effect did not occur in mice treated with the short form of human sFasL.  The 
lung wet weight of normal mice (non-treated mice) was also included as negative control. Each 
dot represents individual mice. Horizontal bars represent medians. Statistical analysis: one-way 
ANOVA with Bonferroni’s post-hoc test. (#) p<0.001 vs PBS, (*) p<0.05 vs short human FasL 
mice. 
 
 
Lung tissue sections stained with H&E were used to evaluate the effects of the 
short and long forms of sFasL on mouse lungs with more detail. The lungs of 
mice receiving the long form of human sFasL showed alveolar wall thickening, 
vascular congestion, alveolar hemorrhage and neutrophilic infiltratres.  In 
contrast, the lungs of mice treated with the short form of sFasL appeared 
normal (Fig. 7.14) 
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Figure 7.14. Representative lung tissue sections from mice at 16 hours after 
intratracheal instillation of the long or short form of human sFasL (25 ng/g). The lung from 
long hsFasL-treated mice showed marked thickening of the alveolar walls, vascular congestion 
and alveolar haemorrhage.  In contrast, the lungs from short hsFasL-treated mice showed 
normal lung architecture, not different form mice treated only with PBS.  This tissue sections 
were stained with hematoxylin-eosin. 
 
 
7.3.3.1.1.2. Alveolar-capillary protein permeability 
 
As shown in Figure 7.15, the concentrations of total protein and IgM were 
significantly increased in the BAL fluid of mice treated with long human sFasL.  
IgM is normally confined to plasma due to its large size (900 kDa), and its 
presence in BAL fluid suggests an increase in alveolar epithelial permeability.  
In the BAL fluid of mice receiving the short form of human sFasL, in contrast, 
the concentrations of total protein and IgM were similar to those observed in 
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mice receiving PBS.  These results suggest that only the long form of human 
sFasL increased the permeability of the alveolar epithelial barrier.  
 
 
 
 
 
 
 
 
 
 
Figure 7.15.  Concentrations of total protein and IgM in BAL fluid of C57BL/6 mice 16 
hours after intratracheal instillation of the long or short forms of human sFasL (25 ng/g 
bw).  The total proteins were measured using the BCA assay (A), and the concentration of IgM 
was determined by ELISA (B).  Only mice treated with the long form of human sFasL had a 
significant increased in total proteins and IgM in the BAL fluid reflecting increase in protein 
permeability in the lungs. Each dot represents one mouse.  The horizontal bars represent 
medians.   Statistical analysis: one-way ANOVA with Tukey’s post hoc test. (#) vs PBS and 
short human sFasL mice. 
 
 
7.3.3.1.2. Mechanisms of lung injury induced by variants of human sFasL 
 
7.3.3.1.2.1. Inflammatory cell recruitment 
 
As shown in Figure 7.16, the BAL fluid of mice treated with long human sFasL 
presented a significant increase in the total number of white blood cells and 
PMN (60%), whereas the short form of human sFasL did not change the BAL 
cell profile compared to PBS instillation.  In mice receiving long human sFasL, 
the number of PMN in the BAL fluid was significantly higher than in mice 
receiving either PBS or the short form of human sFasL, whereas the number of 
macrophages tended to decrease. Confirming these findings, the 
myeloperoxidase activity measured in total lung homogenates was significantly 
A B
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increased only in the lungs of mice receiving the long form of human sFasL, but 
not in mice receiving the short form of human sFasL or PBS.  These data 
indicate that only the long form of human sFasL is biologically active in vivo, 
promoting PMN recruitment and increasing lung epithelial permeability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16. Cell counts in BAL fluid from C56BL/6 mice (A, B, C) and myeloperoxidase 
activity in total lung homogenates (D) at 16 hours after intratracheal instillation of either 
long or short forms of human sFasL (25 ng/g bw).  Only mice treated with the long form of 
human sFasL had a significant increase in total white cells (A) and PMN (B) in the BAL fluid, 
and MPO activity in the lung homogenates.  Each dot represents one mouse.  The horizontal 
bars represent medians.   Statistics:  ANOVA with Tukeys’ post-hoc test (#) vs PBS and short 
human sFasL mice. 
  A
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D
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7.3.3.1.2.2. Activation of inflammatory cytokines 
 
Lung cytokine expression was assessed by measuring the concentrations of 
pro-inflammatory cytokines such as IL-1β, IL-6, KC, MIP-2, MCP-1, TNF-α, IFN-
γ and IL-12, and anti-inflammatory cytokines such as IL-4 and IL-10 in lung 
homogenates (Fig. 7.17).  At 16 hours after intratracheal instillation, the lungs of 
mice receiving long human sFasL contained high concentrations of IL-1β, IL-6, 
KC, MIP-2, MCP-1 IL-1β, MIP-2 and KC compared to mice receiving PBS, 
whereas the concentration of IL-4 was significantly decreased.  The cytokines 
TNF-α, IFN-γ, IL-12 and IL-10 were undetectable in all groups.  In contrast, mice 
receiving the short form of human sFasL had similar cytokine concentrations to 
mice receiving PBS, although they did have an increase in the anti-inflammatory 
cytokine IL-4.  
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Figure 7.17. Cytokine production in total lungs of C57BL/6 mice treated with long or short 
human sFasL 16 hours after intratracheal instillation.  The cytokine concentrations were 
measured in the lung homogenates by mouse-specific immunoassays (R&D Systems, 
Minneapolis, Minn.) using the LUMINEX system.  Only mice treated with the long form of human 
sFasL had a significant increase in the expression of pro-inflammatory cytokines (IL-1β, IL-6, 
KC, MIP-2 and MCP-1) and a decrease in the anti-inflammatory IL-4. The sensitivities of these 
immunoassays were 37,9 pg/mL for IL-1β, 10,53 pg/mL for IL-6, 13.08 pg/mL for KC, 6.69 
pg/mL for MIP-2 , 54.15 pg/mL for MCP-1, 6.82 pg/mL for TNF-α, 22.19 pg/mL for INF-δ, 11.25 
pg/mL for IL-4, 7.47 pg/mL for IL-10.  Each dot represents one mouse.  The horizontal bars are 
medians.   Statistics:  ANOVA with Tukey’s post-hoc test. (#) vs PBS and short human sFasL 
mice. 
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7.3.3.1.2.3. Activation of pro-apoptotic pathways 
 
To evaluate the activation of pro-apoptotic pathways, we measured the activity 
of caspase-3 in lung homogenates.  Instillation of long human sFasL induced a 
significant increase in caspase-3 activity in mouse lungs at 16 hours post-
treatment as compared with mice treated with the short form of human sFasL or 
PBS alone.  In mice receiving short human sFasL, the caspase-3 activity in the 
lungs was not different from that observed in mice receiving PBS (Fig. 7.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18. Pulmonary caspase-3 activity in C57BL/6 mice 16 hours after instillation of 
long or short human sFasL (25 ng/g).  The lysates of mouse lungs were incubated with the 
(Z-DEVD)2-Rhodamince 110 substrate.  Active caspase-3 cleaves proteins which contain the 
amino acid motif DEVD. The cleavage of this peptide releases Rhodamince 110, which when 
excitated at 400 nm emits fluorescence at 505 nm.  Caspase-3 activity is directly proportional to 
the fluorescence signal measured in a fluorescent microplate reader.  Only mice treated with the 
long form of human sFasL had a significant increase in caspase-3 activity. Each dot represents 
one mouse.  The horizontal bars represent medians. Statistical analysis:  one-way ANOVA with 
Tukey’s post-hoc test. (#) vs PBS and short human sFasL mice. 
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In summary, the increased bioactivity of the long form of human sFasL 
compared to its short form strongly suggest that the presence of the stalk region 
in the sFasL molecule is an important structural determinant of the effects of 
sFasL in the lungs in vivo.  
 
7.3.3.2. Stalk region and bioactivity of sFasL: In vitro studies in a human cell 
line 
 
To determine further whether the presence of the stalk region is related to the 
biological activity of sFasL, we tested the cytotoxic activity of the long and short 
forms of human sFasL in human JKT cells in vitro.  The concentrations of both 
proteins were determined by ELISA using a polyclonal anti-human sFasL 
antibody that recognizes the two forms of the sFasL protein, as determined by 
western-bloting.  Serial concentrations of both forms ranging from 12.3 ng to 
1000 ng/mL were added to JKT cells. Exposure to long human sFasL induced 
significant cell death in JKT cells at a concentration of 12.3 ng/mL, as compared 
with cells treated only with media.  The short form of human sFasL, however, 
did not show cytotoxicity until its concentration reached 111.1 ng/mL, which 
represents approximately a 10-fold lower cytotoxicity than the long form of 
human sFasL.  Therefore, the presence of the stalk region in the N-terminus 
appears to be an important determinant required for the biological activity of 
human sFasL both in vivo and in vitro. 
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Figure 7.19. Cytotoxicity of long and short foms of human sFasL in JKT cells.  Exposure 
of Jurkat cells to the long human sFasL led to a significant higher percentage of cell death 
compared to the exposure to the short form of human sFasL at all the concentrations tested. 
Results represent mean ±SD of 3 separate experiments performed in duplicates.  One-way 
ANOVA with Tukey’s post-hoc test. (*) p<0.05 vs short human sFasL. 
 
 
7.3.3.3. Proteolytic cleavage of the stalk region by MMP-7 and bioactivity of 
human sFasL 
 
The previous data strongly suggest that the stalk region at the N-terminal 
sequence is an important determinant of the activity of sFasL, as the short form 
of sFasL lacking the stalk region did not induce lung injury in mice, and it was 
less cytotoxic in human JKT cells in vitro compared with its long form. The 
amino acid sequence of long sFasL contains the “SL” cleavage sites near the 
C-terminus of the stalk region that are susceptible to cleavage by MMP-7.  We 
hypothesized that cleavage of the long sFasL protein at the “SL” site by MMP-7 
could release the stalk region and, thus transform the active long sFasL protein 
into the less active short sFasL form.  To test this hypothesis, we incubated our 
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affinity purified long human sFasL protein together with human MMP-7 in an 
aqueous buffer.  The size of sFasL cleaved by MMP-7 was determined by 
western-blot analysis and the cytotoxicity of the MMP-7 cleavage products was 
tested in JKT cells.   
 
In the western-blot analysis with SDS PAGE gel, the untreated long human 
sFasL showed a prominent band at 25-kDa, corresponding to monomeric sFasL 
and less intense bands at 50-kDa and higher molecular weights corresponding 
to multimers.  After treatment with MMP-7, the band corresponding to 
monomers shifted to a lower molecular weight, indicating that the polypeptide 
sequence of sFasL was shortened.  The addition of MMP-7 was also associated 
with a decrease in the intensities of the 50-kDa and larger molecular weight 
bands, and with the appearance of a new band below 10-kDa that 
corresponded to the predicted molecular weight of the stalk region along with 
the extra 15-aa secreted peptide.  The shift of the bands corresponding to 
monomers and the intensity of the band below 10-kDa increased as the dose of 
MMP-7 was increased.  Cleavage at the SL site by MMP-7 with the consequent 
release of the stalk region likely account for the production of the band below 
10-kDa and for the shift of the 25-kDa monomers to a lower molecular weight. 
Importantly, treatment with MMP-7 was associated with a reduction of the 
cytotoxicity of human sFasL in JKT cells.  These results indicate that MMP-7 
can process the stalk region of the sFasL in an aqueous solution, and that the 
release of the stalk region is associated with a reduction of the cytotoxic activity 
of sFasL.  These results reveal for the first time the importance of the stalk 
region in determining the activity of human sFasL.  Moreover, they also point to 
the proteolytic cleavage of sFasL by MMP-7 as a potential mechanism by which 
the cytotoxic activity of sFasL may be downregulated. 
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Figure 7.20.  MMP-7 cleaves the long form of human sFasL and reduces its cytotoxicity in 
vitro.  The long form of the recombinant human sFasL was incubated with serial concentrations 
of MMP-7 at the final human sFasL and MMP-7 molar ratios of 1:0.033, 1:1 and 1:3.  The 
samples were subjected to SDS Page gel in non-reducing conditions, and also tested for 
cytotoxic using JKT cells.  A) Western-blot of the KH human sFasL non-treated with MMP-7 
(lane 1) or treated with serial concentrations of MMP-7 (lane 2, 3 and 4) using a polyclonal 
antibody for detection of human sFasL.  Treatment with MMP-7 resulted in a shift of the 
monomers (25 kDa) to a lower molecular weight and in the appearance of a new band below 
10-kDa (arrow) corresponding to the predictive molecular weight of the stalk region plus the 15 
aa leading peptide. The horizontal bars indicate molecular weight.  B) Cytotoxicity in Jurkat cells 
of the long human sFasL non-treated with MMP-7 used as a positive control (black bar), and 
MMP-7 alone used as the negative control (white bars).  Incubation of long human sFasL with 
MMP-7 (grey bars) resulted in a significant decrease of the cytotoxicity in Jurkat cells, which 
was not significant different to the cytotoxicity of MMP-7 alone (white bars). These results 
suggest that MMP-7 can release the stalk region and reduce the biological activity of the long 
human sFasL in vitro.  Results represent mean ±SD of three separate experiments performed in 
duplicate. One-way ANOVA with Tukey’s post-hoc test. (*) p<0.05 vs Long human sFasL non-
treated with MMP-7. 
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7.3.4. Role of an oxidative environment on the structure and bioactivity of 
human sFasL 
 
Myeloperoxidase, H2O2 and reactive oxygen species (ROS) increase in the 
lungs of patients with ALI/ARDS 338, 632. In the BAL fluid of these patients, many 
oxidized proteins accumulate in BAL fluid 423. Oxidation modifies protein-protein 
interactions and promotes aggregation of proteins, often leading to significant 
changes in the protein activity 633-635.  In this study, we have found that the 
endogenous human sFasL present in the ALI/ARDS BAL fluid exits as covalent 
multimers (Fig 7.1). We have now investigated whether oxidants present in the 
lung fluid of patients with ARDS may account for the formation of covalent 
cross-links between polypeptide units of sFasL multimers and if they may even 
promote further multimerization or aggregation of this protein. Also, we 
evaluated whether oxidation modifies the biological activity of sFasL in vitro. 
 
7.3.4.1. Effects of BAL fluid from patients with ARDS on the multimerization of 
human sFasL 
 
The endogenous human sFasL present in the BAL fluid from patients with 
ARDS does not dissociate into monomers when exposed to SDS under non-
reducing conditions (Fig 7.1).  This resistance to SDS implies that covalent 
bonds are present between sFasL molecules.  To determine whether 
substances present in the BAL fluid of patients with ARDS induce changes in 
the intermolecular forces between sFasL molecules promoting their 
multimerization, we incubated recombinant human sFasL (rh-sFasL) in BAL 
fluid pooled from normal subjects, from patients at-risk for ARDS, and from 
patients with established ARDS. For comparison, rh-sFasL was also incubated 
in PBS.  The rh-sFasL was subsequently boiled and subjected to 
electrophoresis in SDS PAGE gel without reducing agents followed by Western 
blotting. 
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As shown in Figure 7.21, rh-sFasL incubated in PBS presented bands at 26- 
and 52-KDa, and a less intense band at 78-kDa consistent with the predicted 
molecular weight of glycosylated monomers, dimers and trimers, respectively. 
When rh-sFasL was incubated in BAL fluid from patients with ARDS, additional 
bands appeared at larger molecular weights ranging from 104-kDa to 250-kDa. 
These high molecular weight bands were not present, however, when rh-sFasL 
was incubated in BAL fluid from normal or at-risk subjects.  The ARDS BAL fluid 
alone (without the addition of exogenous rh-sFasL) showed a band at 250 kDa 
that was not present in normal or at-risk BAL fluid alone. This 250 kDa band in 
the ARDS BAL fluid could be a result of nonspecific cross reactivity, although 
we cannot discard that such band represented the endogenous sFasL in an 
aggregated form. These data indicates that the BAL fluid of patients with ARDS 
promotes the multimerization of sFasL by establishing covalent forces between 
molecular units, as indicated by the resistance of those multimers to SDS and 
heat. Because rh-sFasL spontaneously forms large aggregates in basal 
conditions (Fig. 7.11), we cannot be certain that the 104- to 250-kDa multimers 
of the rh-FasL in the ARDS BAL fluid corresponded to further aggregation of 
this protein.  Nevertheless, these data strongly suggest that there are 
substances present only in the BAL fluid of patients with ARDS, and not in 
normal subjects or patients at-risk that change the intermolecular forces and 
facilitate the formation of covalently linked stable aggregates of sFasL.  
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Figure 7.21.  ARDS BAL fluid promotes covalent multimerization of exogenous human 
sFasL into larger molecular weight multimers compared to those present in normal or at-
risk BAL fluid. 
The BAL fluid from 3 normal volunteers, 3 patients at risk and 3 patients with ARDS were 
collected and pooled. Exogenous recombinant human sFasL (50 ng) was added to 10 ul of PBS 
or the pooled BAL fluid samples, and incubated for 90 minutes at 37ºC. The same volume of 
each BAL fluid samples without exogenous human sFasL protein was also incubated to be used 
as control. All samples (with and without exogenous sFasL) were boiled for 5 min and subjected 
to electrophoresis without reducing agents in SDS-PAGE gels. The molecular mass of the rh-
sFasL protein was determined by Western blotting. 
 
 
7.3.4.2. Effects of the antioxidant L-methionine on the activity and 
multimerization of human sFasL in BAL fluid from patients with ARDS 
 
Next, we wanted to determine whether oxidation is a mechanism involved in the 
formation of covalent multimers of sFasL and whether it modifies the bioactivity 
of this protein in the BAL fluid of patients with ARDS.  For this, we incubated 
exogenous recombinant human sFasL (rh-sFasL, from Peprotech Inc.) with 
different volumes (2, 4, 8 and 12 ul) of BAL fluid from patients with ARDS.  At 
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the end of the incubation, we added free L-methionine in order to scavenge the 
potent oxidants such as HOCl.  As a control, BAL fluid from patients with ARDS 
was incubated without rh-sFasL, which was incorporated immediately after the 
addition ofL-methionine to the reaction. The samples were then immediately 
subjected to SDS PAGE electrophoresis under non-reducing conditions, and 
the size of sFasL was analyzed by western blotting. The cytotoxicity of the 
samples containing 12 ul of BAL fluid with or without rh-sFasL was also tested 
in JKT cells.  
 
Surprisingly, the rh-sFasL protein suffered important degradation when added 
to ARDS BAL fluids incubated previously with L-methionine (control samples), 
and such degradation was inversely proportional to the volume of ARDS BAL 
fluid.  In contrast, the rh-sFasL incubated in ARDS BAL fluid without L-
methionine (samples in which L-methionine was added at the end of the 
incubation), was not only prevented from suffering degradation but its covalent 
multimers were also better preserved as the volume of BAL fluid used was 
increased in the reaction.  Compared to rh-sFasL in PBS, rh-sFasL incubated in 
ARDS BAL fluid induced slightly more cell death in JKT cells. This was not 
observed with the ARDS BAL fluid in which the rh-sFasL was added after L-
methionine. These results suggest that oxidation by HOCl and other oxidants 
present in BAL fluid from patients with ARDS prevents the degradation and 
maintains the structural stability of rh-sFasL covalent multimers. Moreover, the 
incubation of sFasL with BAL fluid from these patients seemed to increase the 
cytotoxicity of sFasL in vitro.  Together, these data indicate that sFasL is active 
in the lung fluid of patients with ARDS and that it is protected from degradation 
despite the presence of the elevated levels of oxidants and proteases that 
characterize such fluid.  Moreover, oxidation seems to be a mechanism that 
prevents degradation and dissociation of sFasL multimers, whereas the addition 
of antioxidants makes the sFasL protein more susceptible to degradation in the 
ARDS BAL fluid. 
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Figure 7.22.  Western blotting (A) and bioactivity (B) of rh-sFasL incubated in BALF fluid 
of patients with ARDS.  BAL fluid samples from 4 patients with ARDS were pooled and used 
undiluted.  Exogenous rh-sFasL was incubated in PBS alone or with different volumes (2, 4, 8 
and 12 ul) of ARDS BAL fluid pool at 37ºC for 90 min.  At the end of the incubation, the HOCl 
scavanger L-methionine was added to the samples.  As control, rh-sFasL was incorporated to 
the ARDS BAL fluid after the addition of L-methionine (*). A) After incubation, the samples were 
subjected to electrophoresis in SDS PAGE gel in non-reducing conditions and the size of the 
sFasL was analyzed by western blotting.  B) The cytotoxicity of the samples containing 12 ul of 
BAL fluid with or without rh-sFasL was also tested in JKT cells in free serum media.  Cell 
viability was detected by the Alamar Blue assay. JKT cells incubated with serum free media only 
and ARDS BAL fluid alone were used as negative control.  Results represent mean ±SD of 3 
separate experiments performed in duplicates.   
A
B
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7.3.4.3. Effects of oxidation, nitration and chlorination on the multimerization of 
human sFasL 
 
Reactive oxigen species cause protein oxidation that can change protein 
conformation. This, in turn, can increase protein hydrophobicity and enhance 
protein-protein interactions leading to protein aggregation 634, 636.  Protein 
aggregation by oxidation can cause important changes in the biological activity 
of proteins.  Hypochlorous acid (HOCl) is an oxidant that acts as a strong 
microbicidal agent, capable of killing bacteria, fungi and viruses. This oxidant 
also readily oxidizes proteins, causing changes in their activity and aggregation 
637-640.  Neutrophils are a major source of HOCl, which is generated from 
hydrogen peroxide and chloride in a reaction catalysed by myeloperoxidase 
(MPO) 637, 641.  Both MPO and H2O2  are detectable in the lung fluid of patients 
with ARDS 338, 632.  
 
 
 
To determine whether MPO-derived oxidants can induce covalent 
multimerization of human sFasL, we exposed recombinant human sFasL (rh-
sFasL) to the MPO- H2O2-chloride or MPO- H2O2-nitrite systems using two 
different concentrations of H2O2.  As shown in Figure 7.23, rh-sFasL formed 
covalent multimers only when it was incubated with MPO, H2O2 and NaCl 
together but not when incubated with either MPO- H2O2 or MPO-NaCl alone.  
On the other hand, the MPO- H2O2-nitration system had no effect on rh-sFasL 
covalent multimerization.  These data suggest that reactive MPO products, but 
not reactive nitrogen species, promote the formation of covalent multimers of 
sFasL, and open the possibility that MPO-derived oxidants such as HOCl 
constitute a mechanism by which sFasL multimerizes in the BAL fluid of 
patients with ALI.  
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Figure 7.23.  MPO-derived oxidation, but not nitration, enhances multimerization of rh-
sFasL. rh-sFasL (50 ng) was incubated in PBS-DTPA alone or in the presence of two different 
concentrations of H2O2 (10 or 20 μM) supplemented with or without 50 nM MPO and either 100 
μM NaNO2 or 100 mM NaCl. After 60 minutes, the reaction was terminated with 2.5 nM of L-
Methionine. The molecular weight of rh-sFasL subespecies was determined by wentern-blotting 
analysis.  The rh-sFasL covalently mulimerized when exposed to the three components of the 
MPO-H2O2-Chloride system. In contrast, the MPO-H2O2-Nitrate system had no effect on rh-
sFasL multimerization.  
 
 
7.3.4.4. Effects of myeloperoxidase-derived HOCL on the multimerization of 
human sFasL 
 
To further confirm that MPO-derived HOCl changes the intermolecular forces 
and multimerizes sFasL, we incubated both human and mouse sFasL proteins 
with MPO, H2O2 and NaCl or directly with HOCl.    The reaction was terminated 
by the addition of free L-Methionine, an HOCl scavenger.  The proteins were 
incubated with the reducing agent 2-mercaptoethanol, heated at 96ºC, and 
separated by electrophoresis in SDS PAGE gel.  Unlike recombinant human 
sFas, mouse sFasL forms only monomers in basal conditions (determined in 
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native gel, Fig. 7.24. A.1). As shown in Figure 7.24, mouse sFasL exposed to 
oxidation by the MPO system or HOCl multimerized into dimers, trimers and 
larger multimers.  Human sFasL exposed to oxidation showed bands at the 
molecular weights corresponding to trimers and larger multimers. Both mouse 
and human sFasL multimers appeared in a dose-dependent manner with 
respect to the concentrations of H2O2, MPO, and HOCl. Pre-incubation with the 
HOCl scavenger L-Methionine completely prevented multimerization of human 
and mouse sFasL in the MPO reaction or with HOCl.  When high concentrations 
of these two reagents were used, partial or total loss of protein detection 
occurred.  In general, under these reducing conditions (2-ME, heat and SDS), 
the disulfide bonds and the ionic forces of the proteins are broken, so only 
protein aggregates formed by non-disulfide covalent bonds can persist. This 
indicates, therefore, that multimers of rh-sFasL observed under these reducing 
conditions can only be formed by non-disulfide covalent bonds.  Taken together, 
these results indicate that oxidation by HOCL facilitates multimerization of 
sFasL by the formation of non-disulfide covalent bonds between molecular 
units.  
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Figure 7.24. Incubation with MPO-derived oxidants or directly with HOCl promotes 
multimerization of sFasL. Recombinant mouse sFasL from the R&D systems Co and human 
A.1 A.2
A.3
B.1 B.2
B.3
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sFasL from the Peprotech Co diluted in PBS were subjected to electrophoresis in native gel 
followed by western blot analysis (arrow). The mouse sFasL forms only monomers (A.1.) 
whereas the human sFasL forms trimers and higher molecular aggregates in native non-
denaturing gel in basal conditions (B.1.). We incubated these mouse and human sFasL proteins 
in PBS-DTPA alone or with different concentrations of MPO (10, 25, 50 nM) and H2O2 (2, 5, 20, 
30 μM) plus 100 μM of NaCl (A.2 and B.2).  Also, both proteins were incubated in PBS alone or 
with increasing concentrations of HOCl (A.3 and B.3).  Exposure to MPO-derived oxidants 
induced multimerization of mouse and human sFasL in a dose-dependent fashion, although 
total or partial loss of protein detection was also observed with the highest concentrations of 
oxidants.  Pre-incubation with the HOCl scavenger L-Methionine completely prevented 
multimerization and loss of detection of the sFasL protein incubated with HOCl (A.3) 
 
 
7.3.4.5. Role of the methionine residues on the response of sFasL to an 
oxidative environment 
 
Methionine and cysteine residues are oxidized very rapidly even under mild 
oxidative conditions due to the presence of sulfur in their side-chains.  Oxidation 
of methionine residues is a mechanism by which the activity of proteins can be 
modified 634, 642, 643.  Curiously, human sFasL contains a considerably higher 
number of methionine residues than its mouse molecule counterpart (eight 
versus two, respectively), and this constitutes the main difference in the amino 
acid sequence between both proteins. 
 
 
7.3.4.5.2. Influence of methionine residues on the multimerization of sFasL 
induced by oxidative conditions 
 
To determine whether methionine is involved in the multimerization of sFasL 
under oxidative conditions, we took advantage of the fact that murine sFasL 
contains considerably fewer methionine residues than human sFasL and used 
molecular methods to produce a murine sFasL that contained methionines in 
the same positions as in human sFasL.  For this, we first cloned mouse sFasL, 
and then we used site-directed mutagenesis to substitute only the amino acids 
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matching the location of methionine residues in human sFasL.  We expressed a 
“wild-type” mouse sFasL with its two original methionine residues and a 
“humanized” met-mouse sFasL that contained a total of seven methionine 
residues.  As shown in Figure 7.25, when these proteins were subjected to mild 
oxidation with HOCl, the met-mouse sFasL multimerized more readily than the 
native mouse sFasL.  Multimerization did not occur, however, when oxidation of 
sFasL was prevented by the prior addition of free L-methionine to scavenge 
HOCl.  All of these data strongly support that the methionine residues of sFasL 
are key determinants explaining the multimerization-promoting effects of an 
oxidative environment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.25.  Addition of methionine residues in sFasL enhanced multmerization upon 
mild oxidation. By using site-directed mutagenesis, the number of methionine residues were 
increased in mouse FasL from two (native-sFasL) to seven (met-sFasL) as in human sFasL. 
Addition of methionine residues to mouse sFasL (lanes 6 to 8) enhanced multmerization with 
mild oxidation compared to its native form (lanes 2 to 4). As a control, scavenging HOCl with 
excess of free L-Methionine prevented multimerization of sFasL (lanes 1 and 5). 
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7.3.4.5.3. Extent of oxidation and identification of amino acids susceptible to 
oxidation in human sFasL protein 
 
Most reactive oxygen species (ROS) can oxidize methionine (Met) residues of 
proteins to methionine sulfoxide (MetO) 634, 642, 643. To investigate whether 
methionine oxidation is associated with the multimerization and activity of 
sFasL, we analyzed the rh-sFasL protein from the Peprotech Co. by mass 
spectrometry after exposing it to the MPO system. For this, the rh-sFasL protein 
was incubated in an aerobic atmosphere in an aqueous solution with or without 
the MPO+H2O2+NaCl reaction. The purified recombinant human sFasL was 
then digested with trypsin and the tryptic peptides were analyzed by liquid 
chromatography-electrospray ionization followed by tandem mass spectrometry 
(LC-ESI-MS/MS).  With this method, the following ionized fractions were 
separated according to their mass (m)- to- charge (z) ratios (m/z) and the 
sequences were also determined:   
ESTSQMHTASSLEK (m/z, 768.5),  
SMPLEWEDTYGIVLLSGVK (m/z, 1069.3),  
VYMR (m/z, 284.6),  
YPQDLVMMEGK (m/z, 656.1),  
MMSYCTTGQMWAR (m/z, 812.1).  
 
Analysis by MS/MS of the human sFasL protein not exposed to the MPO-
derived oxidant showed that the peptide fractions ESTSQMHTASSLEK and 
MMSYCTTGQMWAR appeared in major peaks with a mass to charge ratio of 
776.4 and 820.1, respectively, suggesting that the molecular weight of the 
original peptides had increased by 8 Da, corresponding to the gain of one 
oxygen atom in each peptide.  MS/MS analysis of these two modified peptides 
indicated that Met15 and Met132 of human sFasL are partly oxidized to 
methionine sulfoxide in an aqueous liquid even when no oxidants other than the 
oxygen molecules of H2O were present.  After oxidation by MPO-derived 
oxidants, MS/MS showed that ESTSQMHTASSLEK, 
SMPLEWEDTYGIVLLSGVK and VYMR peptides had increased by 8 Da (m/z, 
R. Herrero                                                                                                                 RESULTS 
 
151 
 
776.4, 1077.1,  292.7 respectively), YPQDLVMMEGK by 16 Da (m/z, 672.1) 
and MMSYCTTGQMWAR by 24 Da (m/z, 836.0) corresponding to the gain of 
one, two or three oxygen atoms. MS/MS analysis of these modified peptides 
indicated that each methionine residue in the human sFasL sequence was 
partially oxidized to methionine sulfoxide.  None of the other amino acid 
residues were oxidized, and chlorination of tyrosine was not detected. 
 
These data indicate that spontaneous oxidation of two methionine residues 
(Met15 and Met132) occurred when human sFasL was reconstituted in water in 
the absence of oxidant scavengers and handled in an aerobic atmosphere.  
Previous studies have shown that surface-exposed Met residues of proteins are 
major targets of oxidation. Therefore, it is possible that Met15 and Met132 might 
be located in the surface of the protein and be more susceptible to oxidation. 
Interestingly, all of the methionine residues of human sFasL, including Met15 
and Met132, were oxidized when exposed to MPO-derived HOCl. In contrast, 
other amino acids susceptible to oxidation, such as cysteine, tryptophan and 
tyrosine, remained unmodified, indicating that the methionine residues of sFasL 
are the main target for oxidation. 
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Figure 7.26.  MPO-derived oxidants induce oxidation of methionine residues in sFasL. 
MS and MS/MS analysis of peptides in a tryptic digest of recombinant human sFasL dissolved 
in H2O (panel A) or exposed to the MPO system (panel B). The following peptides were 
analyzed:  ESTSQMHTASSLEK (m/z, 768.5), SMPLEWEDTYGIVLLSGVK (m/z, 1069.3), 
VYMR (m/z, 284.6), YPQDLVMMEGK (m/z, 656.1), MMSYCTTGQMWAR (m/z, 812.1). The rh-
sFasL dissolved in H2O only had two methionines (Met15 and Met132) partly oxidized to 
methionine sulfoxide. After exposure to the MPO system, however, the eight methionine 
residues present in the amino acid sequence of rh-sFasL were partly oxidized to methionine 
sulfoxide. 
 
7.3.4.5.4. Relation between the extent of oxidation and the cytotoxic activity of 
human sFasL 
 
Methionine oxidation can lead to changes in hydrophobicity, alterations in 
protein conformation and target proteins for proteolytic degradation 636.  The 
consequences of methionine oxidation in the biological activity of the proteins 
are variable and depend on the position of the methionine residues in the 
protein.  Whereas oxidation of Met residues leads to loss of biological function 
in some proteins, in other proteins it can have little or no effect on their 
biological function. Recently, it has been demostrated that methionine oxidation 
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can increase pre-existing activities of proteins by facilitating the exposure of 
previously hidden binding sites 634, 642, 643. 
 
To evaluate the effects of methionine oxidation on the biological activity of 
human sFasL, we exposed rh-sFasL (from the Peprotech Inc.) to MPO-H2O2-
Chloride system, and compared the activity of the spontaneously oxidized rh-
sFasL (with Met15 and Met132 oxidized) with the activity of the rh-sFasL exposed 
to the MPO oxidative reaction.  The biological activity was tested in JKT cells in 
vitro, and cell survival was determined by Alamar Blue assay.  Compared with 
the sponstaneusly oxidized rh-sFasL, the cytotoxic activity of rh-sFasL exposed 
to the MPO-H2O2-Chloride system diminished in a H2O2 dependent manner 
leading to an increased survival of JKT cells (Fig. 7.27).  Preincubation with 
oxidant scavengers prevented the loss of the biological activity of rh-sFasL 
mediated by the MPO-derived oxidants. These data suggested that the 
spontaneous oxidation of Met15 and Met132 has little or no effect on the 
biological activity of human sFasL protein. In contrast, additional methionine 
oxidation by MPO-derived HOCl resulted in an important reduction of the 
biological activity of sFasL. 
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Figure 7.27.  Oxidation modulates the biological activity of human sFasL in vitro. We 
compared the activity of the MPO system-oxidized sFasL to the spontaneously oxidized sFasL 
containing only two oxidized methionines. Human sFasL was incubated with one dose of MPO 
(10 nM) and four different concentrations of H2O2 (2, 5, 10 or 20 μM) at 37ºC. After 60 min, the 
oxidative reaction was terminated by adding free L- Methionine and catalase as potent 
scavengers of HOCl and H2O2, respectively. As control, oxidative reaction was terminated by 
the addition of the oxidant scavengers (free L-methionine and catalase) prior to the addition of 
the human sFasL protein.  Also, sFasL was incubated with the oxidant scavengers but without 
any oxidant.  The samples were added to JKT cells for 18 hours. Cell viability was detected by 
Alamar Blue assay. The cells treated with spontaneously oxidized sFasL showed a 50% survival 
whereas the cells treated with the MPO system had higher survival ranging from 75% to 100 % 
in an H2O2 dose dependent manner.  
 
The final effect of oxidation on the activity of a particular protein can be 
diminished by the presence of other proteins with anti-oxidant properties, such 
as albumin 644.  Therefore, we next investigated how oxidation affected the 
activity of human sFasL either in a protein-rich or a protein-free environment.  
We incubated our KH human sFasL present in the HEK supernatant (protein-
rich solution) or an affinity purified KH human sFasL (protein-free solution) with 
serial doses of HOCl.  The activity of KH rh-sFasL in the supernatant tended to 
increase (although it was not statistically significant) when treated with 10 μM of 
HOCl, and no changes in the activity were observed with doses of HOCl as high 
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as 200 μM.   As expected, affinity purified rh-sFasL was more susceptible to 
oxidation.  The activity of the purified protein significantly decreased when 
exposed to very low concentrations of HOCl and it was inhibited with only 0.1 
μM of HOCl. In contrast, more than 2000-fold of HOCl was needed to abrogate 
the activity of the rh-sFasL from HEK supernatant.  The activity of rh-sFasL 
incubated with L-methionine (an HOCl scavenger) prior to the exposure to HOCl 
had the same activity as the rh-sFasL non-exposed to HOCl.  No changes in the 
level of aggregation were detected by western blot analysis with the doses of 
HOCl used in these experiments (data not shown).  These findings indicate that 
exposure of sFasL to HOCl results in oxidative changes of the molecule that 
alter its activity.  The results suggest, therefore, that mild oxidation does not 
decrease the biological activity of human sFasL in a protein-riched environment, 
and that very high local levels of HOCl might be needed to downregulate or 
abrogate its biological activity. This may also explain our previous observation 
that the spontaneously oxidized human sFasL protein, which contained only two 
oxidized methionines (Met15 and Met132), was active and induced cell death in 
the JKT cells in vitro, whereas further oxidation resulted in a decrease of its 
biological activity. 
R. Herrero                                                                                                                 RESULTS 
 
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.28. The biological activity of human sFasL is preserved under mild oxidation but 
diminishes under intense levels of oxidation.  The long soluble form of human FasL (KH rh-
sFas) was cloned and expressed in HEK cells in our laboratory.  The KH rh-sFasL secreted to 
the supernatant of HEK cells was purified by immunoaffinity column.  Either the KH rh-sFasL 
present in the HEK cell supernatant (A) or the purified KH rh-sFasL(B) was exposed to H2O2 
alone or to serial concentrations of HOCl at 37ºC.  After 30 min of incubation, free L-methionie 
was added to terminate the oxidative reaction.  As control, rh-sFasL was previously incubated 
with L-methionine prior to the addition of HOCl.  The rh-sFasL bioactivity in each sample was 
A
B
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then tested in vitro using JKT cells incubated in serum-free media.  Cell viability was determined 
by the Alamar Blue assay after 18 hours of incubation.  The JKT cells incubated with media 
alone was used as negative control.  Results represent mean ±SD of three separated 
experiments performed in duplicate. 
 
7.3.4.5.5. Effects of the reduction of methionine residues on the multimerization 
status and activity of human sFasL 
 
We have found that oxidation of human sFasL results in the oxidation of 
methionine residues to methionine sulfoxide, and that it is also associated to the 
covalent multimerization of human sFasL. To further confirm that methionine 
oxidation was involved in the covalent mulimerization of human sFasL induced 
by oxidative conditions, we used dimethyl sulfide (Me2S) and hydrochloric acid 
(HCl), which are agents that selectively reduce methionine residues in proteins 
630. Treatment of methionine sulfoxide with Me2S and high concentrations of HCl 
results in the rapid conversion of methionine sulfoxide back to methionine. The 
oxygen exchange between methionine sulfoxide and Me2S is acid-dependent 
and the choride anion from HCl is effective in promoting the exchange. The 
reduction of methionine sulfoxide to methionine is completed only at high 
concentrations of HCl, because an increased concentration of H2O in the 
reaction mix is unfavorable for the reaction to occur.  This method does not 
cause irreversible denaturation of the proteins despite the high concentration of 
HCl 630. As shown in Figure 7.29, a 2 hour exposure of human sFasL to a 
mixture of Me2S and HCL efficiently dissociated the multimers of human sFasL 
protein into monomers, strongly supporting that methionine oxidation is the 
mechanism that originates the covalent multimerization of sFasL. 
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Figure 7.29.  Dimethyl sulphide and hydrochloric acid reversed the covalent 
multimerization of recombinant human sFasL  
Recombinant human sFasL (from Peprotech Inc.) was incubated with PBS alone or with 
dimethyl sulphide (Me2S) and hydrochloric acid (HCl) at room temperature for 2 hours.  After 
incubation, the samples were filtreated to eliminate Me2S and HCl and until pH became neutral. 
The samples were then subjected to electrophoresis in SDS-PAGE gel in non-reduced 
conditions, and western-blot analysis was performed.  Purified human sFasL spontaneously 
forms covalent multimers (Lane 3, 4). Incubation with Me2S/HCl complete reversed the covalent 
multimerization of human sFasL (Lane 1, 2).  
 
 
To determine whether the oxidation of methionine residues modifies the activity 
of sFasL, we took advantage of the fact that the commercially available human 
sFas has two methionine residues that are spontaneously oxidized in basal 
conditions.  We investigated whether the Me2S/HCl system, which specifically 
reduces oxidized methionine residues, altered the activity of this form of human 
sFasL.  First, we treated the spontaneously oxidized human sFasL with the 
Me2S/HCl system in order to reduce the two methionine sulfoxide residues back 
to methionine. For this, the rh-sFasL protein was incubated with a mixture of 
Me2S and HCl for different periods of time (10, 40 or 120 minutes) as described 
in Materials and Methods.  After incubation, the samples were filtered to 
eliminate the Me2S and HCl.  The samples were then analyzed by SDS-PAGE 
electrophoresis under non-reduced conditions, followed by western blotting. The 
cytotoxic activities of both the spontaneously oxidized and the reduced forms of 
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human sFasL were also tested in vitro in JKT cells.  As shown in Figure 7.30, 
the reduction of the covalent multimers of human sFasL started after just 10 min 
of incubation with the Me2S/HCl system, and this was sufficient to completely 
inhibit the biological activity of human sFasL.  Longer times of incubation were 
necessary for the Me2S/HCl to completely dissociate the covalent multimers of 
human sFasL into monomers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.30.  Reduction of oxidized methionines reversed the multimerization and 
reduced the biological activity of recombinant human sFasL.  
Recombinant human sFasL (from Peprotech Inc.) was incubated with dimethyl sulphide (Me2S) 
and hydrochloric acid (HCl) at room temperature for different periods of time: 10, 40 and 120 
min. The samples were filtrated to eliminate the content of Me2S and HCl, and until the pH 
became neutral.  The samples were then analyzed by electrophoresis in SDS-PAGE gel in non-
reduced conditions followed by western blotting (A). The activity of both oxidized and reduced 
sFasL proteins were also tested in JKT cells (B).  Cell viability was measured by the Alamar 
Blue assay.  Purified human sFasL spontaneously forms covalent multimers in aqueous solution 
(lane 4). Incubation with Me2S/HCl reversed multimerization of human sFasL in a time-
dependent manner (lane 1 to 3).   After reduction with Me2S/HCl, the biological activity of human 
sFasL significant decreased. 
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7.3.4.5.6. Effects of the reduction of cysteine residues on the multimerization 
status and activity of human sFasL 
 
Dithiothreitol (DTT) is widely used to reduce the disulfide bonds between 
cysteine residues of proteins.  Like methionine, cysteine residues also have a 
sulfhydryl group that is susceptible in solution to both oxidation and disulfide 
formation 645.  The presence of disulfide bonds in extracellular proteins provides 
structural strength.  To determine whether disulfide bonds between cysteine 
residues could be involved in the multimerization of human sFasL, we tried to 
reduce rh-sFasL with high concentrations of DTT without causing protein 
denaturation. As shown in Figure 7.31, incubation with DTT did not dissociate 
the multimers of human sFasL, as an equal level of multimerization was present 
in the rh-sFasL non incubated with DTT. Regarding its biological activity, the rh-
sFasL induced a similar percentage of cell death in JKT cells regardless of the 
presence of DTT in the incubation media. Therefore, incubation with DTT did 
not decrease the multimerization nor modified the biological activity of human 
sFasL in vitro.  These results suggest that disulfide bonds between cysteine 
residues are not involved in the covalent multimerization of human sFasL 
protein promoted by an oxidative environment, and that they do not play a role 
on the biological activity of sFasL.  
 
 
Figure 7.31.  Disulfide bonds are not determinants of the multimerization or the control of 
the  biological activity of recombinant human sFasL.  
We incubated rh-sFasL with 10 and 20 mM of DTT at 37ºC. One hour later, IAM was added to 
prevent reformation of the disulfide bonds, and the samples were then filtrated to eliminate the 
A B
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content of DTT. The samples were then analyzed by electrophoresis in SDS-PAGE gel in non-
reduced conditions followed by western blotting (A). The bioactivity of sFasL was also tested in 
JKT cells (B).  Cell viability was measured by the Alamar Blue assay.  Incubation with DTT did 
not reverse the covalent multimerization and did not change the biological activity of rh-sFasL 
protein.  Results represent mean ±SD. 
 
 
  
 
 
 
 
 
 
 
 
 
8. – DISCUSSION 
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The Fas/FasL system has been shown to play a key role in the pathogenesis of 
ALI/ARDS.  The soluble form of FasL (sFasL) is elevated in the BAL fluid of patients 
who are at-risk for ARDS as well as of those who have established ARDS 467, 468.  
However, only the BAL fluid from the later induces apoptosis in human lung distal 
epithelial cells in vitro 284, suggesting that some factors present in the edema fluid 
control the biological activity of sFasL.  The main goal of the present study was to 
investigate the structural determinants that control the biological activity of human 
sFasL.  In addition, we studied whether factors present in the BAL fluid of patients with 
ALI/ARDS modulate the bioactivity of sFasL by changing its molecular conformation.  
We found that two variants of recombinant human sFasL differing in the presence or 
absence of the stalk region at the N-terminus (long and short sFasL, respectively) had 
different biological activities.  The long form of human sFasL was also more cytotoxic 
than its short form in Jurkat cells in vitro.  Furthermore, only the long form of human 
sFasL induced lung injury in vivo when instilled intratracheally to mice.  sFasL-induced 
lung injury was characterized by local activation of pro-apoptotic pathways, neutrophil 
infiltration, activation of pro-inflammatory cytokines and increase in alveolar-capillary 
protein permeability.  All these pathological events, however, did not occur or were 
significantly reduced in Fas-deficient lpr mice, indicating that long human sFasL-
mediated lung injury was due to the specific activation of Fas receptor.  The long form 
of human sFasL was cleaved when co-incubated with MMP-7 in solution, resulting in a 
reduction of its activity, most likely explained by the proteolytic processing of the stalk 
region at its N-terminus.  These results indicate that the presence of the stalk region at 
the N-terminus is a critical determinant of the biological activity of human sFasL in the 
lungs. 
 
Our study also provided insight into the mechanisms by which the stalk region of sFasL 
and the pro-inflammatory/oxidative environment in the lungs of patients with ALI/ARDS 
influences its activity. We showed that sFasL formed trimers and higher molecular 
weight aggregates that were mediated by ionic forces in basal conditions, and that this 
degree of aggregation was not affected by the absence of the stalk region.  In contrast 
to basal conditions, we found that the formation of multimers of the endogenous sFasL 
that accumulates in the alveolar fluid of patients with ARDS was mediated by covalent 
bonds in addition to ionic forces.  Furthermore, exposure to BAL fluid from patients with 
ARDS increased the level of aggregation of exogenous human sFasL by mechanisms 
involving oxidation.  Exposure to myeloperoxidase-derived oxidants, such as 
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hypochlorous acid, also increased the aggregation of exogenous sFasL and the 
stability of such aggregates due to the formation of new intermolecular covalent bonds.  
The formation of these covalent aggregates of sFasL induced by oxidative stress 
involved the oxidation of methionine residues, but did not involve the formation of 
disulfide bonds. 
 
8.1.   Relevance of sFasL in ALI 
 
FasL exists in both membrane and soluble forms, both of which can bind and cluster 
the Fas receptor on the cell membrane of target cells initiating intracellular apoptotic 
and inflammatory signals 493-495, 625, 646, 647.  Membrane FasL is constitutively expressed 
in the lung epithelium particularly in the nonciliated, cuboidal airway epithelial cells 
(Clara cells) and also in the alveolar epithelial type II cells 283, 468, 502.   Soluble FasL 
(sFasL) can be generated from the cleavage of membrane FasL by the proteolytic 
action of metalloproteinases (MMPs) 482-488, as well as by the rapid release of pre-
formed sFasL in response to cellular stimuli of human monocytes 471, 489-491 and 
neutrophils 577, 648. Importantly, the Fas receptor/Fas ligand system is up-regulated in 
the lungs of patients with ALI and is associated with mortality 284, 468.  In previous 
studies, it has been shown that sFasL increases in the lung edema fluid of patients with 
ALI 284, 468 at concentrations that induce apoptosis in human distal lung epithelial cells in 
vitro 284, suggesting a role of sFasL in the pathogenesis of ALI.   
 
8.1.1.  Human sFasL in animal models 
 
In experiments performed in rabbits, the instillation of recombinant human sFasL 
induced the activation of apoptotic pathways in the alveolar wall and lung injury 549, 
which suggested that Fas-mediated apoptosis of the alveolar epithelium may be an 
initial event in the development of some forms of lung injury.  In our mouse model, 
instillation of human sFasL caused structural and functional alterations of the lung that 
were very similar to those found in patients with ALI.  In contrast, the lung damage was 
significantly attenuated in lpr mice, which lack a functional Fas receptor, indicating that 
sFasL induced lung injury in mouse lungs via the specific activation of the Fas receptor.  
The results also indicate that the intratracheal instillation of human sFasL in mouse 
lungs is a good model to study in vivo the role of the Fas/FasL system pathway in the 
development of ALI.   
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8.1.2.  Apoptosis and sFasL-induced lung injury 
 
Intratracheal instillation of human sFasL in the lungs of mice resulted in important 
structural alterations of the alveolar wall accompanied by an increased permeability to 
macromolecules, suggesting that both the alveolar endothelial and epithelial barriers 
were disrupted.  This alteration of protein permeability was significantly attenuated in 
Fas deficient lpr mice, indicating that the activation of the Fas/FasL system was 
required for the disruption of the alveolar epithelial-capillary barrier.  The intrinsic 
mechanisms by which Fas activation alters the alveolar epithelial-capillary barrier, 
however, are not completely understood.  A possibility that has been proposed is that 
the activation of the Fas/FasL system alters the alveolar epithelial-capillary barrier by 
inducing apoptosis or dysfunction of alveolar epithelial cells 241, 258, 284, 289, 548, 555.  In this 
regard, previous studies performed by T.R. Martin’s group demonstrated that Fas-
mediated lung injury requires the expression of Fas in non-myeloid cells of the lungs 
such as epithelial cells, and suggested that the alveolar epithelium could be the primary 
target of Fas-mediated ALI 555.  In chimeric mice only expressing Fas receptor in non-
myeloid cells (i.e. epithelial cells) but not in myeloid cells (i.e. PMN and monocytes-
macrophages), the  instillation of a murine anti-Fas agonistic antibody (Jo-2 Ab) 
resulted in lung injury associated with neutrophil recruitment and activation of apoptotic 
pathways, particularly in cells of the alveolar wall 555.  Therefore, one possibility is that 
Fas ligation results in epithelial and/or endothelial dysfunction via the activation of 
apoptosis.  The exposure of the basement membrane resulting from the denuded 
alveolar wall may subsequently lead to neutrophil activation, adhesion to endothelial 
surfaces, and eventual migration into the airspaces.  This possibility is supported by the 
finding that alveolar permeability was increased in mice expressing Fas only in non-
myeloid cells, and that these same animals showed significant structural alterations 
with an increase in the number of apoptotic cells of the alveolar walls 555.  In the model 
used in the present study, the instillation of human sFasL increased the activity of 
caspase-3 in the cells of the alveolar wall.  Caspase-3 is one of the executioner 
proteolytic enzymes that cleave proteins needed for cellular function, therefore leading 
to cell death by apoptosis.  In Fas-deficient lpr mice, however, the activation of 
caspase-3 was completely blunted, which was associated with a significant attenuation 
of the increase in alveolar permeability to macromolecules.  Although, we have not 
determined which cells of the alveolar wall underwent apoptosis in our model, other 
studies have shown that subsets of the alveolar epithelial cells expressing Fas on their 
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surface undergo apoptosis in response to Fas ligation 282, 284.  Previous studies by T.R. 
Martin’s group also demonstrated that active sFasL present in the ARDS BAL fluid can 
induce apoptosis in human distal lung epithelial cells in vitro 284.  Therefore, all these 
findings support the notion that apoptosis mediated by the Fas/FasL system is a 
mechanism by which the alveolar epithelial barrier is damaged in vivo in ALI.  This 
mechanism, however, does not seem to be the only one.  Although significant, the 
increase in apoptosis was limited to a small number of cells in the alveolar wall in all 
these models, raising the possibility that epithelial cells may lose their barrier function 
before becoming apoptotic via a mechanism still to be determined. 
 
8.1.3. Inflammation and sFasL-induced lung injury 
 
It has recently been shown that human and mouse lung distal epithelial cells express 
cytokines upon Fas ligation in vitro, including the expression of potent neutrophil 
chemoattractants such as IL-8 and KC 539, 566.  These results suggest that activation of 
the Fas/FasL system not only can induce apoptosis but also cytokine expression in 
alveolar epithelial cells.  The activation of intracellular inflammatory pathways and/or 
expression of inflammatory mediators in alveolar epithelial cells, therefore, could be a 
mechanism contributing to the alteration of the alveolar-capillary barrier in Fas-
mediated lung injury.  The activation of Fas has also been found to induce cytokine 
release by macrophages and neutrophil recruitment 490, 499, 538, raising the question of 
whether Fas-mediated injury is due primarily to its effects on the alveolar epithelium or 
to its effects on the resident alveolar macrophages.  In this regard, R.A. Bem and G. 
Matute-Bello have demonstrated that Fas activation can induce important lung injury 
and inflammatory responses in mice in which macrophages had been depleted 566.  
This supports the concept that the lung damage and the inflammatory responses 
induced by Fas activation do not depend primarily on resident alveolar macrophages, 
and may instead depend on cytokine release by alveolar epithelial cells. 
 
The Fas/FasL system-mediated apoptosis and cytokine expression by alveolar 
epithelial cells could be an initial event in the development of several forms of lung 
injury.  Although PMN may contribute to lung injury in some circumstances, it is not 
clear whether the first event involves PMN migration, or whether epithelial injury occurs 
before leukocytes are involved.  The primary event leading to lung injury in ARDS has 
not been established.  A prevalent hypothesis is that neutrophils are the primary 
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players mediating lung injury in ARDS 279, 325, 329, 649.   In this paradigm, uncontrolled 
neutrophil activation would lead to the accumulation of oxidants and proteases in the 
lungs, which would cause damage to the neighbouring alveolar cells 330, 650-654.  
However, neutrophils can migrate into the lungs of humans or sheeps without causing 
injury to the epithelial barrier 107, 278, 336.  Blockade of PMN chemoattractants or systemic 
PMN depletion blocks lung injury in some animal models, but not in all of them. 
 
8.2.  Controversies in the biological activity of sFasL 
 
The exact biological activity of sFasL still remains controversial.   It has been shown 
that sFasL can exert both pro- or anti-apoptotic effects, and pro- or anti-inflammatory 
effects, depending on the system tested 520, 597, 600, 603-606.  Several studies agree that 
sFasL is less capable of inducing apoptosis and inflammatory responses compared 
with membrane FasL, and that the proteolytic cleavage of membrane FasL is a 
mechanism to downregulate its apoptotic effects 482, 597, 598.  Several mechanisms have 
been suggested to explain the lower cytotoxicity of sFasL compared with membrane 
FasL. Ligation with sFasL rapidly internalizes Fas, which results in less expression of 
Fas on the cell surface and makes cells more resistant to membrane FasL-mediated 
apoptosis 482, 597, 598, 611.  sFasL has also been shown to exert an anti-apoptotic effect in 
human T cells resulting from the activation of cytoprotective intracellular proteins such 
as the Bcl-2 anti-apoptotic family members 655, 656.  In addition, cross-linked sFasL has 
been shown to activate the NF-κB signaling pathway in target cells expressing high 
levels of FLIP, which inhibited apoptosis and propagated pro-inflammatory responses 
514, 528, 533, 657-661.  Even though the capability of sFasL for promoting both apoptotic and 
inflammatory effects has been demonstrated in vivo and in vitro, the intrinsic 
mechanisms by which sFasL initiates inflammatory responses via NF-κB or via other 
pathways are not completely understood.  In animal experiments, intravenous 
administration of human sFasL induced acute liver failure in mice 662, 663.  Intratracheal 
instillation of human sFasL in our mouse model led to lung tissue damage associated 
with the activation of both apoptotic and inflammatory responses.  The mechanisms 
that may explain these discrepancies in the biological activity of sFasL are not 
completely understood, but proposed mechanisms include differences in the degree of 
aggregation of the sFasL protein 597, 615, 619, interaction with accessory molecules 612-614, 
differences in the type of cells studied and in the species of sFasL, and also it may 
depend on different variants of sFasL 483, 492, 619. 
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8.2.1.  The stalk region is an important determinant for the biological activity of 
sFasL 
 
Previous studies have shown discrepancies in the activity of the natural cleavage 
products of FasL.  Whereas the naturally cleaved human sFasL did not induce 
apoptosis in cultured T lymphocytes cells in some studies 485, 597, 603, other lines of 
evidence indicated that the naturally cleaved sFasL was active and induced apoptosis 
in epithelial cells in vivo and in vitro 487, 621.  The extracellular domain of the membrane 
FasL can be processed by matrix metalloproteinases, such as MMP-3 and MMP-7, at 
three different cleavage sites, which may create alternative forms of sFasL with 
different N-terminal sequences 482, 488.  Cleavage at the preferential cleavage sites, 
located closer to the cell membrane and at the beginning of the stalk region (ELAELR), 
gives rise to a long form of sFasL containing the TNF homology domain at the C-
terminus and most of the stalk region at the N-terminal.  Two alterative cleavage sites 
(SL and ELR) located more distant to the cell membrane give rise to a short form of 
sFasL containing the TNF-domain but lacking the stalk region.  Therefore, we 
hypothesized in the present study that cleavage at different sites generates specific 
structural variants that determine the activity of sFasL, therefore explaining the 
differences in the activity of this soluble protein.  We found that structural variants of 
sFasL had different cytotoxic activity depending on the presence or absence of the 
stalk region at the N-terminus.  Our results showed that the long variant of recombinant 
human sFasL containing the stalk region induced lung injury in mice, which was 
characterized by swelling of the alveolar walls, alveolar hemorrhage, neutrophil 
infiltration and increased alveolar protein permeability.  Activation of apoptosis and 
inflammatory responses appeared to be involved in the development of long human 
sFasL-mediated injury in the lung, as it induced the activation of apoptotic pathways in 
cells of the alveolar wall as well as the recruitment of neutrophils and the expression of 
pro-inflammatory cytokines such as IL-1b, IL-6, KC, MIP-2 and MCP-1 along with a 
decrease in the anti-inflammatory cytokine IL-4.  A short form of human sFasL that 
lacks the stalk region, however, was not harmful to mouse lungs, and failed to activate 
pro-apoptotic and pro-inflammatory pathways.  Therefore, the absence of the stalk 
region in the short variant of human sFasL prevented all the tissue damage in mouse 
lungs in vivo.  This indicates that the presence of the stalk region at the N-terminus is a 
critical determinant for the cytotoxic activity of sFasL, which was similar to the lung 
damage found in patients with ALI/ARDS.  The long human sFasL was also more 
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cytotoxic in vitro in our studies, as the exposure of human Jurkat cells to the long 
variant of human sFasL resulted in significantly higher percentages of cell death than 
the exposure to the short form of sFasL at all the concentrations tested.   To further 
investigate the relevance of the stalk region, we used MMP-7 to convert the long form 
of human sFasL to a short form.  Incubation of the long variant of human sFasL with 
MMP-7 resulted in a shift of the sFasL monomers to a lower molecular weight in the 
Western-blot, and in the appearance of a new band below 10 kDa corresponding to the 
predictive molecular weight of the stalk region.  These structural changes were 
accompanied by a significant reduction of the cytotoxicity on Jurkat cells compared with 
the non-treated long human sFasL.  These data suggest that MMP-7 reduced the 
cytotoxicity of the long form of human sFasL in vitro by releasing the stalk region at the 
N-terminus. 
 
8.2.1.1.  The stalk region is not involved in the aggregation of sFasL 
 
The mechanism by which the presence of the stalk region increases the activity of the 
sFasL is still unknown.  The TNF domain has the structural information for receptor 
binding and contains a self-association domain, which mediates the aggregation of the 
sFasL protein.  However, soluble trimers of sFasL only composed of the TNF domain 
do not activate Fas receptor.  Each trimeric sFasL binds to three pre-associated 
molecules of Fas receptor 517, but trimerization of the Fas receptor after Fas ligation is 
not sufficient to activate intracellular signaling pathways 519, 597, 619.  Several lines of 
evidence suggest that the initial formation of the trimeric ligand receptor complexes is 
followed by secondary multimerization into supramolecular clusters of Fas-FasL 
complexes 519, 622, 625, 664, 665.  The formation of these clusters is associated with the 
formation of a death-inducing signaling complex (DISC) at the receptor.  In the DISC, 
procaspase-8 is cleaved and released as active caspase-8, which initiates the 
activation of downstream caspases leading ultimately to apoptosis.  These three steps 
in Fas receptor activation - ligand binding, secondary aggregation of the receptor-
ligand complexes and DISC formation - depend on several factors 519.  Proposed 
factors include the affinity and avidity of FasL-Fas interaction, the manner in which 
FasL is presented to Fas (as a membrane ligand or as soluble form), and the level of 
aggregation of FasL. 
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Cross-linking of sFasL restored the pro-apoptotic activity of sFasL, supporting the idea 
that aggregation is an important determinant of its activity.  It is believed that the lack of 
apoptotic activity of sFasL observed in some studies was not due to a decrease in 
binding affinity to Fas, but to an inability to cluster Fas trimers into larger aggregates.  
In this line, Holler and Berg demonstrated that a cross-linked sFasL retained its 
capability to aggregate Fas and induce apoptosis 615, 616, 619.  In addition, cross-linked 
sFasL has also been shown to induce NF-κB nuclear translocation that is responsible 
for the FasL-induced chemokine production 539.  Therefore, we investigated whether 
the differences in activity of our two variants of human sFasL were due to different 
degrees of aggregation.  For this, we run both proteins in a non-denaturing gel without 
SDS, in which protein folding and aggregation are preserved.  We found that the long 
and short variants of human sFasL spontaneously formed trimers and higher molecular 
weight aggregates in basal conditions.  There was no difference in the degree of 
aggregation between these two variants before or after the purification process.  
Therefore, the difference in the activity of these two variants of human sFasL cannot be 
explained by a different degree of aggregation.  The self-association domain that has 
been identified at the beginning of the TNF domain is present in our long and short 
variants of human sFasL, which may explain the similar ability of both proteins to 
aggregate regardless of the presence of the stalk region.  This also implies that the 
stalk region is not necessary for aggregation of this protein in solution.  The third 
cleavage-site (ELR), more distant to the cell membrane, is located within the self-
associated domain 488, and therefore we cannot discard that other forms of short 
human sFasL have the ability to aggregate. 
 
8.2.1.2.  Potential mechanisms by which the stalk region influences the biological 
activity of sFasL 
 
The stalk region does not participate directly in Fas receptor binding, because the 
binding sites are located in the TNF domain.  However, the stalk region may confer a 
spatial conformation that increases the affinity of this protein for Fas receptor binding.  
It could also provide more stability to aggregates of sFasL, for example by stabilizing 
the TNF domain structure against structural disturbance related to receptor binding.  A 
third possibility is that the presence of the stalk region may promote secondary 
aggregation of FasL/Fas receptor complexes on the cell surface needed for an efficient 
activation of intracellular signaling.  In contrast to the human sFasL, we found that the 
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corresponding long and short variants of mouse sFasL formed monomers and dimers, 
but not trimers.  Both variants of mouse sFasL  presented a poor cytotoxicity (data no 
shown). This is in accordance with other studies showing that mouse sFasL is 
significantly less cytotoxic than human sFasL 619.  Even though previous studies had 
found that a long form of mouse sFasL comprising the stalk region was able to bind to 
Fas receptor 620, we were not able to detect activity of our long variant of mouse sFasL 
in our in vitro model using murine and human lymphoma cells bearing Fas receptor on 
the cell membrane.  In agreement with the notion that the degree of aggregation may 
be an important structural determinant of the activity of sFasL, we propose that the 
poor activity of the long mouse sFasL in our study may be partly due to its inability to 
form trimers and larger multimers.  Therefore, the presence of the stalk region may not 
overcome the requirement of the sFasL for aggregation to become properly active. 
 
8.2.1.3.   Cleavage by MMPs may determine the biological activity of sFasL 
 
Matrix metalloproteinases (MMPs) play a central role in the proteolytic regulation of 
proteins involved in inflammation and repair, in the turnover of extracellular matrix, and 
in the pathological destruction of tissue proteins 360, 361, 363-365, 367-369, 666.  The MMP-3 and 
-7 have been detected in the BAL fluid of patients with ALI/ARDS and both were 
associated with a worse outcome.  MMP-2, MMP-7, MMP-9 and tissue inhibitor of 
metalloproteinase (TIMP-1) were also elevated in pulmonary epithelium of patients with 
ALI, asthma and cystic fibrosis 372-374.  However, the specific roles that most MMPs play 
in lung injury and repair remain largely unknown. 
 
Unlike many MMPs, MMP-7 (also called matrilysin) is constitutively expressed in non-
injured, non-inflamed mucosal epithelia in most adult human tissues 389, 390.  In human 
lungs, MMP-7 is expressed in normal tracheal glands and in tracheal-bronchial 
epithelium, and can be up-regulated rapidly in the airway epithelium by injury or 
exposure to bacteria 391, 392.  Some studies also showed that MMP-7 protein expression 
is up-regulated in injured alveolar epithelium in a variety of human lung diseases, such 
as ALI, asthma, cystic fibrosis and idiopathic pulmonary fibrosis 372-374.   MMP-7 is an 
important extracellular protease necessary for epithelial repair 395.  However, it also 
participates in the progression of lung fibrosis in animal models 384.  This enzyme can 
be expressed by lung epithelial cells as well as by activated human blood monocytes, 
but not by differentiated alveolar macrophages 667, 668.  More recently, MMP-7 has been 
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shown to be released by activated human blood T lymphocytes and bronchoalveolar T 
lymphocytes 669.  In prostate epithelial cells, MMP-7 can regulate apoptosis by cleaving 
Fas ligand, which was implicated in prostate involution 487.  In animal models of fibrosis, 
MMP-7 regulates the expression of KC, an epithelial-derived neutrophil chemotactic 
factor that promotes inflammation 384, 667, 668, 670.  In this line, an important role of MMP-7 
on the transepithelial influx of neutrophils has been reported 384, 670. 
 
The activity of MMP-7 in the lung edema fluid or in the cell membrane of lung epithelial 
cells, and its potential role in the pathogenesis of ALI are currently unknown.  The 
presence of these MMPs in the airspaces of the lungs of patients with ALI together with 
the up-regulation of FasL and Fas in the alveolar epithelial cells and in infiltrating 
inflammatory cells raise the possibility of the cleavage of membrane FasL by MMPs as 
one of the mechanism by which soluble FasL is released into the airspaces.  As 
explained in previous paragraphs, however, multiple cleavage sites can give rise to 
different variants of sFasL with different activities. 
 
Our current investigations are aimed to determine which variant of sFasL dominates in 
the edema fluid of patients with ALI, and whether MMPs released to the airspaces can 
cleave the sFasL under the oxidative and inflammatory conditions present in the lungs 
with ALI/ARDS.  This is an important question, as the activity of MMP-7 can be 
modified by the level of oxidation.  Mild oxidation of MMP-7 resulted in an increase of 
its proteolytic activity, whereas moderate and high oxidation resulted in structural 
changes leading to a decrease of its activity 638, 645.  We have found that incubation of 
exogenous recombinant human sFasL in the ARDS BAL fluid led to the formation of 
covalent sFasL multimers in the absence of protein degradation, even though the 
ARDS BAL fluid is rich in proteases.  Interestingly, degradation of human sFasL protein 
occurred rapidly in the presence of antioxidants (L-Methionine), suggesting that the 
oxidation of human sFasL may confer resistance to degradation.  Nevertheless, further 
investigations are needed to elucidate this phenomenon. 
 
The data of the present study indicates that sFasL containing the stalk region is 
capable of inducing tissue injury in the lungs, constituting an operative mechanism by 
which the Fas/FasL system may mediate lung injury without the requirement for the 
cell-cell interactions that characterize the membrane FasL.  The main limitation of our 
study is that we tested recombinant forms of human sFasL instead of naturally cleaved 
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or released sFasL.  It is currently unknown which form of sFasL is released to the air 
spaces of patients with ALI.  Releasing different forms of sFasL to the physiological 
fluid in humans could explain why some patients with increased levels of sFasL in 
serum did not develop distal organ damage 537, 598, 671.  Different forms of sFasL are 
probably generated in the lung of these patients, and the net bioactivity of sFasL may 
depend on which form dominates in their air spaces. 
 
G. Matute-bello and T.R. Martin (mentors) demonstrated that cells present in the BAL 
fluid of patients with ARDS can release sFasL to the extracellular environment 284.  The 
majority of the cells in the ARDS BAL fluid are monocytes/macrophages and 
neutrophils and, therefore, these two types of cells may constitute an important source 
of sFasL in the airways of patients with ARDS.  Pre-formed sFasL has been identified 
inside these cells 490, which makes possible that part of the sFasL in the BAL fluid was 
directly released from the cytoplasm and not from the cleavage of membrane FasL.  
We do not currently know if this pre-formed sFasL has different structural or functional 
features than the cleavage products of membrane FasL, or if it corresponds to either a 
long or a short form of sFasL.  In prior in vitro studies, however, the sFasL naturally 
released from activated neutrophils induced apoptosis in human lung epithelial cells.  It 
is also possible that the site at which the membrane FasL is cleaved depends on the 
type of cells in which it is expressed or on the type of MMPs present.   
 
8.2.2.   Other mechanisms that may explain the controversies regarding the 
activity of sFasL 
 
Differences in the type of cells can also explain the differences in the bioactivity of 
sFasL reported in previous studies.  The short human sFasL had no effect in the 
mouse lungs in vivo, but it induced cell death in Jurkat cells in vitro (although it was 
significantly less cytotoxic than the long variant of sFasL).  This finding may be 
explained in part by the different sensitivity of cells to FasL-mediated cell death.  The 
degree of expression, aggregation and internalization of Fas receptor in the cell surface 
may also determine the sensitivity to sFasL 664, 672-674.  Generally, cells expressing high 
content of Fas receptor on the surface respond more to Fas ligation 483, 492.  In addition, 
sFasL has been shown to interact with matrix components such as fibronectin, 
vitronectin, and collagen IV 613, 614.  Interaction of sFasL with fibronectin restored its 
cytotoxic activity 613, 614, indicating that binding of sFasL to accessory molecules may 
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also modulate the activity of this protein.  All these are potential explanations for the 
disagreement between our study and the little cytotoxic effect found in other studies in 
which forms of human sFasL that did not contained the stalk region were used 619.   
 
8.3.   Structure and activity of sFasL in BAL fluid of patients with ALI/ARDS 
 
Prior observations from T.R. Martin’s group showed that the concentrations of sFasL in 
BAL fluid from patients at risk for ARDS and from patients with ARDS were very 
similar, but only the sFasL present in the ARDS BAL fluid was bioactive 284.  This 
suggests that cofactors present in the BAL fluid of patients with ARDS potentiate the 
activity of sFasL.  It is likely that the apoptotic effect of sFasL in lung edema fluid 
depends on complex interactions between agents that promote sFasL aggregation, 
soluble inhibitors, and intracellular factors.  Soluble inhibitors of sFasL are present in 
the alveolar fluid of patients with ARDS.  For example, soluble Fas receptor can be 
generated from the cleavage of membrane Fas by metalloproteinases, and act as a 
sink for sFasL 496.  Other potential inhibitor is the Fas decoy receptor DCR3 (TR6), 
which binds and inactivates sFasL 560.  Additional factors that could modify the effect of 
the Fas/FasL pathway include the presence of reactive oxygen species 675 and the pre-
exposure to inflammatory cytokines such as IL-1β and TNF-α 676.   
 
ALI/ARDS is characterized by a neutrophilic alveolitis and the increased presence of 
reactive oxygen species (ROS), resulting in the oxidation and/or nitration of intra-
alveolar proteins 420, 421, 675, 677, 678.  The air spaces also contain a proteolytic 
environment with a large content of proteases 679-681.  Because sFasL released to the 
air spaces of patients with ALI/ARDS may undergo oxidation, we investigated whether 
oxidants present in the BAL fluid from patients with ALI/ARDS modulate the bioactivity 
of sFasL by altering the molecular conformation of this protein.  Biologically active 
myeloperoxidase (MPO) and H2O2 are detectable in the lung edema fluid of patients 
with lung injury 675, 682-684.  Hypochlorus acid (HOCl) is synthesized from H2O2 and 
chloride by an MPO-catalyzed reaction, and this MPO-mediated mechanism is the only 
known source of HOCl in mammals 428.  Activated neutrophils undergo a respiratory 
burst and produce H2O2 which is converted into HOCl by the granule enzyme MPO 
(H2O2 + Cl- + H+ → HOCl + H2O) 446, 685.  HOCl is one of the major oxidants generated in 
high concentrations by neutrophils in response to a phagocytic challenge 428.  HOCl is 
an important component of host defenses against invading organisms, but is also 
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implicated in neutrophil-mediated tissue damage by causing important alterations of 
biomolecules including proteins, lipids and nucleic acids 159, 332, 409, 423, 447,.  This oxidant 
can therefore damage extracellular proteins and inactivate enzymes 159, 332, 409, 416, 423, 425, 
442, 443, 675, 686-692.  Reactive oxygen species (ROS) can induce changes in the structural 
conformation of proteins that ultimately result in modifications of their biological activity 
in vivo 693-695.  ROS force some proteins to adopt new folding structures, promote 
aggregation and also alter the interaction between different proteins 639, 696-699. In 
addition, ROS can facilitate protein degradation 700, 701.  Within the protein, the oxidative 
reaction can take place in either the peptide bonds or the side-chains of amino acid 
residues 701-703.  Oxidation of peptide bonds normally is associated to protein cleavage 
and degradation, whereas oxidation of side-chains of amino acid residues frequently 
creates covalent cross-links that result in formation of multimers of higher molecular 
weight.  Protein degradation mediated by oxidation is thought to be relevant in protein 
turn-over 701-703.  The formation of carbonyl groups in oxidized proteins has been used 
as a marker of damage by oxidative stress in multiple tissues including the lungs 423, 704, 
705.  New lines of evidence show that oxidation can also be a mechanism to promote 
protein activation and may also protect proteins from degradation, as some proteins 
aggregated by oxidation became more resistant to degradation 634, 706.The fate of the 
protein after being oxidized mainly depends on the level of ROS and the intensity of 
oxidation, the intrinsic characteristics of each protein, and the cellular environment. 
 
In basal conditions, human sFasL spontaneously forms trimers and larger multimers 
that can be reduced to monomers in the presence of SDS, indicating that these 
multimers are formed by weak intermolecular bonds such as ionic forces.  In the 
present study we found that the BAL fluid from patients with ARDS had multimers of 
sFasL containing covalent bonds that could not be reduced to monomers in the 
presence of SDS.  This suggested that factors only present in the BAL fluid of patients 
with ARDS promote stable aggregates of sFasL by forming new covalent bonds in 
addition to ionic forces.  To explore this issue further, we incubated exogenous human 
sFasL with BAL fluid from normal volunteers, from patients at risk for ARDS, and from 
patients with established ARDS.  Interestingly, only the incubation with BAL fluid from 
patients with established ARDS led to the formation of covalent multimers of 
exogenous human sFasL.  There are at least two mechanisms that may explain the 
covalent multimerization of sFasL in BAL fluid of patients with ARDS.  First, the lungs 
of patients with ARDS contain proteins and other molecules that may interact with 
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sFasL molecules and form stable aggregates.  Second, reactive oxygen species in the 
lungs of patients with ARDS could cause oxidation, nitration or chlorination of sFasL 
which, in turn, may cause structural alterations and promote multimerization of this 
protein.  Our data strongly support that the oxidation of methionine residues was a key 
event for the formation of stable covalent multimers of sFasL in our experimental 
paradigm, and suggest that it could be a mechanism by which sFasL aggregates in the 
lung edema fluid of patients with ALI/ARDS.  In contrast, we did not find evidence of 
nitration or chlorination in sFasL exposed to reactive oxigen or nitrogen species, 
indicating that the nitration or chlorination of sFasL were not involved in its 
multimerization. 
 
We also observed that there was not degradation of sFasL protein despite the fact that 
BAL fluid from patients with ARDS is a proteolytic environment with high content of 
metalloproteinases 378 such as MMP-3 and -7 372-374, which are known to cleave sFasL 
in vitro.  In contrast, there was an important and rapid degradation of the exogenous 
human sFasL when the oxidants present in the ARDS BAL fluid were blocked by the 
addition of the antioxidant L-methionine.  This suggested that the oxidation and 
covalent aggregation of human sFasL conferred protection against degradation 
mediated by proteases present in the BAL fluid of patients with ARDS.  In general, the 
aggregation or interaction with other molecules under oxidative conditions can hide the 
proteolytic recognition site of proteins and, thus, they may become no longer 
susceptible to degradation by proteases 701, 703, 707.  This could explain in part the 
resistance of sFasL to degradation in such a proteolytic environment.  These data 
suggest that the oxidation of sFasL present in the air spaces of patients with ARDS 
leads to its accumulation and to the formation of covalent aggregates, probably 
resulting in higher stability and resistance to degradation compared with the non-
oxidized sFasL aggregates. 
 
There are several potential sources of oxidants in the lungs of patients with ARDS, but 
our data suggest that the mechanism of sFasL oxidation in ARDS BAL fluid involves 
MPO-derived HOCl.  Some proteins form multimers or aggregates after oxidation with 
HOCl.  Proteins that have been shown to undergo aggregation by HOCl include 
fibronectin, casein, apolipoprotein A-I from HDL, ovalbumin, α2-macroglobulin and Mn-
superoxide dismutase 639, 640, 708-710.  Protein aggregation has been suggested as a 
pathological mechanism for diseases such as Alzheimer´s, atherosclerosis and 
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falciform anemia 693, 711-713.  In the present study, we showed that MPO-derived HOCl 
oxidized and promoted formation of covalent multimers of sFasL in vitro.  
Multimerization of human sFasL was enhanced by MPO-derived HOCl and this was 
associated with oxidation of methionine residues.  These results suggest that MPO-
derived oxidants released to the alveolar spaces in injured lungs enhance the 
multimerization of sFasL, and that such mechanism involves the oxidation of 
methionine residues. 
 
8.4.   HOCl promotes oxidation of methionine residues of sFasL, which results in 
structural and functional modifications of sFasL 
 
All amino acid residues of proteins are susceptible to oxidation, but the sulfur-
containing amino acid residues - i.e. cysteine and methionine - are particularly sensitive 
to oxidation by most forms of ROS 701, 703.  HOCl modifies proteins in a number of ways, 
including the formation of chloramines, the conversion of cysteine residues to 
disulfides, the conversion of methionine into methionine-sulfoxide, the oxidation of 
tryptophan, the chlorination of tyrosine, and the conversion of amino groups into 
chloramines 637, 641, 714-717.  Oxidation of these residues induces a variety of 
conformational changes in proteins that modify their biological activity.  Since two 
cysteine residues are present in human sFasL, we explored the potential role of 
disulfide bonds between cysteine residues in the multimerization process of sFasL.  
Unexpectedly, we did not find evidence of oxidation of cysteine residues or of the 
formation of disulfide bonds between polypeptide chains of human sFasL multimers 
either in basal or in oxidative conditions.  This indicated that the multimerization of 
sFasL resulting from the exposure to HOCL involved the formation of covalent bonds 
different from disulfide bridges.  Importantly, the human sFasL protein has a high 
content of methionine residues (8 methionine in the long variant and 7 in the short 
variant).  In the present study, we determined by mass spectrometry that the exposure 
of human sFasL to oxidants resulted in the specific oxidation of the methionine 
residues of the protein.  The number of methionine residues that were oxidized 
depended on the intensity of oxidation.  Oxidation of all methionine residues by the 
MPO system occurred with the most intense oxidative conditions used in vitro, and it 
was not accompanied by changes in any other amino acids.  Furthermore, there was 
no detection of 3-nitrotyrosine or 3-chlorotyrosine in sFasL after exposure to the MPO 
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system.  Together, these findings indicate that methionine is the amino acid most 
susceptible to oxidation in the human sFasL protein. 
 
8.4.1. Methionine oxidation promotes covalent multimerization of sFasL 
 
To determine whether methionine oxidation was involved in the covalent 
multimerization of sFasL, we took advantage of the fact that mouse sFasL only 
contains 2 methionine residues.  We expressed mouse sFasL (WT msFasL) and a 
mutant mouse sFasL generated by site-directed mutagenesis containing 7 methionines 
in the same position as those in human sFasL (Met-msFasL).  Exposure to low doses 
of HOCl resulted in a higher degree of multimerization of the Met-msFasL protein, 
which had a higher content of methionine residues.  This supports the notion that the 
oxidation of methionine residues promotes the multimerization of sFasL and facilitates 
the formation of new covalent forces between molecular units that are very resistant to 
dissociation.  Reduction of the oxidized methionines by dimethyl sulfide (Me2S) 630 
resulted in the dissociation of the mildly-oxidized multimers into monomers, confirming 
that methionine oxidation was involved in the formation of covalent multimers of sFasL.   
 
8.4.2. Methionine oxidation modulates the biological activity of sFasL 
 
The structural changes mediated by oxidation can lead to modification of the biological 
activity of proteins 634, 703, 717-720.  Therefore, we investigated whether the level of 
oxidation and the number of methionine residues oxidized could affect the activity of 
human sFasL.  Surprisingly, the cytotoxicity of human sFasL did not change and even 
sligthly increased under oxidative conditions.  Very intense oxidative conditions were 
required to significantly decrease or completely inhibit the biological activity of human 
sFasL in vitro.  Evidence from mass spectrometry indicated that human sFasL 
containing only two oxidized methionine residues retained its cytotoxic activity.  In 
contrast, sFasL lost its cytotoxic activity in vitro when all the methionine residues were 
oxidized.  This suggests that the level of oxidation and the number of methionine 
residues oxidized may determine the biological activity of human sFasL in the lungs. 
 
Methionine is a hydrophobic residue and, unlike other hydrophobic amino acids, its 
side chain is flexible 634, 635, 721, 722.  Thus, the oxidation of methionine leads to a drastic 
decrease in hydrophobicity and to the formation of a more rigid structure.  Methionine 
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residues have different susceptibility to oxidation depending on their specific position in 
the protein 635, 721.  Oxidation of methionine at different locations will have different 
physicochemical consequences 707.  In this line of thought, methionine residues located 
near the protein surface are more susceptible to oxidation, but the protein undergoes 
less conformational changes compared to the oxidation of partially or totally buried 
methionine residues.  The buried methionine residues form hydrophobic clusters with 
other hydrophobic residues.  When buried methionine residues are oxidized, this 
hydrophobic pocket may open like a pot, exposing the internal residues.  This can lead 
to conformational changes resulting in significant modifications in the biological activity 
of the protein 636.  The specific mechanisms by which methionine oxidation results in 
covalent multimerization and functional changes of human sFasL are still unknown, but 
the oxidation of methionine residues may facilitate the formation of multimers by 
promoting externalization of its self-association domains.  Methionine oxidation not only 
leads to changes in the structural conformation of the polypeptide backbones but also 
in the charge pattern and the hydrophobicity on the intermolecular surface, which also 
determine the affinity of the protein to their targets and, consequently, the activity of the 
protein 634, 706, 723-725.  Oxidation of methionine residues located in the binding site may 
also lead either to activation or inhibition of the protein 634, 635.  Because human sFasL 
with only two oxidized methionine residues (Met15 and Met132) retained its cytotoxicity 
whereas the oxidation of all the methionines was associated with a complete inhibition, 
it would be interesting to determine which methionine residue/s are implicated in the 
inactivation of human sFasL.  The presence of methionine residues may also have a 
protective effect against oxidative conditions.  In the absence of methionines, high 
concentrations of oxidants can cleave directly the peptide bonds leading to protein 
degradation; when the protein contains methionines, these residues are preferentially 
oxidized potentially preventing the oxidation of peptide bones and other residues. 
 
8.5.   Role of neutrophil-derived oxidants in the oxidation of methionine residues 
of sFasL 
 
Several studies have shown that neutrophils are capable of causing oxidative injury in 
inflamed lungs.  One of the mechanisms of neutrophil-induced damage in the lung is by 
promoting protein oxidation 408, 423, 726, 727.  Methionine residues are oxidized in proteins 
of BAL fluid in chronic bronchitis, which is believed to be caused by activated 
neutrophils migrating into the lung 728.  Activated neutrophils were also capable of 
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oxidizing methionine residues in vitro in newly synthesized proteins 635.  Moreover, 
intratracheal instillation of phorbol myristate acetate (PMA), a well-established in vivo 
model of neutrophil oxidant-mediated ALI, was accompanied by a significant increase 
in methionine oxidation 4 hours after instillation 727, 729  In another animal model, whole-
body exposure to radiation resulted in a significant increase in neutrophil content 727.  
The levels of oxidized methionine in the lungs remained unchanged immediately after 
the irradiation, but they increased significantly in parallel with the influx of neutrophils 2 
hours after the irradiation, suggesting that neutrophil-derived oxidants, but not 
irradiation, caused this methionine oxidation.  Although neutrophil influx was reversed 
within a few hours, the oxidized methionine content remained elevated for at least 24 h, 
suggesting that the oxidative damage associated with this acute inflammatory response 
may persist and exacerbate radiation injury 727.  HOCl is one of the most potent 
oxidants released by activated neutrophils 428.  In an ex-vivo experimental model, 
perfusion of physiological concentrations of HOCl to the lung effectively oxidized the 
methionine residues of proteins 726.  In addition, our data showed that HOCl can oxidize 
methionine residues of sFasL and exert structural and functional modifications of the 
protein.  Altogether, these data suggest that HOCl released by activated neutrophils 
may be an important mechanism to oxidize and modify the activity of sFasL in the 
inflamed lung of patients with ARDS. 
 
Oxidation of methionine residues in proteins can be enzymatically reversed by the 
activity of methionine sulfoxide reductase (Msr), which reduces methionine-sulfoxide 
(MetO) to its unmodified form (Met) 718, 730, 731.  This enzyme exists in various organisms 
ranging from bacteria to plants and mammals, being found in human PMN leukocytes 
and in other tissues 731, 732.  Msr catalyzes the reduction of free and protein-bound 
methionine-sulfoxide to methionine and constitutes a repair mechanism for oxidatively 
damaged proteins.  Supporting the relevance of methionine oxidation in the 
modification of the bioactivity of some proteins, it has been proposed that the cyclic 
oxidation-reduction of methionine residues serves as a built-in oxidant scavenger 
system to protect such proteins from more extensive irreversible oxidative modification 
733, 734.   
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8.6.  Final comments 
 
The sFasL released to the airspaces of patients with ALI/ARDS is active and may 
damage the alveolar epithelium by mechanism involving apoptosis and inflammation.  
Therefore, it was important to study the mechanisms that regulate the activity of sFasL 
in the lung.  In addition to its degree of aggregation, the cleavage sites may be an 
important determinant of the activity of this protein, as variants of sFasL with different 
N-terminal sequences may be generated.  We found that the presence of the stalk 
region at the N-terminus determined the biological activity of human sFasL in the lung.  
Variants of human sFasL containing the stalk region were more active than variants 
lacking the stalk region.  It is possible that the net biological activity of sFasL in the 
airspaces depends on the ratio of the different structural variants of sFasL present.  
The generation of reactive oxygen species by activated neutrophils in the lungs may 
lead to structural and functional modifications of sFasL.  In this oxidative environment, 
human sFasL retains its biological activity and forms stable aggregates probably by 
mechanisms involving oxidation of methionine residues.  It is likely that a certain level 
of oxidation favors the activity of sFasL, as well as prevents its degradation or inhibition 
by other factors present in the lung of patients with ALI/ARDS.  We cannot discard, 
however, that the activity of sFasL may be progressively reduced as the local level of 
oxidants increases in the injured lung.  The presence of metalloproteinases may also 
be a factor that controls the activity of sFasL in the lung of these patients, but no 
information has been reported yet in this regard. We consider that targeting the stalk 
region at the N-terminal may be a potential mechanism to modify the biological activity 
of sFasL in vivo. 
 
Our future lines of investigation will address the effect of the neutrophil-derived 
oxidants on the structure and the activity of sFasL in vivo in an inflamed lung.  From 
our study, we know that sFasL forms covalent aggregates only in the ARDS BAL fluid 
probably by mechanisms involving oxidation of methionine residues.  However, the real 
oxidation status of the endogenous sFasL in the air spaces of these patients is still 
unknown.  It is likely that the degree of oxidation of sFasL varies during the different 
phases of the development of ALI, which could be associated with different biological 
activity.  The high content of methionine residues of human sFasL makes this protein 
very sensitive to oxidation, but this protein can be oxidized while retaining its 
cytotoxicity.  This is in accordance with previous studies showing that sFasL was 
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present in the BAL fluid of patients with ARDS in an active form despite the presence of 
oxidants and proteases that have been shown to alter and destroy other proteins in the 
lung 284.  Under oxidative conditions, the formation of covalent multimers of sFasL may 
be a protective mechanism not only to maintain its activity but also to prevent its 
degradation.  We cannot discard, however, that the formation of covalent aggregates 
mediated by oxidation may also prevent the interaction of sFasL with inhibitory factors 
such as soluble Fas receptor and DRc3 present in the lung edema fluid of patients with 
lung injury, which have been shown to inhibit sFasL.  On the other hand, oxidation may 
facilitate the interaction of sFasL with factors that help restore its cytotoxicity, such as 
the extracellular matrix component fibronectin 613. 
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8.7. Summary of results 
 
The major findings of this study are summarized as follows: 
 
1. Soluble Fas Ligand (sFasL) can be detected by Western-blotting in the BAL fluid of 
patients with ARDS, where it tends to aggregate forming at least dimers. No sFasL 
is detected by Western-blotting in the BAL fluid from patients at-risk for ARDS or 
from normal volunteers. 
 
2. The intratracheal instillation of human sFasL in mice induces severe lung injury, 
which is characterized by important alterations of the structure of alveolar walls, 
increased alveolar-capillary protein permeability, local activation of pro-apoptotic 
pathways, neutrophil infiltration and induction of expression of pro-inflammatory 
cytokines. 
 Human sFasL-induced lung injury occurs via the specific activation of Fas 
receptor, as the intratracheal instillation of human sFasL in lpr mice harboring an 
inactive Fas receptor does not induce lung damage. 
 
3. The presence of the stalk region at the N-terminus is a determinant of the biological 
activity of diverse variants of sFasL. Importantly: 
a. In vivo, only the intratracheal instillation of a long variant of human sFasL 
containing the stalk region induces lung injury in mice in vivo, whereas a 
short form of human sFasL lacking the stalk region does not. 
b. In vitro, the incubation of human Jurkat cells with the long form of human 
sFasL leads to a higher percentage of cell death compared with its short 
form. 
c. Both the long and the short forms of human sFasL aggregate spontaneously 
into trimers and larger molecular weight aggregates under basal conditions, 
which are mediated by ionic forces in vitro. 
d. The co-incubation of the long form of sFasL with MMP-7 results in the 
cleavage of sFasL and in the reduction of its biological activity in vitro. 
 
4. The endogenous sFasL that accumulates in the BAL fluid of patients with ARDS 
forms multimers that are mediated by both ionic and covalent forces. 
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5. An oxidative environment, such as that characteristically present in the airspaces of 
patients with ALI/ARDS, modifies the structure and activity of human sFasL via a 
mechanism that involves its methionine residues, which is supported by the 
following findings: 
a. Only the BAL fluid from patients with ARDS, but not from patients at-risk 
for ARDS or normal volunteers, promotes the aggregation and increases 
the activity of exogenous human sFasL. Despite the high content in 
proteases of ARDS BAL fluid, the exogenous human sFasL is not 
degraded in co-incubation, unless the oxidants in the ARDS BAL fluid 
are neutralized by adding L-Methionine, a potent HOCl scavenger. 
b. The exposure to oxidative agents, but not to nitrosative agents, 
enhances the multimerization of recombinant human sFasL. Free L-
Methionine, a potent HOCl scavenger, prevents the multimerization of 
sFasL under oxidative conditions. 
c. The introduction by site-directed mutagenesis of additional methionine 
residues into mouse sFasL (which has only 2 methionines compared 
with 7 methionines in the human sFasL) significantly enhances its 
multimerization under mild oxidative conditions. Such. multimers of 
sFasL can not be dissociated under reducing conditions indicating the 
formation of covalent bonds between the monomers. 
d. Exposure to MPO-derived oxidants results in the specific oxidation of the 
methionine residues in sFasL as assessed by mass spectrometry. 
e. Aggregates of sFasL containing oxidized methionines are only 
dissociated to monomers by dimethyl sulphide (Me2O) and hydrochloric 
acid (HCl) but not by dithiothreitol (DTT) indicating that methionine 
oxidation but not the formation of disulfide bonds is involved in the 
multimerization of sFasL under oxidative conditions. The dissociation of 
sFasL multimers with Me2O results in a decrease of its biological activity 
in vitro. 
f. Purified human sFasL, without the presence of other proteins, contains 
two oxidized methionine residues, indicating that this protein is very 
susceptible to oxidation. The biological activity of human sFasL is 
preserved and even increases slightly under mild oxidative conditions. 
An intense level of oxidation is required to diminish the biological activity 
of sFasL. 
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The results of the present study support the following major conclusions: 
 
1. The soluble form of Fas Ligand (sFasL) induces lung injury in mouse lungs via the 
specific activation of the Fas receptor. 
 
2. The stalk region at the N-terminus is a critical determinant of the biological activity 
of human sFasL in the lungs in vivo and in vitro, but it does not affect the degree of 
aggregation of the protein. The stalk region of sFasL can be cleaved in vitro by 
MMP-7, leading to a reduction of its biological activity. 
 
3. The BAL fluid from patients with ARDS contains factors that: 
a. Increase the activity of sFasL 
b. Enhance its aggregation by mechanisms involving the formation of new 
covalent inter-molecular bonds, which confer more stability and 
resistance to degradation. 
 
4. The methionine residues of sFasL are critical determinants of the function of this 
protein under oxidative conditions. In particular, the exposure to a pro-oxidative 
environment modifies the bioactivity of sFasL and promotes its aggregation by 
mechanisms involving the specific oxidation of the methionine residues of the 
protein. 
 
 
Globally, the results from the study suggest that: 
a. The biological activity of human sFasL in the lung edema fluid of patients with 
ALI/ARDS may be determined by the ratio of structural variants of sFasL containing 
or not containing the stalk region. MMP-7 and other metalloproteinases released to 
the airspaces of injured lungs may be important endogenous modulators of the 
activity of sFasL by inducing its cleavage at different sites. 
 
b. Neutrophil-derived oxidants present in the airspaces of ARDS patients may induce 
multimerization and modify the bioactivity of sFasL in the lungs of these patients. 
 
c. The stalk region of sFasL may be a valuable therapeutic target for modifying the 
biological activity of this protein in vivo. 
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FUTURE DIRECTIONS 
 
Our studies suggest an important role for sFasL in the pathogenesis of lung injury in 
humans and animals.  Our future directions will include studies to determine whether 
sFasL may cause acute and chronic epithelial injury in the lungs. We propose to create 
novel transgenic mice with inducible over-expression of human sFasL in the lungs to 
test the hypothesis that its release into the airspaces produces an inflammatory 
phenotype that leads to acute lung injury and long term fibrosis.  In addition, we will 
perform experiments to determine the mechanisms by which the stalk region 
determines the activity of the sFasL in vitro and in vivo. We will evaluate whether the 
stalk region increases the affinity of sFasL for receptor binding and/or facilitates the 
aggregation of Fas receptor on the cell surface of target cells needed for the 
transmission of intracellular signals. We will also explore other mechanisms such as 
accessory molecules or proteases that may modify the activity of sFasL in the injured 
lungs. The better knowledge of these molecular mechanisms may help us to initiate 
strategies to modify the biological activity of sFasL in vivo.  This could include the use 
of small molecules to target the stalk region at the onset of the development of lung 
diseases in which sFasL is involved, such as ALI and IPF.  In the long run, improving 
our understanding of the biology of the Fas/FasL system will enhance the 
understanding of the basic pathophysiology of ALI and ARDS, and offer new 
opportunities for the treatment of patients with lung injury. 
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